var title_f7_7_7280="Metformin exenatide place";
var content_f7_7_7280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Change in A1c (A) and weight (B) from baseline in patients with type 2 diabetes treated with metformin plus exenatide or placebo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 510px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: DeFronzo, R, Ratner, R, Han, J, et al. Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28:1092. Copyright &copy; 2005 The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7280=[""].join("\n");
var outline_f7_7_7280=null;
var title_f7_7_7281="Chigger bites - leg";
var content_f7_7_7281=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chigger bites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small erythematous papules are present on the lower leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7281=[""].join("\n");
var outline_f7_7_7281=null;
var title_f7_7_7282="Preauricular cyst";
var content_f7_7_7282=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Preauricular pit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This histologic specimen demonstrates a preauricular pit with cyst (s). Note the proximity of the cyst to the cartilage at the root of the helix (c).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7282=[""].join("\n");
var outline_f7_7_7282=null;
var title_f7_7_7283="Bullous pemphigoid direct immunofluorescence C3 deposits";
var content_f7_7_7283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Linear C3 basement membrane zone antibody staining in bullous pemphigoid by direct immunofluorescence microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 407px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGXAhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKWgBKKXBpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopQKAEopcUUAJRS0GgBKKKKACiiigAooooAKKKKACiiigAooooAKKWkoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKWkooAKKKKACiiigAooooAKKKKACinYpCCKAEopaSgBaKSigBcUUlLQAUlLSUAFFLRQAlFFLigBKKWkoAKKKUAnpQAlKKMU/bQK4i4APHNJ3pwH4Uh4pAJijFGaKAClI4oHWl9qAGYowakK4HakouFxmKMVJjNIevNFwuR0U8im4pjEpaO9KRQA2inYpKAEpaMUlAC0lFL2oASilo6UAFJS0UAJRRS0AJRRRQAUUtJQAUUUUAFFFFABRRRQAUUUUAFFKAT0ooASiiigAooooAKKKKACiiigCUHJ6UpAoK7TSDn6VJAhXPSmGpASDSOKaKRHRRRTGFLRRQAUUUdKAF7UcZpM0UAL3pc56UlB6UhCGkoopjFAzTun0pQuBzxQ3YClcVxCSTS/yoFIcg8UABNIATTlGT61MkZJ6YpN2E3YhK4PFPiheToPxq5Bbgkb+K0ktxsAQYA61lOtymE66joYT28idRxTOVPIzW/LArHAbB96rSWmByAfcUo109xRxCe5k5ZjSdK01st3PalNhhSe9V7WJXtomXmlz61NLbujdCKhZSOtWmmapp7CUYoFGKoYYo4oIpMCgB3BFNIo6UooATFJincUvFFx3IyKUZpxGDR1+lFwuJ+FIadTTQAUv60lH0oAMUEUpPqKM+9ADSKOlOoBoC4H7mPfNMp9Jj0oAbRS0oFMYAUEUUZOPagQlFLilUZOBQMRRz7V6D4e8FWutaGLtJWWQg9Oxrz88Gu0+HXildEvGgvpCLCQfNxnafWuHMFW9lzUH7y/E87M1iPYuWGfvLX1OffTpdO1k2tynKnH1HrVXVVVLxggwK6O71C01XxhLOjMIHO1C1ZfirTX0+/JLh0flSDTo1W5xVTSTQ6FZucY1NJOJh0UUV2noBRRRQAUUUUAFFFLQBZlWoiCtW3TPSoJFI4IrOLMYyI8ZwaHxjrTeRmhuas0sMpaSimULRRS0AJRilzRmgBMUEEU4GjNIQgpDTuvSg80ANpyr3NCcGnepNDBsCSaSgn0ppPFCEhc46UAEsB3NNAJq7YwFn3EdKUmoq4Skoq5Lb2pI6c1cjtsL6mrkNviPc/A9KtRQjA3ABa4J1jzKmIM2C2LMCT8voOpq/cWtwkOSojTvz2rUhMNmnmSqAcZBbv9KgfUFvbQS7fLO/Cg9SK5nVlJ3S0OV1pzldLQxoShcqkbs39/oKui3XaM5z71ejQdQgye9R3qlF3HJ9MDrTdTmdkDq8zsimsO1WCjPNPWMjOQOnSmwOxy2Co9TVpMOMt17EUSbQ5NrczLqESbsL0rNe1JJGOK6WWM7C2QR7VXjhyexrWFblRrTr8qOXltWQ9KRbWR+ldj9lgYHzQox1OelJ9ktsZSUe3Aq/rnka/X9NjkVtJC2CMU5rCYfwn8q66GzXdnzF/wC+ati0jAyTmpljrESzCzPPpImjOGBFM6V3VxpkEudxBrGvdDCZMZz7VtTxkJaM6KWOhPR6HO5ozVia2aKTawOPWmNGdo4rqUkzsUkyLNLmkIwaQCqKDk1KkRJGaWOIkjHWtO3gCoCQM1nOfKZVKiiUGt2xkLUDqBWz9rhtWImjZ89l4xVW5txcL50B+TuPSpjUd/e2IhVd/e2M4EYINKoDfKBz2NPeF06jI9RUZFa3vsb3T2BlKnBpM0vOfWpBExOMU723C9tyLNGPSntGR9aZjFA07igUuRjpz603NHNAC5NGaMigGgAzS5pCeaMigBCM0lOooARGKMCpwR0NST3EtwQZXZyOmTTMDNFFle4WV7jcUUtFMYmKMUUtACUUtFADaKcKTFAGoRkZprIGznrVny8fdPHvQIwcZyD+lcnMcXOUHgPOOarOhWtV12MVPHvUMkYce9aRmaxqGbSVNLEynkVFitk7m6dxKWilAJ6UxiAU4LkVIsYPbJp/lA9qlyJckVjRUzwEdCDUZQjrTTTGpJidKd16U2nK2KAYDig0E+nSmk0CAmlVc+wpBTlVmOFGTQNkkabiAo4rf06EKFOMnsPU1QsICAAR8xrUhleEsYkyw4Un1rjrzvojgxE3L3UTOWF48ZbcirlvY+lXZg88SiPaq45rNhiaGJmmP7xzkj2qW91KS1twIIN7uOGI4FckouTSicMoOTSgE0CZU3cpYrwAT19BVi6gMUMEe0AqOawrOG5vruJ5C5ZmHBHGK6W+CxpGmSWB9entRUThJRvcdVOEoxvdlLUL6extVaFEYnjf6fhVUX7XdqofJZScEVtRmJ0AlRZAOgIzTZobYIfIg2Z/u8VEZxWjjr3M41ILRx17mTBaBpHY7t+OE/DrVlIuSGZgPboKXzQn7oKR6sep9qlGZI0bCkL0HQfQ1UpN7lynJ7kSyGMONxPHANPtmbAziq6M0krKYwVxnipY3MLDcMjqCKGhSjpbqaKtCkTGVlCkcs3eqb32kDo8eQOeSM02aGO7jH8X41mHRMSMindv9e3sKVOEH8cmhUqdN/HJpm8k1u8CSRfdboQcg017gLyDlTVaxtVtrULjGGOEzmorkFMY3EH86jki5WRChFyaTJ5J+QQ42mkMu5s5JHtVQRqwBLHPpUwUYAJ2g+lXypGnLFDb21hlXIbL+4xWVPakDGK1H0+KQYWVhnkdeKSLTnjJ2yFh6Ma1hUUVua06qgviOclg54FMS3JYcGuleyU5OVz6ZqMWOw5ATnuTW6xKsdKxasZ9rBjqM+1akVucAsuKliQxj7qY7kdRUqyDrgMK56lRy2OWpVcnoUb7T45bcvgBh6VFbWhVSFGK1NyupBTBPTHSoWxEvzsOuDj1pKpK3KKNWVuUzjafeyOnJHrUE1nDJnapU9q19hZVZGGD0yKjlh3th12v+hq1VaNI1mnuc1LbvG+V7U3dIeoNb8sABww4qD7PGSeea6VXTWp1xxCa1RjlyeGBpp59K2HslYHvVSWyI6IauNWLLjWiyiFPXANDY7jFTm2YdNwpjxMBg81opI1UkyDj1pMU8xMO1KkTH1qrou6RFiirDwMo6Gq5BB5FNO4KSYUZopKZQtFJSigQZpKfipEiz1pXSBtIgpQCauLbrjNKYVXoDU86I9oiltNFW3jx2qtIMGmpXKjK42ikoqijoEdcYIp6qD06VT5H3Tx6VLAyZw4OfauFxtqjzpRtqiV41PGOajNuT908+lXY5Ijw2PxqZ7dWxsYHIzWftHHcy9o46MxpYyB8wqsIkJNas8bKvA4qqUVj2BP4VvGeh0QqaFI2u7lTmnRWrZ4Umrgt5CflOB7Gr9tFJjBmA+tEq1luOddpbmelm5GcYoeEpxkGtVrKfkhw/wCPWoJ7OSMbiMnuBWSrXe5gq93uZEiEA4FQkE8Yq/InPIIqMJntXQpHVGehQaIgdKiIwa03QjtTCqkcgH8KtVDRVTP9qekTN0GB71a2gA7V/SliTPJbA9BTcxupoNigQDLAsavWdtt5YcnoKfDA5UGNCF/vNUiOgJUlj646muedRvRHLOo5aIsWtq83KYAzyx/pVxwlqoEfzyHqapreSAgDEUY6KOoqykkBBByDjOSevtXLPmvrscc1K+uxW83L5lbk9hV5LpCoHl5AHGTWUzB5enHQVKgdWwAQPfinKCZU6aaNQXwCkGID3FZ91M8swLcA01ZnZwjDcuMlx0FNLIzdeM8Uo01F7EwpqDvY0oTiPjn0qQzdmIH0rMExA+Ug1GzMxOWqfZX3J9jd6luV0ZuDzSLMy5BPBqpuZOduaXPmSGSRiqAfd96vkL5CwlwEchflZu4qMzsOM8elUpmRpWbn2xUqHAG853AcY6Vfs0tTT2aWpP5xXoSPapYrxlzxz61niQnPsacDgZHX2ocF1B011NATOeWP5UjSLgcEZqisxRsnn09qnSVZAGAOO9S4WIdOxPGykEb+D7VbRlVAFIwP1qg5iDAjoackg3dRUSjciULlmSQnhRjP6Uq5ICs5HuKr3G54isTLuPv2qGOOSEEGJy3qDnNJRVhKCaL0onHIZcdOlRPIyx52sMnGCKLCSYZE/Q9z/CKklk67dpHrilazsTazsPgKFQCcADn3NObyipOQvOcDkVV3Z7j8amQJjqpP1qWuonG2oiMYn+Vgy9cU14vPkLgqrE5wegqZgvGQo9Ka4KruOMUJ9hJ9VuUpluoi6Y3Z4wOn1FWbZZBCgmI39SD2pwj8wMwwoUZODUC+W8ay8gN0y3OatvmVjRy5lYssFZCJBkY6VEljHjLEnPOKeMpmNjjH4iphMQMEDK8H2qLtbGd5LYiS1jVwQGIqbyFY45Ve4BqNpyOCwo3js1J8zE+ZkF3ZKihlbk9jVBrct1UVtBlb75/OkMUZOQ2P8auNVx3NIVpRVmYn2MD/APVUkdipPOfetUptBxIM+hFOiCklZAN2O1U67KeIlYyJ7PYRszj3qhcwozH5MHvXTSKqjBY46DNQtaiQcgHmqhXtuXTxNtWcm1sM/LnFOjtNzgHOK6KSyt0Yb3Cg+lRtHYK4QXSbvTvXQsTfY6Fi77XMZrJc/LyKQ6ezY2jitmS3SN9qOD9TTli7M3HtS9uxfWX0ZkpprN95sVMlnHERyWJ4wK1AkUWQG+YAnFNhuFznYCMYxjmodaTIdeciF4IwApH4iofsowf0rRd42+62w+4zSDcAduCfWs1NozVSSMl7Qtn+VVZrQjNawutk5EoITtgc003xaUKsIeM9c9a2jOa6G8alRdDAe3cHpSeQ/pXVSW9rL1jKnGTiq/2S1/vNVrFeRaxmmqKK7GHIx70w4UnaciotxxgGgMQwPeq5S+UsLLgcinLcHGATUE0jGPIwPfFUo3l3nqTQoKSuEaakrmsszdM0xzuHIquHKgM1SLNnqvFTy22J5LaodHIyP8pNTqyupDswPtUGwNznH0prbl6c0NJiaUi1EXQBk3Eg8Y9al+0XHmuXTlvvZFUkmdcgk/hUi3BDbjzz371Dh5EOF+hPkODuZKkS1D42shycDmqE7ox3BsewFC3eT8qAfTvRyO2gOnK3umm2mkIXLjavUjpTRYRsmVlU96qi8lIwDx6UjyysODio5anVmfLU6scbdFkw+cfUc1PbvHCcxQozdi3P6VWhUFsuefzqdigHy8n64FOWujHLXRiykyn9/Kdv90cfpQ/lLDsiZVbuxFVAZEfJKEHtjpUxx1K5NHLYfLYZFCyuD5gbP6VNKdwA4wPQU1GIB3ClBGTjpTbbd2DbbuxowuMA5HOaGkJ5zk+pPNIRu704lVVgFwaAEabcQudo7+9NlZ36YA7Yqs0fOSGqW2ZlP70fL2NVypK6LcUtUIhdW71YLgntnvxSM24YXpQqkDAXmk3clu+rFDc9aRg2cg0jAgnJ/KlVhnnIOKQvMZjB5xmk3jkMwp8/yplaqOApyfzqoq5cVzFkBQAF6U9TtOcjj1qvZlnGe2cA+tTsDnpzSkrOwpKzsJJzluPakLtFAOmCck0YJbnFP2hhsbnHOMdKBbbjBJ8u7BxSiVc5zikYlOByOwph+deFwT1570WTHZMnDAkfNUlxI8arsBwe+eBVeNQsQVutSpIVHBBHpUtaktalU6hLG33AR71ft7jzrXe67WNQS7ZD80akdelRjcx+Y4UcADtVNRktrDkoyW1iwG496kRsKMgE+lRZXO2goSeKixFkE0snnf3VH5GoRfzNII1Bbnr6VKxOOgNIGIzgAHr0qkl1RSStqiyJ3TBwDjtQJkYBQoVc5AI6GqjPnqePSnRsobBNRyIh00XmkV2Ds2Np/h7n3pst2d2eMnrnvWdKsu/MTfL6VEUkMZVhyehJ6U1SXVjVGPVmi025uOKVbgqMcYqnGxVApYkjjNI7lSPlyKfIth+zWxf+1sx5xxTHuM+341Qa4VFJYY9Peno6sAy/lR7NLWweyS1sWPPdTw5z9akE8mByDVIk+Zk8L2xSnpkEmnyIbpo0EaYjO7Hfk1aiumR/mCE47HtWOkhVgFzn1pzoH5BIB4IFZypp7mcqSe5PM1rNOXQks3ON2akSGxEwkMRDj15FUfLVSMrkfyqy8quuOgHTHU1Tj0TY3G2ibLEpjkbesg3e4xSI2GwyjFUyAejfnUqMB0ap5dCeSysWGhBJIJJPXnFNMQAy3QdCKZJMccEHHpUJlyOT1pKLBRkWVjRSQu3kck09l2kYYDiqO84yelSCfPUK3uabgwcGTugbqoY/WniJFOAmcfxDmqjTf7H5UiznPLEGjlY+SVi1IwHUGoCY8/dJoE24cvxQJE7sSfpQlYEmjFz8x54pwccHdx0xTSCVIwBT44wF+7zXa7He7FjaGXg8ehqPyjjIHHqKUZIGSQO1PDbCBnr3rPVGWqI8dMinhxwp6Uq4YkgZxTCctgDFG49x69D8wFIxIGetIBxzTCULYDUJAkP3HHpSYJ5oBCj1prklMY4pgPaMY5PWq7ny3IXqKfbbstvJI7ZqRlDA5HHr3p7OzGvddmVRcsp5UY9qvW0hmUsoyB19qgECHhske1WY1EKbVGF7ilNxa0Co4taLUkUc9KcFBpgZMgEkZ6VIm0ckce1YswYjKFx0xQWwOuKUsu7O386GZewGKBCF+M4zTWdjwOKRiMHkLjvUcEsTMQHGelNLqUo9SRPzo2gnrgUp470IhYDsKA8xAuO/WmkEtlmq06Ky4GMjvUJKrwVzSUhKVxwcDAAPHehpSwwxyPQVHncBgYz605ISTxnPpRZdRWXUdg9f50jLgdRzSiNiMLk1GyYwM/nQgQK3OF5x2p0iI45XNRBmjJB49xUolXgkj3ptPdFNNaocMKmPuilZshfamltwGw5HvT0TP3s8d6l+ZD01ZE6nnoDTYlYOGLcVYIU8ZGKTbt9KfMNS0sRsoJ4BpuArfNxUjDjLHGPeowVzyc59aEND/L3nk8U/YBwafFtz74qnqM7RkKoO49DRG8nYUbylyomZD1HagYHH61l2088c+OWDcEGtPdzVSg46MucHHRjlQE9anPTC1XU9s/n2pRz91iPcVDRm0NYkHAGD70EetEpORjn6imquM9SPUnpVFdAPHQZpuWwalU4BHPPc9qrvuVduPxprUa1Hh8ckYHrRkk55GajCsQAeB71Ix4GDn3p2KaEAI5/nUvmeoGKbnpuOPrUVyzK4IGU7YpWuxW5nYdKkbclRj1pFwOg47UzzAwA29abboyqQTwDxVW01KtpqTMTjjFMBfPQ0vUcCnqBjrk9zS2FsCng+tKZMdqAOTnP1pjgjPcUtGKyYpcscEnFC5BIwcDvTmQmLcoyabFIr8ZwR1p9A6aEgJxyaVjhckZpAoZhg59qbIdoCqPrUi3YjyboxjtyR3NRNcKqndnP0p+M/eGKUnAyQD9eapWRSsitbSyPI24/L2NWScdsmmKQMEAUFiTnuOlU9WVLVkjsEjLFgWHbNMSZZXKJnOM0x13ciiJMS7u5FKysKysSAkHJNPDcdjQDk4wKYV54B/Kp3J3KhGfSpFI25OeKjjB3EnIqUrnFas2fYGkDAKvIFJKAQBmnAY44pjnGc0l5CXkGSicHrU8IABJ5PoarEMegyKmUjYMUSQSWhBOH3nkke3SqvlsZPlH41pY54H40zAGBjFVGdio1LIcAOAOuKazYNOBBOQDxUTrukAAI9zUrzJXmSCRCDx+VC8jrimlCvBp6jAx60O3QTt0J4zwNvNSONynJ61HArIPXP6VJIRlT3rJ7mL30IxDuI3HAp7LhCq5z609CW5GCDSkAA7sZpNsTk7lVSwA3kM3qKkZgQSRjFPCAnJA4qOQhQe31qr3ZV7sqz4IYetUdjg9K1sK+CR+VJJJDHgMAD6VrGdtLG0altEiWM+ZEueuKlTKgCoYXV1BSmvIyuPXt6Vja+hg4tuxak3AYXANUdpikLMxbPPParqZZAWP1qJ1jY7ABz3pRdtBQdtB8bLkHg5FWBIu3BBGO461lrD5LttY4PQVK9z0Cqd1EoX2HKnfYmLnzflP4GgnI685qHaxA+fa3enRqQ3yk/QinZBZD5ARkE5BpphIC4AHtSqGEjZJ68GpOpx+uaV7Cu0JHhHUt09qnmZeSvDVByT83H1pCu9gGzwalq7uS1d3Y62jebJYgEdhQ4KSBeoNJOTErOnygDt1rP+2tJ0OD71cYuWq2LjCU9VsT3APnlScccCmPDvGO4FT22ZoNzqCw4FP2IMZBLepNPmtoVzcunYisy4gIkOSDgH2pZJAwwy5+tT9FHQLTWjzzxSum7k8ybuMjUKTgAe5qRUHUcj1qJgeMfSnxFlNJ9wfcc4wrHHPpUcDEg4HANTRncpzjNCphQKV+jJvZWY1uR0/Ko88gYI9KeXC8YpTgrlfxp7D2GsmBzkUx3CYBYZ9+tSht4APJ7mqs9uXk6YXrn1px8xx1dmS4G360iAbCfyp4XIx2FRMjIDg4FC1GtdCrJI27k8U+GdnbZjdn2qdY0ccqD7inhUgU7VxmtHJbWNHJWtYjZVRuBimyTLFGGI6mmyXAB5Xj3ppVbiPHT0NCX8wJdZAtyOCf0qSZgIiyjnrxUMdoEOS2atKuFAHeiXKtglyp6CWcgmQh8g+p70lznGVACinIFThelG4sMdulT1uiftXRFbMXznjFJLD1ZTzUmBjkflTsqMU763Q763RDEXABYnFPJ3ZyTmpGAKnB/Kqrl1kAB3Z70L3gXvE3GevNJjGeDk9qRQxHzAfWhg2eaBiMoxg1XYEHgkVPuB4PWk2gnoapOxSdhtvIzZ9RUwYg1GgVAQowSaduQkjkUPVierFBINLknp/OkB60Er61IhmewFRXD7OFzuPNOjlV2GDimXEbSPuXnHWtErPU0Ss9SBZj2znvVpRuUE96iigCtubB+lWkwM+tObXQc2ug3HGAcUkeFOAcj+VJKOR1NRE8jZx3qUrkpXLa4DYLYpOJGYjnbTIzluetSI2SanYh6FZ52VyAcCp42LoC2M0kkKZycZNPgiOQqfjTbVhtxtoKVzzwMetKmCcYOPelYHzMFSOcU2RsfKvBHWoI3LEDrtKnBIpJCCeOM1X3KikAZIGSaRJC5BH3fftS5eouTqTJheAf1p4U5GTmqDviQg8GrcUv7vLHgd6cotajlFrUimkcSYGdo61KAHG1+c0NEZG3cjPNKIymO9F0DatoNibBZTwR0FVHADNvHNXOh5A9zQ0e7B6Z9aalZjUrMZYKUV27N0zVoRjqajAxwDxTlJzjrUSd3ciTu7kn3l21GUWMF2IFTKFAJPWs66RmLE0oK7sTBczsWjtmTI6HoaktYBjDYJ96qWETQxEucZOQDV2L7obOM0T00TCel0mEsPHHA7CovuN8569Ktkk4zVO5lRXwF3Ed/Spi29CYNvQWRsuGUjHTFRtnPykim28kdwzIV2v8AzqXblSpzkcZ9av4dGafDoxqsAeeW7+1OEhzu7mkWLc2GOSoqdIiSM4pNpCbQCTcnI475rMltondihK+1bJiXb0zVfYFGAgOaUJ22Jp1OXYZYRiOAoTknkE0SskIBkOc/nT0QoxyCM+tVLy2laVXUZHfNNWlLVlRtKWrLKETAFc4p6hwQCB1qJMRgAVKC4JJYcdQe9JkvyBWHmsARweR6Gi4mRRtOAcc8UxdgnPbI5qOZAjlsZDfoaElcaim9QikVmCqSO+KeXbdt7etVIlYup5znrVxyPN6EAVUkkypJJiMEH3mwachTO0EEjtVadQ0hb2zzTEYjAxT5boOW6LT/ALvlTg+9HLHr0pjkNtJPI5zT43BGACRU20FbS47GKcinGTTgQOADSNycZwo6mpuRciQZlIyMCiVdyn0P6UjSjI2Djt70MdynPDVWpet7mZPbSF8BgwqeAeWm3IJqXJbp1phXC5A471s5NqzN3NtWY5VcPnhl9KkZ8cYOaYvyn+lSgZPPUc1DM5DPKLDJ4pQp71OHBUd6Yx9/pipuyVJvchwc88mmNlG55BqTaCDnk+tKWAX5+aq5SY1FLfdPFQSD98Bg7fapw4K/J/3zSNsKA5x7007MadmJI4VAcnJ61X+0ZbnFWHw8YK9e9ZTqRKQPWtIRT3NacVLc0s/r3pBnJ6igKSqdPc0oGM4OTUkjcgA981XaUoeRxVl+BnHSoGUMOaqNio26llHVlUjpS5B61BACqGnbj6Cpa1JcdSKCLDb2/AVYYfKW6VIEz2pl0NseM8mjm5mHNzMbFhkJzz6VBMxP3TUsfBGKnEEcp4bBx1FO6i9R8yi7sr2+5kO4E7fSpIwuCSvzirAjMMRPQmqp+Ukj6cVN+bYnm5r2HJ9OtPQHsKmt4xK4RPvfyq0Y1jhJA6cVEp2djOVRJ2KBQl/mHbpV2wjKjdjBqxC6TRF3XDg4wKtlVMcbr0B7VjOq9rHPUrP4WiCZEHJ44z0qm0KOgZDg55Oau3AdmLHkDpUZRhCNwxz1qIysiISstzFaNklJYY5pIgEyWPOavzoCpyKp3sZRBjvXXGfNodsZ82gpjWTDDBx6U+PBXI7cCoNMRhvZvumragIhH4iiWjsE9HygspUAVIxBHTntVYDLZNSM3YfTNQ0Q46hGiCXIPPXFSBhIxHcVCrAzIqjPP40/cqTHnGaGgaHlCvbOaFBU8gZp8sgKimhs/MTyanUhXtqPEeUJPGfeqn2keYybSVHGat+YNuD34qq8GXzzzTh/eKhb7RdREeMMOfeozvEmAcjvToW8uLacU5TkZ9ajYy2bAsB71VuIgWLKCeORnrUztg8VFICSNvXvVR0ZcNHcZaQEyb8AYGOO9XUiwS2KbayK2EDDIq7FGzEnqKipN31M6tR31KIUbnI7UI3Xd96rqRRpJ87YHXnuahlg3TPIPuMcjFJTTEpp6EJOcg8GiIbjuOCR0qWSD5Qx4QdTVbftO1egPQU1qtCl7y0JznGM80EZGD3p8EB4diAPrT3iGcjpU8yvYjmSdihKmDgc4pUgJ+bqBU0sLeYSowBUUEhErYPUYrS7a0NVJtaEMxZTheD3NKrsUwR1NSTL1J6UQoW4bhB0qrqxV1YryTZOEUY9TU0biUbjgEcGq9xH5cxx909KfbcKc9+lU0rXRbS5boWYpgknmkC4jDEZJ6CnNDtO9sbfQ0se5kVu2OlF9NBXVtCOVcj5mCj0qe2z5fHPPWqMocSZxketW7AEbgeAegNEl7o5r3SU/wAXJFEK7o+TnPepBtBPGTTHxwOQAO1Z3Mr9CJ4to6njpT/L+XcxOT0NBG1eeT14qTf91cjOO/Sm2xtsrooj3bufTikjK+WVYEk84pzOQQcAg05HUyKFGKepTbItgxkbs9KdghTgVbIXtgZ70saKc7sVPOQ6hWZOgGKjcYIXHPvT32ggZ5zSPKMpkE468VSuWrjXXYuSKiuBkKVOCKlnZWHB2jqD71F8zQtzn3q49yo9yJAd2Q341JdR+ZBkdai3MOePpU6yEoQMeoqndO5o7pplSFJIY8ucZ6CpAy43bQT7UTEuuT970qKFW3ZPC96vfVl76snkbavH6VRCyBskn86vqMoCTx2qNohng0RlYISS0HwMfKbPX1phxjJHFS7dijvTAefm7dKnzIvrdDRhuACOKcnC9AaUHDUuAeQfyobBstpIFU4AqG5QyHOPxpXJVDuxt/vUhm4QYJyOazSs7ozSs7oYISBkelWILWYKWMbgY9K3PBWkDVtSTzZo1it5QWVxw4xnGa9g1i60SGQnUhGIuB8iDPt06cV52LzH2E1TjHmZ5eNzT6vUVKMeZng8yO0SHB4qqQWUgAHHWvcR4c8NXlq2oRhp4snGxiqjnqa56y8J6Nd6lNJBK3k7/wDVMcEg9x7VnTzalZ8yasY086pWfNFq3ked6XH80rdwmKtXELfYeFyc5r03/hW482RrWYRRuMhX7+1Mh+H94SVlkhWMd2brUvM6MnzJkyzahJ8yZ55otlJdQsscbMxcBVAyTXSXHhHWI7BGW2fnkDvXZWlro3gi2Emo3i/am5BCZC/lzWX4m+IbafdWy2WxfNAlJIyHTHA9jXPLFVq9T9xHTzOaWNxGIq/7PG68/Ij0nwDd3VurXUi27Hkhhkj8Kl8WeBYbTRmuLGSR3h5lVudw9R6VkeI/ihdXtlHDpcAtGfHmOTub6A9hXSeBfGSa4v8AZWpIBdMhCv1Eg9CPWs6kcZTXtpbLoY1I4+lFV57J7f10PKzbYYqQQAaqTIjMEJ4B7ivQPFugvp1zJKIz5JGenFcVIQZMsme4x2r1MPiFVjzI9nC4lVo88TJmG3IQ/KPSmoSVIHOO9aUlupHzHBPSqkmyEFV6gZJrtjNNHfGakrIpr8uRgg1OB+69qrnc205+YnGMVaYeXEMkcc1cjSXQag8tiAMse9RlgrEnkipLaVXJz1709YBLMSxwgpXs9RXs3zCxKGUMwPPShgqruI781YkTbsA789aqXLlMKDktzURfM9CIvmeg2RvPAcjCjgCrauV2Fup6Cq1vCcN5nH405iWI7Y9BTlZ6IcknoiWRiXJwcdDipExwvf3qQW7eSu0kN3HrVe13GRjIoxu71F01oZXTWnQkOBnjJ6VDbRs8jFh8pOAa1TEnlNsx8tES8FQv6Vn7Sy0M/a2TsUVhRuCuB2NTxPIIjg9OlWUsprh1hiQsScgKOasvo1/HOqSW0i7uB8vWolVjs2ZyrQ2kzC+aTLN97rnNXbQtsA/g69K7ay+H9zc2W4sVlA3BDwKil8E6qAEEG0HjjnNc8sfQlpzHNLMsPL3VI5C9x5QVTx1qvbW7O+WGUHJxXoMHw9t2uoINQ1ER6hIpdbYHBx/jXS2HhPQbRDa3l3A913XzQpX2IrKWZUoK0bsxnmtGnG0Lv5HjkscrNk/dzgVIm5FClT75r1K80nwfC7CbUcMvUo2QprlvFehfY4YLq1cTWVwu6KUdGqqeOjUai01fuVSzCFVqDTV+5x125QNIp/CqUMgzuPc1entpNpbawUjg44qjHC2RGhPufWvTg48p61Nx5SX77L1we3rUgUqNuKijkAcgdO1Tb1JPJAFDuDuiJwrcNUaoqktJz6CpZIwZVJPGM1FJuJwB8tNFRHxOsrY5H41MQAwFV7aEknbwe2asoh8xdwJX196UrJ6CnZPQiaEnnB2+wqa3jBHAqadixG0FQOPxphJCKAeRUczaM+ZtDSBnDLgHpz1qu+BJyceuavJE0ylMjGPyrc0zw/t8M3+p3ceZFz5Yx1x3FZzrxpK8vT7zKeIhRV5PdpfecrcTRqhVV565p0TRvGjg9QapXG5lHTHpTbOVopAnWNjg+1dXJ7uh2+z93QuSRhVHv7dahVNrdM+wrrF0WSOzgu5QTG56H0+lXLy1sIYUnkTy1XHAXNcf1yK0WpwfX4J2Wpy2m2k17cCKBW345BHStOfw/ewqxZdx55FX9G1aFLotbKqlv7w5NdDdXRsYNzYZZs/JuxtJrmr4qrGaSRy4jGVoVFGMTz9NNkZGk2cgcCs6SN97JJkZ7V3NxC32IzBOc/w1hR2LPeK78AHJBrppYm92zqo4vmu5GFIm0AEHce5p0AKvhsbTXZT6Al7s+zqR6ntiqviHQIdMtont5BKzcMBTjjacmodWVHH0ptQ6s5C7QbiEPOeKZGuExnkVckg2Dce9MXADN2HWu1S00O9T92yKrglzj0poTA/eHI9KlTLlmPGe1McfMBmrT6GifQcvQDOQOgNOyME9aYR8pPSoxKVPHI70WuK19ibcScCmMMHpzSrJk4xzStnIz0pbAtCJupBqpJKythTxV903Hg1EYuecVcZJbmkZJbkpRy3lsSRV+x06a9uIreBC0jEACllhZbra3ChsE13vhe40fR4Dc6hMIWU4DMMlvZa4MViXSheCuzzMXi5Uqd4K7e1ilZ6HcabepbyzG33NkkcbmA+7WPqmufb7q6iZiFV9oOfTg1D8Q/GJ1y/WGzUR2tuxKOhwXY981x9q7CUndyefrU4bCTnFVa/xW2JwmBqVIKviNJW27Ha2PiJtHlgLkz2qcNAzfKwPXiuiu/Gmgx2DLYQSGUFXSRU2sT3HPYV5jJIJT83NII8xsSR7Vc8uo1GpSvf8y6mV0KrUp3v5dT0iP4gTXmpQT3DSLbRY2xh8njuata78TbyZtmmMYYsYYnBJryuGXyyzZ4IxQZ2ZcAYFT/ZVDmT5dif7Gw3Mny7fcber6zeaxN/pExbHQntVTVJhdC12Oz7I1DBhgqw6j6VnIxBqSOTa25h+VdkaMaduVbHfGhGnZQVrE6r0w1T2t7PZ3Kz28rRzxnKupwQapNKSxKVWkfL9ear2fNoyvZ86tI9v8FeJP+Ex0+fR9YuM6hjfA2APMx1H1ri9X0qeyu3jbgAnnvXHafdy2VzHLC7I6MGR1OGUjuDXt9okXjbw7BrCbDfIPLukTtIO5HbIwfxrxMTS+oVPaQ+CX4M+fxVH+zantYfw5b+T/wAjzG9i+4rnlecVSlt23MYwCvrW5qunyxTuZI2+91NWoNFuxZ/aEiZ0IzwM10rERjFO51RxUYRTvucnInkj/poe59KZKGEcJHQ11Nl4T1TV3ka1tSQnJzx+VVL7S2trpra6Uqynbj0rWOKpt8qd2bRxlJvlTu+piafbNK5OBgcfWrrRBPkz05OKsFBG6rEp2DgVcgiV513KCG44pTq63FUru/N0KEkQdYeOelVLyPDKBkMOnHQV6NpvgO6uzGzXCQKRkHqaxNW8O3VjNJ9ohZmT+IA4Brmp42k5cqkclLMKLlyqRyewx7eMuRTrOAyzhcEdz9K6fRfDs+sXUQdZo7PJ8yYJwPQA11N78PX0+3EthKbncMOHGCPTHrTqY+lB8repVXMqNN8jep56W2hjn24qvcIgnYYYD6967CPwhqruyGzdSrd+Kgu/AmuXPMNi5A6tnr9KUMXRv8SJhjaHNrNfeY9uVEAXqWHP1rU0PSJL6SURxyZA+UL3bsK7jwx4X07SdLhn1mPZdsCCJSCqg8D8aytR8VaFoJNrZTGYJkYj6knrzXFPFSqycKEW2efPGTqylTw0W33Oo8M+GU0u182N0lvX+9IR8qAdVH+NR6h4k0xNQjtZ547dl5DMuVRu+T715VqPjO/8t4bSZ7eBmJ2BjxWNLqzOso+VjcJhywyQRRHKqtR89Z7hDJq1V89d7npWo/FJvPli0+1QohIWVuSwHfHauT1L4keIZkZVvDChbgRKFOPc1w5kkiB2tg+tRIS7FnOfUV61LLMPT15b+up7dHKMNT15b+uptPruoXV3LcT3UkkjDDFzk4rr/BXhi48Qu9zLOViU8knLMf8ACvO4VXf17c133gjxKujkLKjvH0O084qcdTlCk/YKzJzGlOFF/VlZ+nQ1dV06DRZ7mKS0M9uflYse/sa1/AU1jeeH5dAvQzT5aSLc2eD6emKx/EHiIarDIqQpHg8dywrkLjV7lbwzW1wwuVURlk42j2NedTw9SvS5Z6P/AC2PJpYWriaPLPSW979Vseta/wCB3vo7ZbSaOIRRiPy2GAMd68r8S6PeaPcSQ3MZjc+3Uev0rT0nx5qHh+3dVJumnO5mmJJB9a6Hxoz+JPC2ka3FuBdWRkxnbg88/WnQVfCTjGp8DdrlYdYjBVIxq6wbtfz/AK7nmVqN29iBkDp6VZQK3zMOOtP+zhYwq/xdeP0qKUF5Sq8KvyjFes3zM9ty5noSypsViAef1qBByQ38Xf0q00oaADsOnrmmQQNI7t8oVRyxPT/GpTstSFKy1Io/k3fN0+79aW3lkMqoSGB/u9qlZot5XIEeDye9dF8ONFg1DWfLnUvlCUI6Z96irVjTpuclsRXrRpU5VJLYdovhi5u3WWZtozuAPequu+H7u01ZbeNDKJOQVHGSa9W0u3udr27wrvjJCsOhXOM1n6hqtvBqb20EBuJ4wDJID9zHOF9/evDhmFZ1G0ro+dhmdd1W0rrsQ+FfBcOmW7T6uglnPKIw4UY5+pq7rmr2kNxHp15GhjnXYg3BAARx7CsO88djSmj/ALQha5kmZmV0bAVR0AH8zXnfjrxWmv6jFNb2ot4402KCcsfcmro4Kvi6vNV27l4fAYnG1ueqtH1/yJPG+gPoGpJF1glTfE4IIYexHWpND8LyyxxXUowh+YCsm01e3hEAlSS5dfmjEjfu0P8Au1614f8AEmj6tDb2kL+XfSIA8bREKhAyxz6da9HF1cTh6SSV+7PUxtbFYWiopX7sbDZvdQRKxQRxLjDHj61heIjDZW0nzxyA8Hd/F9BWBr3il01WSKykZrGNiNpOPMI7+1Ov7q3t4rN7wu97NH5mxfuwqeAT6muSlg6kHGU9n0/E46OBqwlGU9n0/Eg063hmkM6r5cScktUd9fXlxCJ7aISwpJ8q8szAfxewqa61PSxbta6cs3mlcebc87j3GBwO9amma3pUzRwNILW7jXYZBgRtj0+veuuTnH33Bv8AyO2bnH944N+vREOj3lxeSeUYHjiYdGGADWmqxI4MwVsnacHkVNBLBte7muovs6DcWEowAenHr7VyeteIobEXVvpLLLKz8XmMYX0UGueFOVebUI2/rucsKc8TUcacbf13/pnZR2V1HY3AguFYRguY85YL6464rRsNPttQ0ZWlIaaNcsBzn6V45H4k1I3EUsty7SJwH6Nj6ivY/CqTXH2M9EuY/tBdOi54ZfTrzWWOwtTDRUpPXyMcwwdXCQUpSV2+hwer20LT+Wi7cE4ArnZg0bMp4wa7fxJYNbawyAZRskMO9cbfqVnbAz65r08HU54rU9fA1eeCs+hTaQ5IOMCq8LeZI/oOlLO/VR1PpUUA2SFexr0lHQ9WMfdHzkkBQcAUyBSASenvVtYt/wAwAOKZswSD19qSlpYFJWsQ5G7GcUE/Kc9KPLOTnoKUqGwCPlqtCtBySgDrSEqxyCalaOONBt61GVQnoKlNEpp6o9FuNf8AB6SrMtpeXjkEtGAI13e7GuG8R63ca/Pvmijhjj+WCGIYSJfQep9TWahGDg1LCFChgeR2PSuehg6dB8yu35s5sPgaWGfMrtrZt3sZ8kZQDNMUkHIqW4be5Ynv0qGvRW2p6i1WpKsh3CrKscH09Kpr94VYDHgYqZIiSElxjg0ISVx6cUKm+UgYxUqwc8c0m0hNpKwSttwAB701JM8Y596d5R9aSLdnaAMZ696nSxOlhwhYjPrUctuw5q8hXdgEE07HOCBtqOdoz9o0zMQNvG7Ndd4B12bwzrIvly0Djy54wfvL/wDWrB2Luyqgmh8JuUc55FRWjGtFwktGRXjGvB05LRnv8culeKLZ0sfLdphuUZwR9PX6VUbVbXw9dw2l26rEgwU3Dn614cb6eK2EFtI0a5DNtOMt60kkskj7mlklY43M5yc14qyXWzn7vY+fWQa2c/d7H01p99bXsRuLUkoeoIA4/DtXA+IPD01xqTujeY8nI9qg8DeK9Ns9INnqMjrO2Ar4yBXQN4i03St93e3UczMv7qCI5dj79gK8r2VbD1WoJ/dueL7GvhazjBPstNzjl8LX7uI/LPocjiui0jwLcm5je5kWOBeSepP0FNsvilBJOVu7FIYsHDoxbn3zWdr3xMnubWVNPtkt06CQtk11uONqPk5bHdKOYVHyctj0iSFdMgaeSYi3giLMzDniuWb4laOWCTIzxfxnb/nNcNqHjyW98Gw6fMWa9kdjNJnqoOQK4C8JIyP4jmtcJlHPf2+mptgsj57/AFi61srfme1a18VtNgiEOi25mlJ/5aLtQfgKwovHt6Zbi8mnZ5D8sEBGEBxy3HpXl1uu1tx5IGcVcN4gC5GO5xXespoQXLFXPSWS4aC5Yq/mz1PSvixdRW7R6tYie4/5ZSxHYCP9of4U/WPHby2UdzDJiUkfJnGBXlzXe5/kX5D0yKilmMjZY9O3apeV0ZSUuWxDyfDykpctjpvEniu+1iZ/OuXktFOUXG3P1Arj7rDyBkOPWpt4C4J96pTTANhBwPWvRw9CNJcsFY9XC4eNFctNWRNOSyBs5FNhuAq4PUc81XjmKgjrTSQ+ccV0KHRnUoaWZY8/zGJP5VajkAXO1QCOuM1lcg1Y80OUGMACiUOwSp9h4JMmQetXfNkgVT261TjdQ4A/Or5KvFtHbvWc+l0ZVOl0NOozSqVEjBSOcd6S2j23CMW4PUVVQhGI981PEW4I7elJxSVkS4KKtHQ0tQmR1IIUrjgY6V6T4ItbvWPAF1Z2j5kt7gSRjswK8qPfjNePzyuHbmvXPgdqSLb3FpJMiGRxtQ9WOOorzMzpuGG5l0aZ5GbUnDC80ejTOP1m0exmVJonR8kBcHk9zWZLdLGhA5du/pXu/jvT7e98P3N08S+dByHI5Izg14iYIDeuhHzKM8d6ywWKVeF5LVGWX4tYiF5LVEEUbAKpy24dvWrWppPa2MatDIFbnO3GTWv4Nsf7V1y1txEWj8wFznoo65r13V7/AEd7O7t5TERBGXZAm5lUcZA6nFZ4rGujUUeW5ni8wdCrGHLzdWfOxJkkdthUHgKOgr1H4Qy2umaPrF5M48yFQQT2XHT86wNNk8GRzT3Go6nLKp3bbeO3Yjkde3NWH8X6Qvhi50nRbG4hgclfPnxuf14FXi5TxEPZRg7XWtrfmXjZVMVT9jCnJK6u2rL8Tnrjxdqp/tKGyuJEjuHLkg/MoPUKewPen+FtVn8yRLm4CzlCkbSdGGOhNYjwxQwxPEzGRs792MdeMen41E8o7rgdvrXc8PTlBwjG1z0HhaUoOEI2v1t2Fkd2Zkkctgnqc9+1ZU5AlIHTNWpJF2nnk9qpkAnJrupxsejSjYQI7BmUZC9TWjaXJiRTvIccgqcEVn4Z2yo6VIEPU5zVTSkrMqaUlZnRaFol3qrGeyC/u2By3PNT6zpl7Hqcj6iu65lbgKcBj7e3tV34aTzw6sY4pWETJl0PQnPau78XNY25W5uERgEyrEjIPtXhYjF1KWJ9na6tp3PncVjqlDF+ytdNadzxmaNoZWWQFWHUehqhNzJkVe1XUPtl7LJwNzcH0FVEAZmOQcHGe1e3TuknI+hp8yinLcknECzj7K0jxgD5pFCtnHPA980ki/LxyTTRhWp5lAHHNPUeqsRWsayXcccjFEZgCwHIFe1eCtaW000WBxGUixDI4wA2TwT715VoNi17qaKjKAo3M5/hHrXRXKJeYNrOsqxkAkHOTnj8a8zMYRxFqcv+GPHzWEMTalJ7fgd9M9rrcLskqu0ABaQepOMVwvj22tLaS3W2YGRhk7fSrnh2eaS6nihRRGwaNyBjeRznP1FVPEOk3GoRrdWyl5l4ZO5H0rz8LTWHrpOVkv17nm4SksNiEpStFfr3OKbAY7jgjvUsUTMFYDA9aaIWMx3jG3qPWr0bAdF6fpXvylZaH0k52WgqqAo9KgkYicYHBqdTvY1HOpL9uRWS31Mo76lW7yT8nTPOKRBhAWOMDNSFBg5696Y65jA7jmtU9LGyelgDEnn86Rx8x5oj+9g8H1qTHoOKewXsUlcKMYoZjgAcCo5W3biBxUeWwPStlE6FHqPKgnNJIoFOjGepqUpuAFF7BezKy0hY5qYxFG6ZFQsPmODmqTuUmmPhfYT71bVmzx0qioORWgqrsUg8monYipYkUhgBmh0G07O9NjQnJbp2q2pQDkZNYN22OeTs9DPQEHjI5q7kMAPWptyKp+QZ96hEgjy2BwOKTlzdCXJy6COwh4JzVUzhm3HAx3qvcyFjjPFRocD3raNPS7N40tLsnjn46fMTxU0RK5LH8KhgXdJjvRPJtfaucZ4z3oau7IbSbsi4JztwDxSzSsEGTkn3qG1TcN74PtUYZDPhidveo5Vcz5Vf0LaTrlRJknHQd6sl0kt5TIPlI+XHY1lNIv2ghTuAOAasktINkQ9yPWplDYmVPZleSRV4BqzEY5UUn+HqKzmjO/BPJq5EuxTt7djWkkrGs4q2haBiVsoOPTrUDw4bfgYPQUBthBPTFJuL4Yn5fSoSaMkmhWdNpAOCBwKi8zAw3OPeop8K5OfwNPt18yUAdKvlSVzRRSVyERzStlFY/QVE6sHIYc11QeK3t9kYwM8nPJNVZjBcWxRY1Mmc7+4rOOId9tDOOJbfw6HOkc0AkHirc9u0QBGCWqBYSRluBXSpJq51KaauRUoqQoF6MCaGX0HFO47ixguQF/E1owoGU7m2471SskYzZX7o61piLMbcferCrKzsc9aVnYzmA83ru7HFKjtyB8qg0OhRyrAj0pGbnHQ1W5e5HcMTjNdL4E1FNM1WC7m3GKJtzhetc75RJ+fpU7gCAiPg9x61FaCqQdN9TKvCNWm6T2Z7pqesDxR4blk0t5GCOS0f9/n+led/YCbtgFJcg9PWpvhZr0Wl3wtr5m8uRgFU9MmvUb608O6Is2rX0imEvhMfeDf3QPWvmZOWAqSoxTae3mfJzcstqyoRTae3mUfC+lL4V8LX2p3Q8u6eA4z1GR8oH4mvGLi4vIppGaeVWIZS4YgkHqPxrsPGfjWfxDJ9ntW+zafH8yo3U49feuLS7RJUEw3oGDYPOeelehgaFSPNUqr3pdD0suw9WHNVrK8pdDtfA/wzOs6aL7UriS2ik/1UaAbiPU5rG8Z+FJvDF+IhL5kEnMUh4LD39xXsHhLxPpmpxpbWEqh44gzRYxtHSuC+NF5HNq9pbK4Z44yzjP3cniuXDYzE1MXyVNE76djjwmPxdXG+zq6J30tsjzi3Lv5gbqD271BKCW64qYNsJKH8abkZyw4Pf1Ne+t7n0y0dyqy4IwDz3NMClpFwflNOclpMdqibIc4rZG6LaYAwF69KvaTYSX99FAisd5yQOwHU1mpJkAHmvXPhL4fhuLKXUbs7XclE9gP/AK9cOOxH1ak5vf8AU87McV9Uouo99l6m3ZWtlDpKeYiWyIuFwME/jXkfiTU5b6+lQyl7dGwgB4xXb/FOWSyS3gjk/wBeCVKn+Eda8yk4XArgymhePt5O99jzclw14/WZO/Nt5FQoBuB69qWP5YyM9aVvmyaaemK97c+k3J1lQWzRiMFyfvn0oSONYcuwLencVApzUjEVLXYlxtsWrG/mtDL5BCGVPLJxzitPQtZTSobuJoWdp9u0jGARn1+tYBzuqd5Abcq6guTwfas6lKM1Zrcxq0IVFaS3t+B0+n+XY3rXEOpiVZnEYiTORk/Nkew7161axWr3kl3bxsUZAp7D0/8A115B4J0C61qd5LZMpbjJx1J9BXsmh3aW+nfZ71Vgks1HnKeo7183m9lJKLu1ufKZ3yqajGV5LR/oeN+LLT+y/EF9F5bRxltyqTnAPasjzCRgd+or1Dxa2maxqsbzIZCYx86ttCL2J98Vxsfhsvo0mrG7gSIMxVC3zMobA4969HC4uLpR9po9F8z1cHjYujH2uj0Xq/6RjofmBHcYptwcMT17VKkTZxwxP6VBMrbduOeprtVmz0I2bK7MScZpC4C88ADk07A5HoOtQXDfLjHGa2SubpX0CJw0oycDNXD8pINZag7gcc5q4WJPNVOJU46mcScmlY5ANBGTR29q2OgRDhhVpZAEIBxjp71WA+anPnHHSk1cmSTLEUnIBpDsZj0FQq21Pc05jmPIHSp5SeWzGSAq5qSOTC4Oc1GvzHJP50hHccVVr6FNX0ZdW4GMHgVG12d3yjiqynrkZ9KQgmp5ESqcbls3z4x2qE3BbI9ajZT9RSEYpqMVsNQitgwWPSngAHmpIh8mQdv1pkxzggk++MUXu7Dvd2JoeGJJIwM/Wo7icSSAhcAU3cxAwcdjSbTihJXuyVFXux6MxOAT83Yd6UKBIAxOO+KVYgqBt3J7VHIxPApb7AtXoRgkNkVeRtluRyrEYzmqcIBcZ6VbmPygdR2on0QT1aRDbozSDgkLyTViV0U4jJYnqT/Kq6upYgE7aUDPtmk1d6ktXd2TXUxlcPgDjGBVYh8grU6jkL3p7IoI6lu9JNR0Emo6FdIy7ZbJatDyvsscZI/eSfdHoPWq9u3lXDDAIUc57VpvsnMci/wJgCs6knddjKrN3XYhlB2pnnI6VGPkJzxU8aFpBg5JPejWIljTKHnPas01dRMoyXMo9yhIwJzg7ahuXAAK5FWQvm2hYMAEwMtwMnsKqbDIwQnhfxreNjphb7hB0GR+VGCFY44qSf8AdIo45GOKiznoc8Va11LWupoWQRIgMrvf9KuTbjEMDj1FYiSuo9quw3uU2YNYTpu9zCpSd7obfEkLVdPmcE8mrNy2VB9arBsLtUEk96uOxpD4bExkB5PI7moomLS5HIp17ldqgYOB0pYQIowedxPH0pq1rgrcty4zmOMN90noe9aNxq97qVrHbahOXhM3nHI5DYA/LArGuplkEKjO5TzQ9wTMoHasXSUrNrUwdFSs2tV+BLcv+/k2cKOxPas6Rm83J/KtCVC67jgkdahf58KVGR6VpBpGtNpF3RtTudLukurRsSLkEHowPUGkupbi9llubuQvLKcljVFjt4yBih7lsYUmp9mubnS17keyXNzxWvcN4RwCwx6Clup/NO0DCZ4FVlGXz1NTORy3QCtXFXNnFJoqMT5hI9akxvb3700OOpGKaGw2RWljWxYiIVmIGfSva/AHiCwtPDMEM9xEmFYNn+H614cCc1NEz/dDEA+hrhx2CWLgoydjzsxwEcbTUJO1nc6XxRqb6tq0k+4mFcrEPQVhswxR5hJKdlFN2GRfl5PpV06apxUVsjWlSjSgoLZFZ8dajI5p7HBKnORTR3NdSOtaCIpB5BxUxjII3DmolLDuamZywy3pik7ile4xjk89e9K5JG3260qDIHvW3o2i3GpvHBZRF7hzk+gHvWdSpGmry2MqlWNJc0tEafhjXr7R9EZNLnNs7SfvpSgIAPTFM07VL6+1CHT4ZmP2uYLJIxwZMnv7V2+ifC7zLYpql66SnkJEMgfXNYtl4Ol0/wAeJaTS5gtAt08wH8APp61431rCTdRx31e39XPA+uYKbqSjbm1d7f1cp/ENriO/W2lXZ5aBHKDCsQOo/Cuegu7q4sI7dypt7clkAHOfevT/AB1pv/CR6lEsDxkxry8fT/aPp6Vgah4bXTtNWG2LSEAvI+P4s9M/SowuMpKjCEvi/rUjB46iqEKcvi/rU4+JmMwyMHoabOVbdtGTmrc8Jt03MPmbgZ7CorSzeRWOOO5r0VJfEeopx+Iz8LMBsR1AHzE/3v8ACo541ZcnPWtGSMQRbQc5PPvVRsGNwSfatozvqjeE76oqrCF+YnnoKhfKsRk1IMl8MMe9K5XPTNbJs6E2nqUcHGTSYqRVJBpABk5rW5vcj70obnmlYU3aaYxzEEgA8VIinHXIqFevIp4BxjNJiaF2DGATmlYYUcUoB3YomY7dvbrS6k9RBgigkABs/hTF+659qWLnK9qdh2Bnyc0oG4c4prJjGKmhgZyMDPoKG0kDaSFDFhtpzEKlJcL5Xyt9+otxK46iptfUhK+o8LuGcYFIgBBLcCmrKVG3GfamsTnOMe1OzKsyd2VkHt2qvnJqQDKAj72cClKgD5h8w4xQtAWg6JPlLDrTZSHOBkipsoqBEYt6moyfnxUp63JT1uN8lghYqcDrUqoSwbHAo8w/dJ49PWlWQJJuVj6YPpSbYm2ya2G5wCBg8ZNW540spl80ZMalmz3J6CqsS77gZPyj5jj0qPUbh7mZgeOcnms2nKVuhi4uU7dBsl0skKxKoB3FmPrWppoQRDeM9qw4U/fKCcj1rdjPlwg+vSlWSSshYhJLlRdYRJGXGcjoKyNUn3RqBnOckU+4uizBOy9SKo3UnmNwM+tRSptO7IoUmmmySwtp72C4SFd/lgSMuegHWomyjZAxx0rQ8NzLDdzIwBEqBee3NUdRuFkuZTg53EdK1Tk6jjbQ2UpOq420IZF8yPPQj3qNGVYipGSe/pTPMIBAPBpmea3SOhR6FrYSOOR1p0KHcMdqgWQg4PIq7buiDe3boKiV0jOd4oS7UmMbyc+lRLlVQnjstTNIZSWbp3NVzJ5smW4x0qY3tYUb2sy1eFdy/wB6orgq1soVT5oPXPamiJmO7JPf6UoxtAI565oStYSSVrdCOH7wLHihjtm4p2M844oZDgbearqX1J3uP3fXmqnmEDOeT6Ukm7dhhgdqaoBOM8U4xSCMEkDSnbgU3cTxVnYiwtkAt2qBEA5b8qaaKTQ0ErnjmpsloBk96mtLZ7mXYgGQCajvl8m6aNTkJxx60uZN8vUXMnLl6kBHA96RF+anna6g/hSwxlplQHGTiqvoVfQkjt5JQXVSQOOKkFtLHh2UgZrTneKxtFjy7M38PTP/ANaso3cokYg4B/hxxWEZSnqtjnjOdTVbE0IHLNnmmPKoYkHHpipUuIplw2VYjn6/4VXFuS5XcA3amt/eGt3zFZ8lyT1pMkcVIyldwJBYHGKjGWrZHQiQNhP605jhUXueTTEQkhT3NKTkE9GHakTYehJkABHWvR/hrfW1lq5SZwhdcBmPFeZxFi4wea0FnznaSD61y4zD+3g6b6nHjsN9Ypuk3ufR+o+JtK0qI3F1dxnC5Cq2WPsBXiXifxPc6zrF1eR77aKZRH5at1QdAa5hWO/c5J+pzU7SZbJHbFcGEyynhnzN8zPOwWUU8I+Zvmf9dDpvhxqUFv4kigv5JFjlBjhcudsbnpkdMHpXd6ybhLC00q0XzHSeRJ5B65HB/nXiszfvExwV9K9K8JakXsYt1+EuZZVZ2mOVI6dRyD0+tZZjhbSVeP3fqYZrg7TWJj93n0Zc1nw0xTcf4B8x9KbqGhLYaA88bjeQMD610OqXu7Wksbi7t7a2T5p1LYaQnp9BXWxaXp9/YxeUFntu2DkZ/DvXkfW6sFHm23PD+u1oRhzPTf5Hz/eWsqRq7xvtJ+9tOPzrIO5ig5HpX0b4r0n+0PDk+mQoqLgNEQMbXHIP06ivn64DW8jxlcSA7SfTHpXtYDGLERelmj6DLcesVFq1milMoXOOWqsck1fuY87ABgkZqNYlAwetenGSsetGasZJf04FNU80rDPNNrqR2ocDnilXO7GaRMbTnrSGgRLMoVR6mot2MGkyaShIaViXqN2fmoyMZYEmowTxTyMD5qVhWGZPOO9SW4y/Xmoj1pyEhhTew3sWZlG3KcmmeayKME5pQGPGR7mpVtR5e5gSPU8VndLcyuktSAsCVLElu+ac53LwPl6mkZkYYxz2pDgkKvb+dMojAPJxjPSliXdIAakVRvwxqzHBGeUlBbtxQ5WFKdhhMaoGGQ3Sq7vgevvUjRFZWDHOBmq7ghqIpBFIdGWZgAe9TrE+/dtO2ordWMqkAnHNaEVzj5esfWlNtbCqSa2KDhyx7j2pmTnrUjN8zepNNVeapMpMvaaxYSIrDzDgjPfHUVUlBjYjHNIhMbApwwOQa2bhY5LKS4jC+YcAoTyD3IrKT5JX7mMpckr9GZmnwGaXA6VsTkCFVGMAZqnpbCGFpPXiku5id2eMcdazneczKpedS3YpyP5su1ePUjvUxjAj+XG6obdDuJzgmlkLB+DWrXRG73siW1LRXMT4GNwBHqM0zVlQanc7B8m88Vd0aOOXUIo7psITkEdyKz7lJJLmYHOS54/Gpi/3nyIg/wB4/QpsBnjpSqhbGOacY2XcGU5FWrWNpIz5KbmA5AreUrK50SlZXKoiO5R/Kr9jZvcMVfIVR37VNpdlNJMpAyw6ADJBq5qsoiQxoSHfh2H61zzqty5I7nNUrNy5I7mNelUkMMLZRT97+8ahiIyaYVw5C81LCFDAEZJ4re1lY6LWjY0LR0ihIkBO7k1FLKjzHywAp61BOzJuTkAcDNQwuVYbhkVmofaMlTveRauR3HCDjioRIMDGaW4IkPy5ApkI2vz0PWqS0Kivd1IpSS3PFMBq9qAjKI0fbg8VRq4u6NIPmVyxEwKHPQUxpFzwDiiIjoKJ+Xyq4GKVtQtqWLO4MRYxg7jwfpTbhT5rFGEinnNQkFYgB1PWm8qOM5pcqvdEqKvdE8axgHzjgnp7Gr9uLeyt1nf99MeQOwqlZWzTy4c7UA3MT6U+4cSEEDCDgD0FRNcz5bmc1zPlv6jLieS4lMshyzenQD0qvMzE7SelSNICTximSDcoIFaRVjWKS0sRgZIxVtbuSIEo+GI5yAc+9V4x8pJpjHmm0paMbSloya4B3hgdwI+9601XC9s+1S2s6RrJ5sYkyPlB7H1qqTzQl0YJPZmtYWy3srMTiNRzzjFUDkyH8s+vvUIY5zk5q1hSobsR0qLOLI5XF3voR9WwnBNTABBjOSe9VyBuJFSRDdgHjPU02OSF398/T6VPC++NzlQUHc8n6VV2r5hGeKkRwqsFGc96TQpRTWg3q+elaFncmBBhmyDkYNZnI5pGlbdxRKHOrClT51Zmo11Pe30tzdSvJK5yzMeTWxo+r6npxcabezx+b8pRG+9+FczayMJNzDIra0G/NhqMd0UWQKfut0rmr0lytWT8jlxNJcjXKmktj27wL4ml1+za2njYXdquJjJ3NeZ+LtGmtNYZGTBlHmcdOean+HXiEW/js7gBb3u6OT3ODhq9QnuvD+oCW3vbi2lUcEBhlD357fSvnZ82AxDcY6NX/r5ny1Tmy3FNxj7sknbt/wAMzw37I53MFZgB2HQVB5ZH3hg17qLnwjo1ylh5ltHNcfMA/OM9MntVHV/AtleXQntSIkdASqkYz6j2rojmqT9+LSezOqGcpP8AeRaT2Z865zzSd6VME4Y4FOdcH1r6c+vEyNuO9NxzQOtC9etAC9KAATSOSTzUkIywz36YoDZXI8Y5oY5+tTSxlDg1CVxQncSaY2n7vlxTTRTKJeWxk1LdTmXaoJAAANRKTswOp70mKiyuRZXuIOAW/AUq5AJHU00jilBKjFUMmLr8rdG9qI5CGOwZNQE0isVPynFLlFyaF2Ib3fJy2KSeJRAGc/N0X3qC2laGQSDBx2PQ0k8plYE8AdBU8r5iOV83kWtPP7qcEHkAZHapr2ye3Ma4O513VFaruEIXjcwBHqa6LWBGnkksAqrxntXPUqOM0l1OarVcKiS6nMSxlDhutNDFehp1y25y1QhieuTXQtVqdUVdaj87u3NMdiQDk5HvTg208DNA2tuY/lT2Hsa1oyx26pcY3su/6LWbczrJKAgwgpjSkxbR17/Soc9wKiNOzbZEKdm5MmU5P3sGpMZH3uRUMYJIAqUMY8jHNU12Ka7E9sSrq/dRn61sBPMSOSCMGVxtDMen1Nc/5h4H5gVbbUpUcbCBGBgDFYVKcpPQ56tKUneJLdRvOrF2RpVOAyHOfrS2UU1tIwhiZnZOXBwo9zWfLcNNKD0AOcinS3U0se15HKemeKr2crWK9nLl5ehtWF/BpSzYkM1zICrOnQe2fSsvUL8zlQEAULgD0qoRlcVHsOPenCjFS5nuOFCEZc73GlizZq/pNo11PklVjTliTjPsKqxRHqRwOST2pXkXGFJC1pK7Voms7yXLElvirTnawI7YPSoFGAST0pAQfpQeF4zTSsrDSsrDoH/ejd0NHWQ85Ge1Nx83PWpI3XYRgfWh9wfdEk7ho1QKABVUj0qdjkd8npVck7v6CiKCCsT20WAXk4QfrSvTJ3Z2GeABwKYCxbrRZvVhZvVjmO0U0H1FD/pVi0j3oxIobsrg2krs0dIvIz+6uYxtIIVwe/vVe9jWKQoGBGMj2pgXyI2fj2FZ8jl2JNZRp3k5IxhTTm5R2FcgninK2BxUNOQkHit7HS0Tj/VAelVz1q4iZhb2qm3WlFkwd7k0S4QvjJqI9TT43wNp6GmEEdRimtxrccgHU1fePy4sEhs9vSqSKzcqMnNaFxKI55EI5Ygn8qzne6SMqjd0kVJY8EBQcGhAcMe+OBVmPbIjD+L+QpVjTnYcsByKnn6Mnn6MzehFSr907eQOT7UlzjzMKMU0AhTg9e1a7o23Qu7dnHalVRIV7YHNMQNwRUgQEjZmh6A9CTowx90ipllyuB0qBUOeSaVwUAweO9ZtJmbSehYtb02lyssZ2yocqw7GrCyeZECGIXdv5PU1mEBiD3qUk4Az04qZQTd1uTKmm7rcv3bvcXPmzPudjkk9a9b0rxzpllplrBdSu0qRgHAzXjKy8cnkU2SX5uK48TgYYlKM+nY8/F5dDFqMZ7LsUhy2akkYGMYqEdacSMYr02j2GgGApJ6npTaX0pBTAliQzM3TKrmpgfKC5X5uw/rTtLKi5wwyrDFSRuGlffjcSeTWUpa2MpS1a6EMhaVgBy3c0SQ7DtYHd2qSN0UNjr1zTJpsktzu6DPakr3shJu9kQPGR1BBpgXJqynzRgsMnpmopDtOMAVab2NFJ7Dfummuc9KC2etNqrFJCg0pPFKi5qRYy5wlJtITaREAMHmmVJKFzhAcD170zFNDQUDniggg1dsYAx3uehwAOpNKUlFXFKSirsmsYmiliYkB/vc9FHqam1OeOUKkDMyJwWY/ePt7VDqVxE7rHAgjjQYbnO9vU1V84bAMDPSsVFyamznUHJqbFVC4xySOlRnCtjvT1cc8kHtTAoLbvxrRGy8x9sQ0oBGc0rRnewxTYI5GuF2qQc+lW7/MT/Ku0ep70m7SsiJO0rIpuhH1pNvyjHWrNvH5mSSPWnyQLwTxjrRz2dg57OxXBCYz27VHKx3EnvzU7PEoKgbj6iop87VyeOw9Kcdyo7kW40hP5UFSBk0bTV6GmgKcNnqDSyHBwOlKq496HU5FLqLS4iyHgYFW4gmeScYqtGmOT0qzgsBtP4VMiJ2B5MRMg5U9jVZY9ynAqWXIzkYpsbEA4OKFotAjotCGNdz4PSrMcZBZv4AP1pFUZyaspKrQvFtB3jH0pSk+gpyfQoSYDnnNNDYNWLiNU27eoHNVj1q4u6NItNExdQAVyWqMA/e7CrNgiMSZBnjFOuYBDbIp/wBY7Fse1TzJPlI50nyldjkAnvQpxzTArHgZOKWM7XG4ZHcVViraDnX0q9ZKVgPqTUCMs0gRF2g1cVNq7OgHSspy0sY1JaWZDe4FvgfeB5rLrVvUJjwKy8HNVS2Lo/CJTk+9T2B2KMfjSRD560ua30LkWFU56MMVSkUqxBrSA4QdDUF+gBBAxnrWUJamMJe8UgM1YU5TH8PeoSQAMfjQj7e2RWrVzVq5f07AuJG+5iNjkduKpyPuOckn3pRM24noCMfhUXAJyKlR1uSo2bbLUDEpgHBPU0uSHG0nP86iX5I/MBB7Y71H5jUuW7Fy3eg6RSZTznmnqcKc9qjU4OT+FPkIMfB5zzTfYp9h6uducYFSQMpdSF4HWq+75cc1ZsdmW3kD0qZKyM5qyuSzYEp52heQapBiSVznmr0sJlGC2F/hbtVMxBHOGDY7ilBqwqbVhFBZwBTiwJwBz0o+6SynBNLBIqrISPmC8fWqfcp9yDJDHmncn3qLDHnBp28iqsaNEdFLg0YPpVFCUoGaCCOvFFAEkUmyRW9Kd5mZNwA61DUqKGwQealpbktLcV8EEjINRDOeamZCq5PfpUOcUIEWI5iibAOO+ahlbcc96QEHrTiuaEkhJJO435ce9IwA6HNIRg0VRRLFlsKoy1XY4trCEEFm+9VCMsvzLwR3qzZv8x/vYOKzmn0M6ie6FniQTssfQdKrSHDYP5VIrYPYH1qBiWbJ604ocU+pYjIYcKOKmnkMECoh+duWYfyqmj7c470srMVUE8DpScbsThdkZOTzSUUpFaGoAmno+KjoosKxeSZwgAc49KinkdyNzE46U6xdRcR+ZjbnnNadppf2qa7TOHjj81R6isJSjTd2YTnGk7yMm3cxtnPWrjSFl2s4T37Vbt9NjljVVkXJ5yf6VHeWa2bqGcOfQdhUOpCUrdTN1YTlZbmQ5wxAJxTRWk0MDFmGSg9ucVRmYM2VAC9hW8ZXOiM+YbnK46n1p8S7wRn3AqUQRFN32lFPoQc037OnBE60cyDmRcXTrgWK3ZjIgJwG9alubby5EikUAlA/4GtbRtafTtMkjeOO5QpsUOM7R7VhXV688rOwAJGB7CuWEqkptNaI44Sqzm1JaLZkcz/MxAG30NLp/nXFwkEAXfIcKvqapsxfOOasWSyxTRTIxQowKsOxrocbROmUbRfc6XxDplnpliII0kkvCQzzufl9wBXLqjNKAnJJxit/VNVCyeZasfPkOZkblc+uPU1LbTabfab5kkMcF8pIOzjII64rjpTnSgnNN3/r7jiozqUaac03f+tuxzMp2vhMlR39afHcKp+5k4qzbwPLJtRdxHr0xV/xDYrp0kMURUFo95GORnpmul1I8yg92dTqx5lTe7Ma4fzDkHPvioCpp/Ic5I+tWreNvKe4CEqnAOO9aX5Ua35EX9KtFKv5hwsY8yT/AGQO31rNurhru5aTG0HhF9B6VY03zWiu0UtiROT6moGiWKMAsC/oO1ZRVptsxirTbb1I8Mj7VFRgjJyOamVDtLHgDrUZTb8+DtJ4rVM2TRNZACcHj8auuPQ5FUYZMSbhj0rRjIeJux61lU3uY1b3uQTHKZwcjtWZJ/rDWrcEAHnBxWT1ck9KukaUdiQRswBFWLO3ZpASOKW3GQcHk9q1LRVMTLkB1+771NSo0iKtVxREYMMfTFULvnr2rauAqk4PNZN2QN3ce9ZUpXZlRld3M4j5sCkI7U4thuO1NJy2TXYdwoGRSfWnA54zgUYLnAoC4+BQ4KHqelNeMoDu4OelXLOFUV3dv3i/dWq3zMWL5Pc5qFLV2M1K7dhbfGyUtyQuR9ahwetOQ4BFSAhIiT1PSq2K2ZEp9etODFT1pitQRzxTsOxP8zDknb6UknDYHanx7eFqSeFHI2ferO9nqZ3SepVLDIA6U7dgHHWmFShINI3WrsXZMcHP4UqqD1z+dM7AVIp46UMGCny3wCCKkSRTJkjrVQmrEOGjYEZPalJdRSWlxkp3N9KhrWFssgBQjJGCD1FZ9zA1vKUfr1xShNPQITT0IasWwGRkZBNQAE5wKsWp4x3JqpbFT2FkibPGeabNbtEoZiOfStS2hZlYKhcry2Ow9aragoEXp079feso1LuxhGq3LlKLR4QNkYPSpF2+UcfeqAAlTjoKdGTkYrVo3aEbOeaegYsAOSaeYyw3UqoCwBzntilcTloNuQI9qDr3+tLb5+V1Gdh+b6VHOcvjHTjmiF2jbcpII7ii2gW90mmRTIdpwD0zUBTGfap5bhZ3LyRgOeu04B/CoCxwRRG9tRRvbUaaGOQKOAMGjHyVRY2lpKWmMKSiigBa19O1ExXsM4wGC7GyeCOlY9Sg4AwMmonBTVmZ1IKaszXuJlWQSRKTGO3YVVFzu3s+T79a6SC0jsdGWO5RQ7r5ju/RAeg+tclwZHVW+U9zXNRlGd7dDkoSjUvZbdQkmkySp2qwwQOhFQgM3OOKkcZAxnFIuVGB0rpWmx2KyWhHjHWl60OcmhRk4qiidJGCYHT0prK8km1FLMewGalsrU3ExTO1FG53PRRUlxfBB5VkPLiH8X8T+5rNvW0TJv3rRWo1dOuP4gif7zgVdWyu3iWMNCQOmJRmsn7xy3J9TT0UYz6GlKMn1/D/AIJMoye7X3f8E0ZtHvOrwsT65zVKSzuEkwYnAB9Ks211NJKAssiqv+1Vj+1LmNjskJHo3NZqVRaaGSlVi7aMTSpTBP5k4JWMb9p7kVmX15PfXUlxcOXkc5J9PaugtdejkxFqdlDNAeDgbW+oNZWqnTGUmwWaOTd91jkY+tKk37R80de+6FRbVRucNe+6KMZf7ynBHepVublPuTMB7HiktrWaYArwh7mtaXT7MzRxxzyKqDMjOuRnHatJ1IxdmbVKkIuz1EFyY7KISkNNLlmOOQO1Z8luyr5uPlPQnvSssst1koQvQZrorixhudKtsTIrwEq6dC2ehFYymqTXmc8qiotef9f8A58RM8UEaD55CW/oKffSIqC2iAKp1b1NWr155Nifuo4412ggfMB7mqKi3UEPIznttFXF31ZcXzWbKGSp4q7bzHZ15qrIo3EqMD0pYldVMqj5FPfpmt5JNHTJKSLN23ygDqapDqKluHLfNj7w/KoDkcUQVkFNWRet8Yz6dauWjYOc96zInx39quQNt59OlZVImNSJYuHZZTjPBqtfn91Hj+InmrKguu5Rk1V1XKiEHqB0qYfEkRT+JIolOlNIy3HShjnFOB2jFdJ2F3SrJrqfaoyi8ux6AVHfvEspjtyCoPLDv9K0NMcQaZPPI5ETMF8v++fesaQguzAAAnoOlYwvKbb2RhC86jb2QQytFIHQ/MPWppZGl+8ffiq461PHgqB+VayS3NZJXuMVCTkdadOhADHoPlqxHGY8swy3Zf8AGoLk5lCnkAdvWpTuyVK70IkXLc9KlkiMeCc47U1OnFTygtAuTnFNvUbk7lYgj5qWKUq+TQoO04phX86ZWj0Y6ZwzHb0qMUlL3ppWGlYeMFvSp/MVABjtnpUMQUuN5wvc1LNEpf5WBXtUu17MiVr2ZDJGUGcfL0zRCwVxknb3p0su9cYA5qGqWq1KWq1NKO4TBDAuMHoe/rVGQ5OaarEHipHkDYJUcCpUeV6EqHK9BbaXymOQCp6ipnVUkVkIwxyKqZpwJXBHIocdbjcdbmtZ3jW6yZ+ZXX8qoX0wlc7SSOuTUSzFVIqNhipjTSlciFJRlzCAkZx3qaDBfJPFQU9WxzWjVzVq6NDcygrswcZ571UaVgxY9c0vnyZDDsKidy9RGNtzOMLbkwkSXicEN0Dj+tQOAGIByBSLnoKD1qkrFpWHoo2E9xTD7U5QcGmEmmMSp7eFrh/LjxvPQE4zUPWpIUZ2+Xt39KHsEthChXIYcigxOEDFSFPQ44Na8ukTpEZ3eOVcbiY3B49TVV5TGsbLyuMFDyKyjVUvh1MY1lL4dSJbGRrNrgcheSvcD1qnWzHqi2uTEgk3IUKHhce9Y561VNyd+ZFUpTd+ZegldR4YsrSPbe6o6oi8xqe59cVzK/eFTPKzyBmOccgelTWg6keVOxNenKrHkTtc19e1RtSvXO3bCpwi/wBTWSU2844qPzCWLHqakWZsUQpqnFRjsFOkqUVGK0RIsblQSMKehPeoZTt4pXJJHOPekdlaPod+atFpERPFKnDDNG0gZPSlAx1qiy614sdi8ESYaQ5dj/KqUbAE560+QKQMCmEetTFJERiktOo9mHBFIDtGfTvSxxbsfN160+UkoIoxkA5JHei/QLrYS3fZLkjKnr704NluaiClCc8U0saLXDlu7lggdjxVdxknFKXOKSKNpXCr1NNK2o0raskjuJo0xHIQKet1NtbMjc9DUotliQmZgCBwKru67cCp92WyIXLLZCied25lbP1q7Hd3AQDzTx0yM4qjEvPPWpwVVTnrUzSfQU4xeljofDt3HeSOuqtbtEV2uG+ViPY1k6/b2VreEadKZIfrnH41mCQnAIAH0qRGzkdRWcaPJUc09O3Qxjh/Z1HNPTt0NDTtIkuolnLqIieQOtLrEEaBVjkBVf4V6VnrI6xGNZWWEnJUGmGbPBGF9BVck3LmbL9nNz5m9Bu792FPUVGw6HsaezBicVEfTtWyOhIsGLCblOaljlVlVcYIPNVA7AYBOKdCTvGaTjpqS46am1D8i565NZ2q83BbselalsQIQWA5xzWbqGHuDgcVz0vjOai/fKI5PWk5qe2tpLiYRxLlj71pXOjSRSIgcE4yx2kYPoK3lUjF2bOiVaEHZszopSYPJJ+UNuFROpU9OKuXFukUuxGO5R8xYcVC5YYGQfehNboIyT1RX6n3qRjsA28GkI+bAGTTGzmr3L3NURm4thIqvvUEsxPBqi0ZKbiD9atR6giWsUCRk45ck9T6fSrDO1zARJIqBV3BSP0Fc6cobrQ5k5Qeq0MgsRT/AD2xjtUbDk0yuiyZ02TJQ5HIpeoz3qKnBjjB6UWHYRhikxxmijtTGPVv3ZXjJpVcgYFNAyatokCoPMyWPPFRJpESaRSPWkooqywooooAKdnim0UAFLSUoHegANFJT4kaRwq8k0BsPXIX1B61HjmnNkfWmgFjgcmkhItlCB5ZQZHepEs/lDuRg8e4ptq6xZVpMHHRalNyhbIOQRjmsW5X0OeTlsiC4i8ttucrjOaqHrV+eEm1ScOpUnbjPIP0qrCq+Yvmfd74q4S0NIS0uRAc1s+H4POW4XgOVGwnv7VkzJ5cpQ9PWlhuJYnVo3YFenNFSLnG0QqxdSFos2b1jaX0sQXy1+6V9CRWPOzbsNwR2qa8upLyV5p23Svyx9aqysWYE9cYqaUHFK+5NGDilfcZRRRWxuOX7wz0qZmQDpk0loQLhNyhl9DW0tlZv8zjy2/u561lUqKD1MKtVQepgdaB0qSVQJWA6A8U0gAH1rS5te4u47QOMUHGDxSJ1GRnHapJHbyynGCc9KRL0GgfuzkZPanxRhvvZzUcbYIDfdq/CuXBGCD1qZOxM5cpFNakKdrDI6571EqgLyMkVNPM6ydtg4A9agaZndi2Mt3pR5mtSY8zWo0hS4wcL3p3Kn5TgdveljA8on1OKbMQmFXg461XWxe7sRsx3ZzzTTSYp23gGq2L2DBIHFTw/IM5w1MXlgvrSjk1L1JlqOlBcEknNV+Ohq3jCmq0i4NEWKD6Fja3lgjn6UiAg4ccnjmmwvuG05z606Quq4AODS12Js9iKT72BzimgkHg1JEyqDuXrxmowMkiqRohVUuQo60FDuwaaDg96fkjBNAO44fKhwBio2/nTpJN2MDHrUZ9TQkCQlOjJDDFIKOn1qhmmt7mBYgANvU+tVppQXY459c96rA04Asw4rNQUTNU4xZf0m7S18zzCUZuQ4GT9BVmbWllbkS+7k5Y1jyHcelNCnr2qXRhJ8z3IdCEpc0ty3IPtFziEj5hySaRhbxKy7mdx3HSq3O0gDikOMe/pV8vQ05el9BFYhsinnDFifwqPHNWT/x7k7QABimym7DoYo40Ekkilj91F5P1PpRIdybiSRntTYgFhJI61CGYDGfl9KlK7uQld3GHrRwaUjmm1oaigE9KUgjGe9SW3Ey5BI74qe+QLIzD7vGDnrUuVnYhytKxTpV5PNBFCiqLHE7ehpGck9aRhzSUrCsJRRRTGFFLilU4NABigilJGOKTjFIQKM0/jYeM1GvWpAOD6UMGRmrulRsZnlAysSFm/KqiLk4rQilS3sZ4VceZNgH6VFR6WRnVb5bLqUD70sZxuPTjinyoIeDhn7j0qIkt1qlqi1qhvQ5FX9KhS5uMTHAVdwwOp9DVEA59xViO58uRmjXYrdgc4pTTasiaibjaO5t6n5KQKiKiDG7AO7nsK5+QjccDAqW4mDjCZ29ye9VzUUqfItSKFPkWpJM/meXkcqu361HtNLk0uSRitdjXYUjp70SRso3EHb0zREVViW7dKHlZgRk4PUUtbhrcioooqii1YyFZQuCQTyAMk4rVjgkBee6+/wBFTP3RWNbzPbyb4iA2MZxStcTSElpGJ+tYzpuT0MKlNyeg2Q5kY9iaa4AxzQelNJzWqNkh8X3snpUzfMvAqGI4NP3EH+VJ7ktaibQq+9TRztGw29PSkXLjnHNIYypKnGfapdnoyXZ6MdO/mSAkgZ7Co9nOBnikcbSCp5HpUkYLDPejZBstCxZWxmRxnOO3vVK5AWdgpJA4561Mu9A6KeCOeaiMTPzjtzSjo22xR0k22ECg/NkbhyARmpVhJODUEZKHitLz/MijZ15QfmPSiba2Co2noZxBD/L+dPQYY07ehYnb+tPHlnpkU2xtkbE4x6VEeTzVyKAyyhUK8/xMcAe5pLm3RT+6cPjjcOAfpSU0nYSmk7EMEe45GQetWZFO1kCnLdTVhY44ljkBDjH5GojcIp+ZQc9CazcnJ6GTm5O6KMkUigbjj2qEE5471sSgSxqVT5ox909xWd5ayS4X5Qeue1aQndamsKl1qNZenHWlVcg5NLOyqdinO3vTE656VXQroDp1pjgjAPpUzORgdqY5DHjimmxpsYOBSAcZpQpIzyaU8dqZQi8NzU8TjO0DIqE9MClik2Z4zSauJq6JCAXIHX3pi/e9RTGbLZHU0m8544osJRLUZwrYA57VHKo8pWAwwJDHPX0qLcc5HFPLMYyCBjPWlazuHLZ3IwelTF2TqAyMOQaiUAsA3A7mrssMLhBDOGPA2niiTS3FNpPUZOv7lNg+UjioAoPB+8O1XI3SJyhIZUGAf51RkKlzsztzxmlC+woXegjgDAHWm085ChieT0p8Um0P8oIIxyKsu+hNCVit5geNwABz3qO7cOylTlQAKf8AZ1ksxJDvLqcOOwHrVbkDr+FRFJu5EUm7je9TxqBC7H6A1AetLuO3GeOtW1c0auAoxSDmimMSiiigBc0CiigApSKKKAE6VZso0muFSQkBuMiiipn8LIqfCyaW2a1LiTG7tiqbA5ooqKUnJXZnRk5R5mNY5NNoorU3RNjMfHBqKiikhIcp5GelOI5oooBjDyafkY6UUUAxp9aaaKKAQUUUUxig4ozzRRQAo56im96KKQh6jApWY4x2oopCJYFyDk471YeMtGHzyTiiispuzMZtplUoUYb+hqdcbCeqiiiqburjbukyKOQhyQeKdu5KNwPX1oop21Ka1IJeHx1FSo/7vaTwecUUU7XRTV0iOTPXtSRsQ1FFPoPoSkfN8vQ9qmK5Crxmiis2ZS0IzK8cjhT8p4K9jT/LWYqVPI/X2oopvRXQS0V0OYvDJuB69KrM5Dlv4u1FFENdR09dSLPenE8cUUVoaihS3NOMYVct+VFFRfWxnd3sRhtvI6HtSFgTyKKKuxpYTOaOlFFMYmKUDnmiigB2PTpTSfWiikhISnIOc+lFFDBmiLdE01rhjl5DtRfQdzWeiEuAaKKyptu5hTk7S9WPuhtlKj+Hik27YwfWiirWyNV8KNO2RorZMn93IpYkd8VkE5YmiiopO7bMqDu2xAM07GCKKK1NxHGGOKbRRTGf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Direct immunofluorescence microscopy of perilesional skin from a patient with bullous pemphigoid reveals characteristic linear C3 basement membrane zone staining.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7283=[""].join("\n");
var outline_f7_7_7283=null;
var title_f7_7_7284="Endoscopic view of the duodenum";
var content_f7_7_7284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Endoscopic view of the duodenum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The duodenum distal to the duodenal bulb has distinctive circular rings (valvulae conniventes).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7284=[""].join("\n");
var outline_f7_7_7284=null;
var title_f7_7_7285="Metabolic and inherited diseases affecting the skin";
var content_f7_7_7285=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metabolic and inherited diseases affecting the skin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/7/7285/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7285/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7285/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/7/7285/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7285/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/7/7285/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7285/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/7/7285/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This review will discuss a number of metabolic and inherited disorders with prominent skin findings in adults, including ichthyosis vulgaris, necrobiosis lipoidica, and pseudoxanthoma elasticum. Other disorders that affect the skin, including myxedema, neurofibromatosis, and tuberous sclerosis, are discussed in more detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ICHTHYOSIS VULGARIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disorders of cornification (ichthyoses) comprise acquired and inherited disorders characterized clinically by generalized scaling and histologically by hyperkeratosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7285/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Ichthyosis vulgaris is a common (incidence 1:300) autosomal dominant, inherited disorder. Patients have defective keratohyalin synthesis, lacking a major component, filaggrin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7285/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ichthyosis vulgaris is characterized by dry, scaling skin; it is named because of its clinical similarity to fish scales (ichthyosis, fishlike). The onset is usually between one and four years of age, becoming more extensive with age, often at puberty. Ichthyosis is worse in dry weather, particularly winter. Many patients have coexistent atopic dermatitis with increased palmar skin markings or the keratin follicular plugging of keratosis pilaris.",
"   </p>",
"   <p>",
"    Clinically, scales are generalized and are characteristically rectangular, often best appreciated with a magnifying hand lens. Lesions are usually most severe on the shin, back, or heels, sparing the flexural areas (",
"    <a class=\"graphic graphic_picture graphicRef61258 graphicRef68882 graphicRef79894 \" href=\"UTD.htm?37/23/38266\">",
"     picture 1A-C",
"    </a>",
"    ). The diagnosis is usually made clinically based upon the appearance of the lesions, their distribution, and associated characteristics. Severe xerosis or dry, atopic skin may resemble ichthyosis, but the skin findings of the latter are usually more dramatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is lifelong and consists of the use of emollients and avoidance of dry environments. Instruct patients to use urea or lactic acid creams or lotions chronically (eg, Carmol&reg; 10, Carmol&reg; 20, Ultra Mide 25&reg;, Lac-Hydrin&reg; Five, AmLactin&reg;); these are available without a prescription. Best results occur when the creams are applied to moist skin directly after bathing. Humidifiers also may be helpful for patients who live in dry environments.",
"   </p>",
"   <p>",
"    While oral retinoids are sometimes used for the more severe ichthyoses, these potentially toxic drugs are rarely used for ichthyosis vulgaris because of the chronicity of the process and its relatively mild course [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7285/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients and their families will desire disease information, genetic counseling, and support. For information regarding ichthyosis vulgaris or more rare ichthyotic diseases, contact: Foundation for Ichthyosis and Related Skin Types (FIRST):1601 Valley Forge Road, Lansdale, PA 19446; Phone 215-631-1411; Fax 215-631-1413;",
"    <a class=\"external\" href=\"file://www.scalyskin.org/\">",
"     www.scalyskin.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NECROBIOSIS LIPOIDICA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrobiosis lipoidica is an inflammatory skin disorder of unknown cause, occurring three times more often in females than in males. The name of this disease aptly describes its clinical findings: necrobiosis refers to the type of inflammation that occurs when lesions are examined histologically; lipoidica is the yellow appearance of lesions due to lipid deposits occurring secondary to inflammation.",
"   </p>",
"   <p>",
"    The disease is frequently associated with diabetes mellitus. Although lesions occur in less than 1 percent of all diabetics, more than 75 percent of patients with the skin lesions either have or will develop diabetes mellitus, have a positive family history of diabetes, or have impaired glucose tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7285/abstract/6\">",
"     6",
"    </a>",
"    ]. There does not appear to be a relationship with diabetic metabolic control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic skin lesions usually occur on the shin (15 percent of patients will have lesions elsewhere) in young or middle-aged adults as oval or irregularly shaped, indurated plaques with central atrophy and yellow pigmentation (",
"    <a class=\"graphic graphic_picture graphicRef74010 graphicRef50781 graphicRef63574 graphicRef76411 \" href=\"UTD.htm?24/8/24714\">",
"     picture 2A-D",
"    </a>",
"    ). Peripherally along the margins there is either red-brown or violaceous pigmentation. Telangiectasias are sometimes seen and ulceration occurs in one-third of cases.",
"   </p>",
"   <p>",
"    The diagnosis is usually made clinically by the characteristic skin findings and associated patient factors. The differential diagnosis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Granuloma annulare",
"      </strong>",
"      &ndash; asymptomatic annular red plaques occur more commonly on the dorsum of the extremities or posterior neck and lack a yellow discoloration (",
"      <a class=\"graphic graphic_picture graphicRef76216 graphicRef62354 \" href=\"UTD.htm?16/0/16391\">",
"       picture 3A-B",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22922?source=see_link&amp;anchor=H35143181#H35143181\">",
"       \"Granuloma annulare\", section on 'Clinical features'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Sarcoidosis, rheumatoid nodules, and xanthomas",
"      </strong>",
"      &ndash; all can be differentiated by biopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, treatment of necrobiosis lipoidica is suboptimal and often chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7285/abstract/7\">",
"     7",
"    </a>",
"    ]. For initial treatment, consider using a moderate strength topical steroid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide 0.1 percent cream [60,240 g] three times daily). If there is no improvement after two weeks, consider using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    dipropionate 0.05 percent twice daily, monitoring for skin atrophy. Intralesional triamcinolone (5 to 10",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    diluted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    down to 2.5 to 5",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    can be attempted cautiously if no ulcers are present and the perceived risk is low. Avoid using topical or injectable corticosteroids if any ulcers are present, and reduce the steroid strength to the lowest potency and duration that will control inflammation. Referral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    consultation are often indicated. A case report raised the possibility that topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    might be of some benefit in early-stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7285/abstract/8\">",
"     8",
"    </a>",
"    ]. A case series reported improvements with antimalarial agents (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7285/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For ulcerative disease, a number of cases of successful therapy with agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , granulocyte-macrophage colony stimulating factor, hyperbaric oxygen, systemic corticosteroids, high dose nicotinamide, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7285/abstract/10-17\">",
"     10-17",
"    </a>",
"    ]. However, there have been no consistently successful therapies identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PSEUDOXANTHOMA ELASTICUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudoxanthoma elasticum (PXE) is a disorder of abnormal elastic tissue and calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7285/abstract/18\">",
"     18",
"    </a>",
"    ]. Both sporadic and autosomal recessive and dominant forms have been observed; the underlying defect is a mutation in the ABCC6 gene on chromosome 16 that encodes an ATP-binding cassette transporter [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7285/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary organ systems involved include the skin, eyes, and cardiovascular systems; gastrointestinal bleeding also can occur. Progressive skin lesions develop in 80 percent of individuals before age 20 years. The characteristic skin findings are 2 to 5 mm yellow to orange papules, which may coalesce into irregularly shaped plaques bounded by normal skin. Because such lesions have a pebbly appearance and are yellow, they are named pseudoxanthomas. The texture of the skin has been likened to plucked-chicken skin. Lesions occur most commonly in flexural areas such as the neck and axillary folds, periumbilically, and on the inner lower lip (",
"    <a class=\"graphic graphic_picture graphicRef80952 graphicRef59135 graphicRef70421 \" href=\"UTD.htm?17/17/17690\">",
"     picture 4A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The primary ocular finding is that of angioid streaks, representing tears in Bruch's membrane, but this finding is seen in other disorders as well (",
"    <a class=\"graphic graphic_picture graphicRef77863 \" href=\"UTD.htm?31/8/31873\">",
"     picture 5",
"    </a>",
"    ). Severe vision loss occurs in 3 to 8 percent of patients.",
"   </p>",
"   <p>",
"    Common cardiovascular manifestations include accelerated atherosclerosis, which is thought to be due to calcification of the internal elastic laminae. These changes can result in myocardial infarction, cerebrovascular disease, and renovascular hypertension at a young age. A common PXE mutation in the ABCC6 gene also may predispose to premature atherosclerosis in the general population. This was illustrated in a comparison of 441 patients in the general population who had coronary disease under the age of 50 and 1057 matched controls without coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7285/abstract/22\">",
"     22",
"    </a>",
"    ]. The prevalence of the PXE mutation was 4.2 times higher in the patients (3.2 versus 0.8 percent). This relationship was independent of other coronary risk factors.",
"   </p>",
"   <p>",
"    The diagnosis of PXE is based upon the clinical appearance and findings on histologic examination of lesional skin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7285/abstract/23\">",
"     23",
"    </a>",
"    ]. Additional studies are necessary to determine the role of genetic testing for ABCC6 mutations in the diagnosis of PXE [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7285/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment consists of close ophthalmologic management, monitoring and treatment of any cardiovascular symptoms, and dietary consultation. Patients should be educated to avoid contact sports (because of the risk of ocular disease) and referred for genetic counseling.",
"   </p>",
"   <p>",
"    Patients with PXE can be referred to support groups such as the National Association for Pseudoxanthoma Elasticum (NAPE) at",
"    <a class=\"external\" href=\"file://www.napxe.org/\">",
"     www.napxe.org",
"    </a>",
"    or PXE International at",
"    <a class=\"external\" href=\"file://www.pxe.org/\">",
"     www.pxe.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8726455\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ichthyosis vulgaris is a prevalent, autosomal dominant disorder that is characterized by dry skin with &ldquo;fish-like&rdquo; scales. Ichthyosis vulgaris is common in patients with atopic dermatitis. Treatment involves the use of topical emollients and keratolytics. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Ichthyosis vulgaris'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Necrobiosis lipoidica is an inflammatory skin disorder that usually develops in association with diabetes mellitus. Lesions usually present as yellowish, indurated plaques with central atrophy. Telangiectasias and ulcerations also may occur. The shin is a common site of involvement. Topical corticosteroids are frequently used for the initial management of nonulcerated lesions. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Necrobiosis lipoidica'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudoxanthoma elasticum is a genetic disorder that affects the skin, eyes, and cardiovascular and gastrointestinal systems. Cutaneous findings include multiple small, yellow to orange papules on the neck, axillae, or abdomen that cause the skin to resemble plucked chicken skin. Other findings in pseudoxanthoma elasticum include angioid streaks in the retina, atherosclerosis, and gastrointestinal bleeding. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pseudoxanthoma elasticum'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/1\">",
"      Williams ML. Ichthyosis: mechanisms of disease. Pediatr Dermatol 1992; 9:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/2\">",
"      Shwayder T. Disorders of keratinization: diagnosis and management. Am J Clin Dermatol 2004; 5:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/3\">",
"      G&uuml;nzel S, Weidenthaler B, Hausser I, Anton-Lamprecht I. Keratohyalin granules are heterogeneous in ridged and non-ridged human skin: evidence from anti-filaggrin immunogold labelling of normal skin and skin of autosomal dominant ichthyosis vulgaris patients. Arch Dermatol Res 1991; 283:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/4\">",
"      Muller SA, Belcher RW, Esterly NB, et al. Keratinizing dermatoses. Combined data from four centers on short-term topical treatment with tretinoin. Arch Dermatol 1977; 113:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/5\">",
"      Happle R, van de Kerkhof PC, Traupe H. Retinoids in disorders of keratinization: their use in adults. Dermatologica 1987; 175 Suppl 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/6\">",
"      Cohen O, Yaniv R, Karasik A, Trau H. Necrobiosis lipoidica and diabetic control revisited. Med Hypotheses 1996; 46:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/7\">",
"      Lowitt MH, Dover JS. Necrobiosis lipoidica. J Am Acad Dermatol 1991; 25:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/8\">",
"      Harth W, Linse R. Topical tacrolimus in granuloma annulare and necrobiosis lipoidica. Br J Dermatol 2004; 150:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/9\">",
"      Durupt F, Dalle S, Debarbieux S, et al. Successful treatment of necrobiosis lipoidica with antimalarial agents. Arch Dermatol 2008; 144:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/10\">",
"      Darvay A, Acland KM, Russell-Jones R. Persistent ulcerated necrobiosis lipoidica responding to treatment with cyclosporin. Br J Dermatol 1999; 141:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/11\">",
"      Remes K, R&ouml;nnemaa T. Healing of chronic leg ulcers in diabetic necrobiosis lipoidica with local granulocyte-macrophage colony stimulating factor treatment. J Diabetes Complications 1999; 13:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/12\">",
"      Bouhanick B, Verret JL, Gouello JP, et al. Necrobiosis lipoidica: treatment by hyperbaric oxygen and local corticosteroids. Diabetes Metab 1998; 24:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/13\">",
"      Heymann WR. Necrobiosis lipoidica treated with topical tretinoin. Cutis 1996; 58:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/14\">",
"      Petzelbauer P, Wolff K, Tappeiner G. Necrobiosis lipoidica: treatment with systemic corticosteroids. Br J Dermatol 1992; 126:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/15\">",
"      Handfield-Jones S, Jones S, Peachey R. High dose nicotinamide in the treatment of necrobiosis lipoidica. Br J Dermatol 1988; 118:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/16\">",
"      Kolde G, Muche JM, Schulze P, et al. Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica. Dermatology 2003; 206:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/17\">",
"      Hu SW, Bevona C, Winterfield L, et al. Treatment of refractory ulcerative necrobiosis lipoidica diabeticorum with infliximab: report of a case. Arch Dermatol 2009; 145:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/18\">",
"      Bercovitch L, Terry P. Pseudoxanthoma elasticum 2004. J Am Acad Dermatol 2004; 51:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/19\">",
"      Le Saux O, Urban Z, Tschuch C, et al. Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet 2000; 25:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/20\">",
"      Ringpfeil F, Lebwohl MG, Christiano AM, Uitto J. Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci U S A 2000; 97:6001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/21\">",
"      Bergen AA, Plomp AS, Schuurman EJ, et al. Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet 2000; 25:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/22\">",
"      Trip MD, Smulders YM, Wegman JJ, et al. Frequent mutation in the ABCC6 gene (R1141X) is associated with a strong increase in the prevalence of coronary artery disease. Circulation 2002; 106:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/23\">",
"      Lebwohl M, Neldner K, Pope FM, et al. Classification of pseudoxanthoma elasticum: report of a consensus conference. J Am Acad Dermatol 1994; 30:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7285/abstract/24\">",
"      Plomp AS, Toonstra J, Bergen AA, et al. Proposal for updating the pseudoxanthoma elasticum classification system and a review of the clinical findings. Am J Med Genet A 2010; 152A:1049.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5570 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-257308528F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7285=[""].join("\n");
var outline_f7_7_7285=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8726455\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ICHTHYOSIS VULGARIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NECROBIOSIS LIPOIDICA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PSEUDOXANTHOMA ELASTICUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8726455\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5570\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5570|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/16/34054\" title=\"picture 1A\">",
"      Ichthyosis vulgaris 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/15/13558\" title=\"picture 1B\">",
"      Ichthyosis vulgaris 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/28/8645\" title=\"picture 1C\">",
"      Ichthyosis vulgaris 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/36/10816\" title=\"picture 2A\">",
"      Necrobiosis lipoidica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/29/16849\" title=\"picture 2B\">",
"      Necrobiosis lipoidica 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/21/40274\" title=\"picture 2C\">",
"      Necrobiosis lipoidica 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/45/7891\" title=\"picture 2D\">",
"      Necrobiosis lipoidica 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/51/32563\" title=\"picture 3A\">",
"      Granuloma annulare hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/32/19968\" title=\"picture 3B\">",
"      Granuloma annulare foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/44/24261\" title=\"picture 4A\">",
"      Pseudoxanthoma elasticum neck 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/26/35235\" title=\"picture 4B\">",
"      Pseudoxanthoma elasticum neck 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/29/39376\" title=\"picture 4C\">",
"      Pseudoxanthoma elasticum lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/8/31873\" title=\"picture 5\">",
"      Angioid streaks",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22922?source=related_link\">",
"      Granuloma annulare",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_7_7286="Endocrine surveillance in childhood cancer survivors";
var content_f7_7_7286=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endocrine surveillance in childhood cancer survivors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/7/7286/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7286/contributors\">",
"     Susan R Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/7/7286/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7286/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7286/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/7/7286/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7286/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/7/7286/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have survived cancer may return to normal health, growth, and development. Alternatively, they may experience late effects of the cancer itself or of the therapy that permitted survival. The late effects of the tumor and its treatment cannot be separated because the children have, by definition, experienced both.",
"   </p>",
"   <p>",
"    Improved therapies have increased childhood cancer survival rates (from 20 percent in 1954 to 83 percent in 2006), so that it is estimated that one in every 900 individuals between the ages of 15 and 45 has experienced and survived cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In 2007, the survival rates for adults below 50 years of age were reported for the following childhood malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brain tumor: 60 percent",
"     </li>",
"     <li>",
"      Leukemia: 72 percent",
"     </li>",
"     <li>",
"      Non-Hodgkin lymphoma: 80 percent",
"     </li>",
"     <li>",
"      Hodgkin disease: 91 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Childhood cancer survivors are at risk for the following long-term effects of cancer",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/2-14\">",
"     2-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endocrinopathies [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/3-6,9,11,12,14-16\">",
"       3-6,9,11,12,14-16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Obesity, metabolic syndrome, or diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/6,11,12,16-18\">",
"       6,11,12,16-18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neurologic effects on memory, learning, or attention [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/15,19-21\">",
"       15,19-21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Stroke",
"     </li>",
"     <li>",
"      Hearing loss",
"     </li>",
"     <li>",
"      Alopecia",
"     </li>",
"     <li>",
"      Dry eyes, mouth, or skin",
"     </li>",
"     <li>",
"      Small jaw",
"     </li>",
"     <li>",
"      Temporal mandibular joint or dental problems [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cardiac malfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/19,23\">",
"       19,23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Infertility [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Thyroid nodules [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hepatitis C",
"     </li>",
"     <li>",
"      Musculoskeletal problems: scoliosis, muscle weakness, leg length discrepancy, osteoporosis, bone spurs [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Secondary malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endocrine problems may be the most common late effect after childhood cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/4,28-38\">",
"     4,28-38",
"    </a>",
"    ]. An overview of endocrine surveillance for childhood cancer survivors is provided here. Surveillance for the other effects in childhood cancer survivors is discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H696721410\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for particular late endocrine effects depends upon the location of the tumor and the treatment modalities that were used [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/3,4,39\">",
"     3,4,39",
"    </a>",
"    ]. A careful review of an individual's cancer and cancer treatment history permits estimation of the relative risk for various endocrinopathies (",
"    <a class=\"graphic graphic_table graphicRef69558 \" href=\"UTD.htm?6/28/6604\">",
"     table 1",
"    </a>",
"    ). As a general rule, any structures that were within the radiation field are subject to altered function (eg, irradiation for Hodgkin lymphoma directly affects function of the thyroid gland and the gonads; craniospinal radiation for medulloblastoma affects function of the hypothalamus and thyroid gland). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2058?source=see_link\">",
"     \"Epidemiology, treatment, and prognosis of medulloblastoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=see_link\">",
"     \"Overview of Hodgkin lymphoma in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although systemic chemotherapy is associated with more generalized transient effects, the gonads or the hypothalamus may be permanently affected [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/40\">",
"     40",
"    </a>",
"    ]. The practitioner must be vigilant in monitoring for the development of new endocrinopathies (both expected and unexpected) for as long as 10 to 15 years after completion of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/41-44\">",
"     41-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ONSET OF ENDOCRINOPATHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     During chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are undergoing chemotherapy often experience slowed growth rate, weight loss (or gain if they are treated with steroids), fatigue, anorexia, alopecia, and weakness. These findings may be non-specific side effects of cancer therapy or caused by a cancer-related endocrine deficiency (eg, cortisol deficiency, growth hormone deficiency, hypothyroidism). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39223?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a symptomatic, stressed child who is receiving cytotoxic chemotherapy (not including steroids), the following hormone concentrations usually signify true endocrine deficiencies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Morning cortisol less than 18",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Pituitary thyrotropin, also referred to as thyroid stimulating hormone (TSH) greater than or equal to 20",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"     </li>",
"     <li>",
"      Free thyroxine (T4) less than the lower limit of normal for the child's age and the assay being used",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repeat monitoring should be performed every four to six months if the initial tests are normal but the child continues to be symptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     After chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children typically exhibit catch-up growth and weight gain after completion of therapy as their health returns toward normal. Some children transiently develop breast buds corresponding to this period of newly improved nutrition. These children should be examined every three to six months. Progressive or persistent (greater than 12 months) breast buds signify entry into puberty.",
"   </p>",
"   <p>",
"    Symptoms of endocrinopathy after completion of cancer therapy include any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure to show catch-up growth, slow growth rate",
"     </li>",
"     <li>",
"      Failure to thrive",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Persistent fatigue",
"     </li>",
"     <li>",
"      Anorexia",
"     </li>",
"     <li>",
"      Dry skin and thin, brittle hair",
"     </li>",
"     <li>",
"      Constipation",
"     </li>",
"     <li>",
"      Fractures",
"     </li>",
"     <li>",
"      Altered timing of onset of or progression through puberty (eg, persistent signs of puberty before age nine years or at a short height, rapid progression through puberty, failure to enter puberty by age 12 years in girls [13 years in boys]). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"       \"Definition, etiology, and evaluation of precocious puberty\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"       \"Diagnosis and treatment of delayed puberty\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7401?source=see_link\">",
"       \"Pubertal development and gonadal function in survivors of childhood cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer survivors require the following yearly surveillance for endocrinopathies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accurate height and weight measurements; arm span measurement (an alternative estimate of height) if there was total body or spinal radiation or scoliosis.",
"      <br/>",
"      <br/>",
"      Bone age (radiograph of left hand and wrist) should be performed in children who are growing too fast or too slowly. In addition, IGF-I and IGFBP-3 should be measured in children who are growing too slowly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=see_link\">",
"       \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ascertainment of Tanner stage and interpretation of whether the pubertal status and tempo of progression are appropriate for age and height. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"       \"Normal puberty\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Measurement of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), sex steroid levels (testosterone or estradiol), inhibin B in males [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/45\">",
"       45",
"      </a>",
"      ] and anti-mullerian hormone in females [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/46\">",
"       46",
"      </a>",
"      ] should be performed in children with delayed or interrupted progression of puberty.",
"     </li>",
"     <li>",
"      Assessment of bone mineral density by dual-energy x-ray absorptiometry (DXA) at 5 and 10 years of age after tumor therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/35\">",
"       35",
"      </a>",
"      ], and more often if DXA results are low.",
"     </li>",
"     <li>",
"      Free T4 and TSH (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39223?source=see_link\">",
"       \"Growth failure after childhood cancer: Role of hypothyroidism\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Thyroid ultrasound after neck irradiation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7286/abstract/5,7\">",
"       5,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Additional surveillance for those conditions for which the patient is at high risk based upon the type of cancer or treatment (",
"      <a class=\"graphic graphic_table graphicRef69558 \" href=\"UTD.htm?6/28/6604\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other interventions include dietary counseling to avoid obesity and assessment of adequacy of dietary calcium and vitamin D intake. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=see_link\">",
"     \"Calcium requirements in adolescents\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H696720880\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improved therapies have dramatically increased survival rates for childhood cancer. As a result, childhood cancer survivors must be monitored for the long-term effects of cancer",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endocrine problems are some of the most common late effects of childhood cancer. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk for particular late endocrine effects depends upon the location of the tumor and the treatment modalities that were used. A careful review of an individual's cancer and cancer treatment history permits estimation of the relative risk for various endocrinopathies (",
"      <a class=\"graphic graphic_table graphicRef69558 \" href=\"UTD.htm?6/28/6604\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H696721410\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      As a general rule, any organ that was within the radiation field is subject to altered function.",
"     </li>",
"     <li>",
"      Although systemic chemotherapy is associated with more generalized transient effects, the gonads or the hypothalamus may be permanently affected by chemotherapeutic agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While a child is undergoing chemotherapy, symptoms of an underlying endocrine problem are often non-specific and include weight loss, poor growth, fatigue, anorexia, alopecia, and weakness. In such patients, endocrine evaluation that results in low morning cortisol levels, elevated pituitary thyrotropin (TSH) levels, and lower than normal free thyroxine (T4) for the child&rsquo;s age generally signifies true endocrine deficiencies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'During chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After chemotherapy is completed, symptoms of endocrinopathy include failure to show catch-up growth, failure to thrive, obesity, fatigue, anorexia, dry skin,",
"      <span class=\"nowrap\">",
"       thin/brittle",
"      </span>",
"      hair, constipation, fractures, and abnormal pubertal development and gonadal function. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'After chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cancer survivors require yearly endocrine evaluation, including growth measurements, assessment of bone age and Tanner stage, and monitoring of pubertal and gonadal development. Further evaluation is performed if there are any abnormalities noted in the initial yearly surveillance or if there are conditions, such as the type of cancer or treatment, which make the patient at high risk for an endocrinopathy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Altekruse SF, Kosary CL, Krapcho M, et al (Eds). SEER Cancer Statistics Review. 1957-2007. National Cancer Institute. Bethesda, MD. file://www.seer.cancer.gov/csr/1975_2007/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/2\">",
"      Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res 2010; 174:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/3\">",
"      Patterson BC, Truxillo L, Wasilewski-Masker K, et al. Adrenal function testing in pediatric cancer survivors. Pediatr Blood Cancer 2009; 53:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/4\">",
"      Sudour H, Chastagner P, Claude L, et al. Fertility and pregnancy outcome after abdominal irradiation that included or excluded the pelvis in childhood tumor survivors. Int J Radiat Oncol Biol Phys 2010; 76:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/5\">",
"      Taylor AJ, Croft AP, Palace AM, et al. Risk of thyroid cancer in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study. Int J Cancer 2009; 125:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/6\">",
"      Gregory JW. Metabolic disorders. Endocr Dev 2009; 15:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/7\">",
"      Hudson MM, Mulrooney DA, Bowers DC, et al. High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance. J Clin Oncol 2009; 27:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/8\">",
"      Han JW, Kwon SY, Won SC, et al. Comprehensive clinical follow-up of late effects in childhood cancer survivors shows the need for early and well-timed intervention. Ann Oncol 2009; 20:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/9\">",
"      Bonato C, Severino RF, Elnecave RH. Reduced thyroid volume and hypothyroidism in survivors of childhood cancer treated with radiotherapy. J Pediatr Endocrinol Metab 2008; 21:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/10\">",
"      Landier W, Bhatia S. Cancer survivorship: a pediatric perspective. Oncologist 2008; 13:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/11\">",
"      Stava CJ, Beck ML, Feng L, et al. Diabetes mellitus among cancer survivors. J Cancer Surviv 2007; 1:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/12\">",
"      Steffens M, Beauloye V, Brichard B, et al. Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). Clin Endocrinol (Oxf) 2008; 69:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/13\">",
"      Nandagopal R, Laverdi&egrave;re C, Mulrooney D, et al. Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. Horm Res 2008; 69:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/14\">",
"      Chemaitilly W, Mertens AC, Mitby P, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab 2006; 91:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/15\">",
"      Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 2004; 10:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/16\">",
"      Eyal O, Sundararajan S, Inge TH, Rose SR. Obesity in patients with craniopharyngioma. Endocrinologist 2006; 16:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/17\">",
"      Inge TH, Pfluger P, Zeller M, et al. Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy. Nat Clin Pract Endocrinol Metab 2007; 3:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/18\">",
"      Nathan PC, Jovcevska V, Ness KK, et al. The prevalence of overweight and obesity in pediatric survivors of cancer. J Pediatr 2006; 149:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/19\">",
"      Alvarez JA, Scully RE, Miller TL, et al. Long-term effects of treatments for childhood cancers. Curr Opin Pediatr 2007; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/20\">",
"      Mulhern RK, Fairclough D, Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol 1991; 9:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/21\">",
"      Walter AW, Mulhern RK, Gajjar A, et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol 1999; 17:3720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/22\">",
"      Kaste SC, Hopkins KP, Jones D, et al. Dental abnormalities in children treated for acute lymphoblastic leukemia. Leukemia 1997; 11:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/23\">",
"      Heikens J, Ubbink MC, van der Pal HP, et al. Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease. Cancer 2000; 88:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/24\">",
"      Henderson RC, Madsen CD, Davis C, Gold SH. Bone density in survivors of childhood malignancies. J Pediatr Hematol Oncol 1996; 18:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/25\">",
"      Kaste SC, Hudson MM, Jones DJ, et al. Breast masses in women treated for childhood cancer: incidence and screening guidelines. Cancer 1998; 82:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/26\">",
"      Pui CH, Hancock ML, Raimondi SC, et al. Myeloid neoplasia in children treated for solid tumours. Lancet 1990; 336:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/27\">",
"      Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006; 91:3494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/28\">",
"      Crom DB, Smith D, Xiong Z, et al. Health status in long-term survivors of pediatric craniopharyngiomas. J Neurosci Nurs 2010; 42:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/29\">",
"      Mostoufi-Moab S, Grimberg A. Pediatric brain tumor treatment: growth consequences and their management. Pediatr Endocrinol Rev 2010; 8:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/30\">",
"      Baxi SS, Matasar MJ. State-of-the-art issues in Hodgkin's lymphoma survivorship. Curr Oncol Rep 2010; 12:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/31\">",
"      Laverdi&egrave;re C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/32\">",
"      Abou-Mourad YR, Lau BC, Barnett MJ, et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant 2010; 45:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/33\">",
"      Frange P, Alapetite C, Gaboriaud G, et al. From childhood to adulthood: long-term outcome of medulloblastoma patients. The Institut Curie experience (1980-2000). J Neurooncol 2009; 95:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/34\">",
"      Green DM, Sklar CA, Boice JD Jr, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27:2374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/35\">",
"      Thomas IH, Donohue JE, Ness KK, et al. Bone mineral density in young adult survivors of acute lymphoblastic leukemia. Cancer 2008; 113:3248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/36\">",
"      Bauditz J, Lochs H, Ventz M. [Long-term follow-up of patients with suprasellar germinomas]. Med Klin (Munich) 2007; 102:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/37\">",
"      Leung W, Ahn H, Rose SR, et al. A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore) 2007; 86:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/38\">",
"      Benesch M, Lackner H, Sovinz P, et al. Late sequela after treatment of childhood low-grade gliomas: a retrospective analysis of 69 long-term survivors treated between 1983 and 2003. J Neurooncol 2006; 78:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/39\">",
"      Burns KC, Rose SR. Endocrine sequelae of pediatric malignancies. Endocrinologist 2009; 19:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/40\">",
"      Rose SR, Schreiber RE, Kearney NS, et al. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab 2004; 17:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/41\">",
"      Rose SR. Endocrinopathies after childhood cancer. Endocrinologist 2003; 13:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/42\">",
"      Hameed R, Zacharin MR. Long-term endocrine effects of cancer treatment: experience of the Royal Children's Hospital, Melbourne. J Paediatr Child Health 2005; 41:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/43\">",
"      Daousi C, Dunn AJ, Foy PM, et al. Endocrine and neuroanatomic features associated with weight gain and obesity in adult patients with hypothalamic damage. Am J Med 2005; 118:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/44\">",
"      van den Bos C, Heinen RC, Sukel M, et al. Screening for late effects in survivors of childhood cancer: growth hormone deficiency from a pediatric oncologist's point of view. Growth Horm IGF Res 2004; 14 Suppl A:S125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/45\">",
"      van Casteren NJ, van der Linden GH, Hakvoort-Cammel FG, et al. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer 2009; 52:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7286/abstract/46\">",
"      Lie Fong S, Laven JS, Hakvoort-Cammel FG, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-M&uuml;llerian hormone. Hum Reprod 2009; 24:982.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6240 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-213.131.41.98-64F77B4D5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7286=[""].join("\n");
var outline_f7_7_7286=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H696720880\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H696721410\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ONSET OF ENDOCRINOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      During chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      After chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H696720880\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6240\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6240|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/28/6604\" title=\"table 1\">",
"      Endocrine risk cancer survivors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=related_link\">",
"      Calcium requirements in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2058?source=related_link\">",
"      Epidemiology, treatment, and prognosis of medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=related_link\">",
"      Growth failure after childhood cancer: Role of growth hormone deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39223?source=related_link\">",
"      Growth failure after childhood cancer: Role of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=related_link\">",
"      Overview of Hodgkin lymphoma in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7401?source=related_link\">",
"      Pubertal development and gonadal function in survivors of childhood cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_7_7287="Betamethasone: Patient drug information";
var content_f7_7_7287=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Betamethasone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     see \"Betamethasone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/7/28791?source=see_link\">",
"     see \"Betamethasone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Celestone&reg;;",
"     </li>",
"     <li>",
"      Celestone&reg; Soluspan&reg;;",
"     </li>",
"     <li>",
"      Diprolene&reg;;",
"     </li>",
"     <li>",
"      Diprolene&reg; AF;",
"     </li>",
"     <li>",
"      Luxiq&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Betaderm;",
"     </li>",
"     <li>",
"      Betaject&trade;;",
"     </li>",
"     <li>",
"      Betnesol&reg;;",
"     </li>",
"     <li>",
"      Betnovate&reg;;",
"     </li>",
"     <li>",
"      Celestone&reg; Soluspan&reg;;",
"     </li>",
"     <li>",
"      Diprolene&reg;;",
"     </li>",
"     <li>",
"      Diprolene&reg; Glycol;",
"     </li>",
"     <li>",
"      Diprosone&reg;;",
"     </li>",
"     <li>",
"      Ectosone;",
"     </li>",
"     <li>",
"      Prevex&reg; B;",
"     </li>",
"     <li>",
"      ratio-Ectosone;",
"     </li>",
"     <li>",
"      Ratio-Topilene;",
"     </li>",
"     <li>",
"      ratio-Topilene;",
"     </li>",
"     <li>",
"      Ratio-Topisone;",
"     </li>",
"     <li>",
"      ratio-Topisone;",
"     </li>",
"     <li>",
"      Rivasone;",
"     </li>",
"     <li>",
"      Rolene;",
"     </li>",
"     <li>",
"      Rosone;",
"     </li>",
"     <li>",
"      Taro-Sone;",
"     </li>",
"     <li>",
"      Valisone&reg; Scalp Lotion",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Addison's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691735",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat asthma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat brain swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691790",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat COPD (chronic obstructive pulmonary disease).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691910",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling in parts of the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat organ transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sarcoidosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat spinal cord injuries.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ulcerative colitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691372",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help mature the baby's lungs. It is given to pregnant women who may deliver early.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to betamethasone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700365",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bad yeast infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid being near anyone with chickenpox or measles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are being treated for any infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have stomach ulcers, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have TB (tuberculosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body fat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin changes (pimples, stretch marks, slow healing, hair growth).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697932",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cataracts or glaucoma with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698688",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been exposed to chickenpox and have not had chickenpox or had a chickenpox vaccine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695878",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the morning if taking once a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take calcium and vitamin D as you were told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696150",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To use on the scalp, part your hair. Put drug on the affected skin. Rub in gently and let it dry. You may wash your hair as normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11263 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.80.101-FFB583D007-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7287=[""].join("\n");
var outline_f7_7_7287=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140644\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140645\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022487\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022489\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022488\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022493\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022494\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022496\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022491\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022492\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022497\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022498\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=related_link\">",
"      Betamethasone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/7/28791?source=related_link\">",
"      Betamethasone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_7_7288="Evaluation and management of edema in children";
var content_f7_7_7288=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of edema in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/7/7288/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7288/contributors\">",
"     Rudolph P Valentini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/7/7288/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7288/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/7/7288/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7288/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/7/7288/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edema is a clinical condition characterized by an increase in interstitial fluid volume and tissue swelling that can be either localized or generalized. Severe generalized edema is known as anasarca. More localized interstitial fluid collections include ascites and pleural effusions.",
"   </p>",
"   <p>",
"    Optimizing the diagnostic approach to edema is based upon a thoughtful approach to the pathogenesis of its formation. Once a diagnosis is established, specific treatment of the underlying disorder can be given. If specific therapy is not available, general treatment such as fluid management can be considered.",
"   </p>",
"   <p>",
"    The evaluation and management of edema in children will be presented in this topic review. The pathogenesis and etiology of edema in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1657?source=see_link\">",
"     \"Pathophysiology and etiology of edema in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the evaluation of a child with edema include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determine the underlying pathophysiology, character of the edema (localized or generalized), and cause as it will guide both evaluation and treatment (",
"      <a class=\"graphic graphic_table graphicRef68106 \" href=\"UTD.htm?2/56/2957\">",
"       table 1",
"      </a>",
"      ). A more detailed discussion on the etiology based on the pathogenesis of the edema is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1657?source=see_link\">",
"       \"Pathophysiology and etiology of edema in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Identify those conditions that are potentially life-threatening or have serious medical consequences, although most causes of edema are self-limiting disorders. Potentially life-threatening or serious medical disorders include anaphylaxis, hereditary angioedema with laryngeal involvement, decreased cardiac output (especially as a result of myocarditis or restrictive pericarditis), and hepatic and renal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a child with edema begins with a thorough history. The following should be included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Edema location.",
"     </li>",
"     <li>",
"      Duration of symptoms. Establishing a time course is important in distinguishing an acquired condition from a congenital condition.",
"     </li>",
"     <li>",
"      Associated complaints that suggest systemic disease or major organ dysfunction. As an example, shortness of breath suggests heart failure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary edema.",
"     </li>",
"     <li>",
"      Additional concurrent illnesses or signs. A streptococcal infection one to three weeks earlier may point to post-streptococcal glomerulonephritis.",
"     </li>",
"     <li>",
"      Past medical and family history. A family history of recurrent angioedema, for example, may suggest hereditary angioedema as a possible diagnosis.",
"     </li>",
"     <li>",
"      Weight gain and tight-fitting clothes and shoes. Such changes may have been ignored by parents as they were thought to be normal signs of growth, rather than the onset of edema because of nephrosis.",
"     </li>",
"     <li>",
"      Patient age at time of edema onset. Edema of the hands and feet of a newborn girl is suggestive of Turner's syndrome.",
"     </li>",
"     <li>",
"      History of allergies and current medications. Allergies and adverse reaction to certain medications can present as angioedema in childhood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The focus of the physical examination includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measuring the child's growth parameters.",
"     </li>",
"     <li>",
"      Fully evaluating the cardiovascular system, including vital signs. Findings of tachycardia, tachypnea, gallop, rales, or hepatomegaly are seen in patients with heart failure, whereas tachypnea and rales alone may be indicative of pulmonary edema. Increased blood pressure levels may reflect hypervolemia resulting from",
"      <span class=\"nowrap\">",
"       acute/chronic",
"      </span>",
"      renal failure or glomerulonephritis. Blood pressure measurements are interpreted in relation to the patient's age, gender, and height percentile (",
"      <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"       table 3",
"      </a>",
"      ). The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) or for girls (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"       \"Definition and diagnosis of hypertension in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Characterizing the edema as localized or generalized, and assessing the extent of edema. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Edema'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral edema is detected by the presence of pitting after pressure is applied to the edematous area. Pitting reflects movement of the excess interstitial water in response to pressure. Because peripheral edema locates preferentially in dependent areas, it is primarily found in the lower extremities of ambulatory patients and over the sacrum in patients at bed rest.",
"   </p>",
"   <p>",
"    When the edema is nonpitting, lymphedema (which may also be associated with pitting edema) or pretibial myxedema should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1828?source=see_link\">",
"     \"Pretibial myxedema in autoimmune thyroid disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As mentioned above, the evaluation is affected by the location of edema:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Generalized edema &ndash; If generalized edema is present, the child should be evaluated for pleural effusion, pulmonary edema, ascites,",
"      <span class=\"nowrap\">",
"       scrotal/labial",
"      </span>",
"      edema, or evidence of skin breakdown in regions of edema.",
"      <br/>",
"      <br/>",
"      Pulmonary findings of decreased breath sounds and dullness to percussion are consistent with pleural effusion, although pulmonary edema is suggested by adventitial sounds such as rales. Ascites is associated with abdominal distention, and shifting dullness and a fluid wave on percussion of the abdomen. Patients with the nephrotic syndrome also may have prominent periorbital edema because of the low tissue hydrostatic pressure in this area.",
"     </li>",
"     <li>",
"      Localized edema &ndash; With regional edema, the clinician should localize the area of swelling to help deduce where a region of venous or lymphatic obstruction is likely to be present or localized allergen exposure has occurred. Because cellulitis also can manifest with regional edema, assessment of the patient for fever and local signs of inflammation is important. If the edema is localized to the face, the child also should be carefully evaluated for concurrent airway involvement, which can be life threatening.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clues from constellations of symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child with edema must be assessed for associated symptoms or other medical conditions that may help suggest the underlying etiology. The following are grouping of signs and symptoms found in a variety of diseases that cause edema in children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A child with diaphoresis, dyspnea on exertion,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a history of heart disease may have edema secondary to cardiac failure. Findings on clinical examination include tachycardia, tachypnea, rales, hepatomegaly,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gallop.",
"     </li>",
"     <li>",
"      A child with a history of food allergies may present acutely with urticaria and angioedema after allergen exposure. If there is airway involvement, this is a medical emergency and requires emergent therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of jaundice, failure to thrive, steatorrhea, or abdominal pain should point the clinician toward a diagnosis of chronic liver disease or possibly a protein losing-enteropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7288/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A child with progressive anasarca with a significant periorbital component, but minimal systemic complaints, may have the nephrotic syndrome.",
"     </li>",
"     <li>",
"      Cola-colored urine with either generalized or facial edema strongly suggests acute glomerulonephritis. These patients also may have hypertension.",
"     </li>",
"     <li>",
"      Edema, anorexia, and growth failure can be seen in a child with chronic renal failure.",
"     </li>",
"     <li>",
"      Family history of angioedema favors a diagnosis of hereditary angioedema.",
"     </li>",
"     <li>",
"      A newborn girl with edema of the hands and feet, webbed neck, nail dysplasia, high palate, and short fourth metacarpal may have Turner's syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on urinalysis, complete blood count, serum chemistry tests (serum creatinine, BUN, albumin, and liver function studies), echocardiography (if clinically indicated), and other tests may suggest or confirm the underlying cause of edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A urinalysis including a dipstick for proteinuria must be obtained in all children with edema. Dipstick testing principally detects albumin. The finding of a markedly positive dipstick for protein in combination with hypoalbuminemia and clinical edema is virtually diagnostic of the nephrotic syndrome. False-positive results may be obtained with very alkaline or concentrated urines, or when urine is contaminated by some antiseptic agents (such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/9/44180?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    or benzalkonium chloride). However, highly positive results (&gt;300",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    cannot be explained by a concentrated urine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link\">",
"     \"Evaluation of proteinuria in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link\">",
"     \"Congenital and infantile nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of the urine sediment may reveal hematuria, pyuria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cellular casts. In the edematous child with renal disease, different patterns of urinary findings favor different renal diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With glomerular diseases, for example,",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematuria with red cell casts and dysmorphic red cells, with or without heavy proteinuria, is virtually diagnostic of glomerulonephritis, such as poststreptococcal glomerulonephritis. This constellation of urinary findings is called a nephritic sediment. The absence of red cell casts does not exclude the diagnosis.",
"     </li>",
"     <li>",
"      Heavy proteinuria, but few cells or casts, is most consistent with a noninflammatory cause of nephrotic syndrome such as minimal change disease or focal segmental glomerulosclerosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Serum laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial serum laboratory evaluation in the child with edema without an apparent cause should include a complete blood count, and serum chemistries including renal and liver function tests and serum albumin level. Based upon the results of these initial tests, the clinical history, physical examination, and urinalysis, additional serum laboratory tests may be indicated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal disease &ndash; In the child with suspected acute glomerulonephritis, the serum complement component 3 (C3) level is a useful test, as causes of glomerulonephritis can be classified as either hypocomplementemic or normocomplementemic (",
"      <a class=\"graphic graphic_table graphicRef53697 \" href=\"UTD.htm?41/33/42523\">",
"       table 4",
"      </a>",
"      ). In addition, the presence of antistreptococcal antibodies, antinuclear antibodies (ANA), antiglomerular basement membrane (GBM) antibodies, and antineutrophil cytoplasmic autoantibodies (ANCA) favors the diagnosis of particular disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link\">",
"       \"Differential diagnosis and evaluation of glomerular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If only the nephrotic syndrome is present, a series of serologic tests also are frequently ordered as part of the routine evaluation. These include C3, C4, ANA, and anti-double stranded DNA to screen for diseases such as membranoproliferative glomerulonephritis or lupus.",
"     </li>",
"     <li>",
"      Serologic screening for markers of occult viral infection also may be performed. These include tests for hepatitis B (hepatitis B surface antigen and core antibody), hepatitis C (antibody), and HIV (antibody) infection. However, a positive serology does not prove that the renal disease is a result of the viral infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H460668475#H460668475\">",
"       \"Differential diagnosis and evaluation of glomerular disease\", section on 'Patients with a nephrotic presentation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Most causes of acute or chronic renal failure in children can cause edema. The evaluation of this problem is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=see_link\">",
"       \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"       \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic liver disease or protein-losing enteropathy &ndash; A diagnosis of chronic liver disease or a protein losing-enteropathy is suspected in the child with hypoalbuminemia, but no proteinuria. In this setting, liver functions tests, total serum protein levels, and prothrombin times should be obtained [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7288/abstract/3\">",
"       3",
"      </a>",
"      ]. In addition, stool level of alpha-1 antitrypsin is the best screening test for protein-losing enteropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=see_link\">",
"       \"Protein-losing gastroenteropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link\">",
"       \"Diagnostic approach to the patient with cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Venous thrombosis &ndash; In the child with suspected venous thrombosis, coagulation studies should be obtained. If thrombosis is diagnosed, additional studies may include the measurement of antithrombin III, protein S, protein C concentrations, and Factor V Leiden levels. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"       \"Protein C deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link\">",
"       \"Protein S deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"       \"Antithrombin (ATIII) deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemolysis &ndash; Severe hemolysis in the newborn period can result in a hydropic infant with generalized edema. One notable cause for hydrops is hemolytic disease of the newborn, which may be because of ABO blood type incompatibility or Rh disease. To diagnose this disorder, a complete blood count and serology testing should be obtained. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=see_link\">",
"       \"Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Angioedema &ndash; With suspected angioedema, plasma levels of the complement components, C1q, C4, C2, and C1 inhibitor may help diagnose inherited or acquired C1 inhibitor deficiency. With the inherited forms, C4 and C2 levels are chronically low in the majority of patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link\">",
"       \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different imaging studies may be indicated based upon the results of the clinical evaluation and laboratory studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Renal ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of safety, ease of use, and the information provided, the most commonly used radiographic technique in patients presenting with renal disease is renal ultrasonography. Ultrasonography allows the clinician to characterize kidney size and assess for cystic renal disease and hydronephrosis. Renal ultrasonography is helpful in the following clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An edematous newborn male with bilateral hydronephrosis may have obstructive uropathy from posterior urethral valves.",
"     </li>",
"     <li>",
"      A teenager with renal failure and small shrunken kidneys may have congenital renal hypoplasia, scarring from reflux nephropathy, or simply chronic renal failure of any cause.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Doppler ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler ultrasonography (or other studies assessing vascular flow) is indicated in the child with suspected venous thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=see_link\">",
"     \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiography is helpful in detecting cardiac failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography can evaluate ventricular function, assess for the presence of a pericardial effusion, and aid in the diagnosis of cardiac disease in the child suspected of having heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A renal biopsy is a consideration in children with suspected glomerulonephritis, particularly among those with significant renal dysfunction, normal complement studies,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    heavy proteinuria. A biopsy also may be obtained in the setting of unexplained acute or subacute renal failure.",
"   </p>",
"   <p>",
"    A child with presumed idiopathic nephrotic syndrome is",
"    <strong>",
"     not",
"    </strong>",
"    typically biopsied and is treated empirically with corticosteroids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective therapeutic intervention is to treat the underlying cause. As an example, corticosteroid therapy for a patient with steroid sensitive nephrotic syndrome will resolve",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    edema by inducing a remission and correcting the underlying pathogenesis.",
"   </p>",
"   <p>",
"    For the following causes of edema in children, further discussion concerning the treatment of the edema and, if appropriate, the underlying conditions are discussed in detail elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nephrotic syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link\">",
"       \"Treatment of idiopathic nephrotic syndrome in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acute and chronic renal failure (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Sodium and intravascular volume'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=see_link&amp;anchor=H535581857#H535581857\">",
"       \"Prevention and management of acute kidney injury (acute renal failure) in children\", section on 'Hypervolemia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cirrhosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link\">",
"       \"Initial therapy of ascites in patients with cirrhosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Venous thromboembolism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=see_link\">",
"       \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Heart failure (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"       \"Treatment of acute decompensated heart failure: General considerations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=see_link\">",
"       \"Use of diuretics in patients with heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"       \"Treatment and prognosis of diastolic heart failure\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Protein losing enteropathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=see_link&amp;anchor=H18#H18\">",
"       \"Protein-losing gastroenteropathy\", section on 'Treatment'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anaphylaxis",
"     </li>",
"     <li>",
"      Hereditary angioedema (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=see_link\">",
"       \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lymphedema (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"       \"Prevention and treatment of lymphedema\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     General treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;General supportive measures may be considered prior to",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    during the implementation of specific therapy based upon the underlying cause. In some cases when specific therapy is not available, general measures may be the only treatment offered and include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sodium restriction",
"     </li>",
"     <li>",
"      Diuretic therapy",
"     </li>",
"     <li>",
"      Intravenous albumin",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Sodium and fluid restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium restriction is usually appropriate in the setting of generalized edema, which includes patients with renal failure, acute glomerulonephritis, heart failure, hepatic ascites, and nephrotic syndrome. A sodium-restricted diet is tailored to provide the child with approximately two to three mEq of",
"    <span class=\"nowrap\">",
"     sodium/kg",
"    </span>",
"    per day, the amount of sodium required for a growing child. A 10 kg child should therefore receive between 20 to 30 mEq of sodium per day or 460 to 690 mg of sodium per day. This strategy is continued up to a maximum sodium intake of 2000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in larger children.",
"   </p>",
"   <p>",
"    Fluid restriction can be considered in patients with generalized edema but must be done cautiously in patients with reduced effective circulating blood volume of non-cardiac origin. This includes children with nephrotic syndrome and hepatic cirrhosis. Fluid limitations are based on specific patient characteristics and underlying cause. Patients with edema associated with the nephrotic syndrome who are being managed in the outpatient setting should be treated with sodium restriction, but not fluid restriction. Fluid restriction may result in a compromised intravascular volume, which could exacerbate the thrombotic tendency of this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with edema and an associated expanded intravascular volume may be candidates for diuretic therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with heart failure with increased hydrostatic pressure and hypervolemia due to water and sodium retention may benefit from fluid removal. This can be achieved with the use of loop diuretics (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Diuretics also are useful in the treatment of edema resulting from renal dysfunction with acute glomerulonephritis and acute or chronic renal failure. However, diuretics need to be used cautiously in children with edema and a reduced effective circulatory volume, as observed with ascites due to cirrhosis. There are two major concerns with diuretic therapy for cirrhotic ascites: overly rapid removal of fluid and progressive electrolyte imbalance:",
"     </li>",
"     <li>",
"      Aggressive diuresis of these patients may precipitate hepatorenal syndrome and overt renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7288/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. The clinician must therefore closely monitor the BUN and serum creatinine concentration, as any unexplained deterioration of renal function would imply an untoward effect on renal blood flow.",
"     </li>",
"     <li>",
"      Loop diuretics can induce a hypokalemic metabolic alkalosis, which can lead to increased ammonia production by the renal tubules and result in a hepatic coma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7288/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in the child with cirrhotic ascites, it is probably most prudent to use sodium restriction and possibly add",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"     spironolactone",
"    </a>",
"    to avoid the risks of hypokalemia. Spironolactone also is occasionally combined with loop diuretics in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7288/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link\">",
"     \"Initial therapy of ascites in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'Sodium and fluid restriction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the child with nephrotic syndrome, diuretic therapy also should be used sparingly and with great caution. Some affected children, particularly those with severe hypoalbuminemia, may be intravascularly volume depleted. Thus, an aggressive diuresis may lead to further intravascular volume depletion, thereby possibly precipitating acute renal failure and increasing the risk of thrombosis in this already susceptible group of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7288/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diuretics without albumin administration are not currently recommended in the setting of the childhood nephrotic syndrome. Albumin raises the intravascular oncotic pressure and thereby protects the intravascular compartment against volume contraction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18598?source=see_link\">",
"     \"Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6679?source=see_link&amp;anchor=H4#H4\">",
"     \"Symptomatic management of nephrotic syndrome in children\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If diuretics are utilized in patients with either appropriate or depleted intravascular volume, blood urea nitrogen levels should be monitored. In general, a significant decrease in tissue perfusion secondary to excessive diuresis and inadequate mobilization of peripheral edema can be detected simply by an otherwise unexplained rise in the blood urea nitrogen (BUN). A stable BUN implies that perfusion to the kidneys (and therefore to other organs) is being well maintained and that the diuresis can be continued if the patient is still edematous.",
"   </p>",
"   <p>",
"    Diuretics are usually of little benefit in chronic lymphedema resulting from obstruction, and may promote the development of volume depletion. The reason for this is as follows. When diuretics are given to treat the usual forms of peripheral edema, the initial fluid loss comes from the intravascular space. The ensuing reduction in venous and therefore intracapillary pressure allows the interstitial fluid to be mobilized and the plasma volume to be maintained. However, this sequence does not occur with lymphatic obstruction, as interstitial fluid cannot be mobilized into the vascular space.",
"   </p>",
"   <p>",
"    In addition, the use of systemic therapy such as diuretics for a regional problem (lymphedema) will undoubtedly result in untoward effects in unaffected regions of the body, such as the central venous circulation with its resultant undesirable hemodynamic effects. Therefore, diuretics should not be used in this clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Intravenous albumin infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some children with edema secondary to low oncotic pressure may benefit from intravenous albumin infusions in conjunction with loop diuretics. This may include subgroups of the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with nephrotic syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7288/abstract/8\">",
"       8",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link\">",
"       \"Treatment of idiopathic nephrotic syndrome in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36008?source=see_link\">",
"       \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Children with protein losing enteropathy or protein malnutrition",
"     </li>",
"     <li>",
"      Children with cirrhosis and severe ascites [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7288/abstract/9\">",
"       9",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=see_link\">",
"       \"Treatment of diuretic-resistant ascites in patients with cirrhosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This therapy is reserved for patients with severe ascites or pleural effusions leading to respiratory embarrassment or infection, a contracted intravascular volume with acute renal failure, or severe edema resulting in impending or actual skin breakdown. This therapy should not be considered for milder cases because of the expense of the therapy and possible complications including hypertension and pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7288/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who meet the above criteria can be given salt-poor albumin at a dose of 0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    infused over four hours in conjunction with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum dose of 40 mg). Albumin dose of up to 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per dose also has been used [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7288/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a summary and recommendations on the evaluation and management of edema in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The practitioner approaching a child with edema must identify potential serious and life-threatening causes of edema. The first step is a thorough history and physical examination to guide in the diagnosis.",
"   </p>",
"   <p>",
"    The focus of the history should include edema location, duration of symptoms, any associated complaints, additional concurrent illnesses or signs, medical and family history, age of edema onset, and a history of allergies and current medications. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'History'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The focus of the physical examination involves measuring the child's growth parameters, fully evaluating of the cardiovascular system, and characterizing the edema as localized or generalized. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Physical examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If generalized edema is present, the child should be evaluated for pleural effusion, pulmonary edema, ascites,",
"      <span class=\"nowrap\">",
"       scrotal/labial",
"      </span>",
"      edema, or evidence of skin breakdown in regions of edema.",
"     </li>",
"     <li>",
"      If regional edema is present, the clinician should localize the area of swelling to help deduce where a region of venous or lymphatic obstruction is likely to be present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clues from constellations of symptoms and signs may help suggest the underlying etiology. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Clues from constellations of symptoms and signs'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless the diagnosis is apparent from the history and physical examination, the following laboratory studies are recommended in the evaluation of a child with edema:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urinalysis including a dipstick for proteinuria",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Serum chemistries including serum albumin, renal and liver function tests",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the results of these tests, the clinical history, physical examination, and urinalysis, additional laboratory tests and imaging studies may be indicated. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Laboratory evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective therapeutic intervention is to treat the underlying cause. However, general supportive measures can be used as adjunctive therapy or when specific intervention is not available. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium restriction is the mainstay of general supportive therapy. The recommended dietary intake is 2 to 3 mEq of sodium per kg weight of the patient (maximum intake 90 mEq (2000 mg) per day). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Sodium and fluid restriction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diuretic therapy is recommended in patients with increased hydrostatic pressure as a result of increased intravascular volume. It should be used cautiously, if at all, in patients with either reduced or appropriate intravascular volume. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous albumin infusions are recommended in a small subset of patients with low intravascular oncotic pressure and significant clinical complications from their edema. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Intravenous albumin infusion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Brasitus TA. Protein-losing gastroenteropathy. In: Gastrointestinal Disease: Pathophysiology, Diagnosis, Management, Sleisenger JS (Ed), WB Saunders, Philadelphia 1993. p.1027.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7288/abstract/2\">",
"      Braamskamp MJ, Dolman KM, Tabbers MM. Clinical practice. Protein-losing enteropathy in children. Eur J Pediatr 2010; 169:1179.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis LG. End-stage liver disease and cirrhosis. In: Saunders Manual of Pediatric Practice, Finberg L (Ed), WB Saunders, Philadelphia 1998. p.521.",
"    </li>",
"    <li>",
"     Rose BD, Post TW. Edematous states. In: Clinical Physiology of Acid-Base and Electrolyte Disorders, Rose BD, Post TW (Eds), McGraw-Hill, New York 2001. p.478.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7288/abstract/5\">",
"      Schrier RW, Ecder T. Gibbs memorial lecture. Unifying hypothesis of body fluid volume regulation: implications for cardiac failure and cirrhosis. Mt Sinai J Med 2001; 68:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7288/abstract/6\">",
"      Zavagli G, Ricci G, Bader G, et al. The importance of the highest normokalemia in the treatment of early hepatic encephalopathy. Miner Electrolyte Metab 1993; 19:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7288/abstract/7\">",
"      Sullivan MJ 3rd, Hough DR, Agodoa LC. Peripheral arterial thrombosis due to the nephrotic syndrome: the clinical spectrum. South Med J 1983; 76:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7288/abstract/8\">",
"      Hogg RJ, Portman RJ, Milliner D, et al. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000; 105:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7288/abstract/9\">",
"      Gin&egrave;s P, Guevara M, De Las Heras D, Arroyo V. Review article: albumin for circulatory support in patients with cirrhosis. Aliment Pharmacol Ther 2002; 16 Suppl 5:24.",
"     </a>",
"    </li>",
"    <li>",
"     Niaudet P. Steriod-sensitive idiopathic nephrotic syndrome in children. In: Pediatric Nephrology, 5th ed, Avner ED, Harmon WE, Niaudet P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.549.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6104 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7288=[""].join("\n");
var outline_f7_7_7288=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clues from constellations of symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Serum laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Renal ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Doppler ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      General treatment approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Sodium and fluid restriction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intravenous albumin infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6104\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6104|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/56/2957\" title=\"table 1\">",
"      Causes edema childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/45/7894\" title=\"table 2\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/46/7910\" title=\"table 3\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/33/42523\" title=\"table 4\">",
"      Causes of glomerulonephritis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18598?source=related_link\">",
"      Acute kidney injury (acute renal failure) in minimal change disease and other forms of nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=related_link\">",
"      Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=related_link\">",
"      An overview of angioedema: Clinical features, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=related_link\">",
"      Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=related_link\">",
"      Evaluation of proteinuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=related_link\">",
"      Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1657?source=related_link\">",
"      Pathophysiology and etiology of edema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1828?source=related_link\">",
"      Pretibial myxedema in autoimmune thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42249?source=related_link\">",
"      Prevention and management of acute kidney injury (acute renal failure) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6679?source=related_link\">",
"      Symptomatic management of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=related_link\">",
"      Treatment of diuretic-resistant ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=related_link\">",
"      Use of diuretics in patients with heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_7_7289="Gastric volvulus in adults";
var content_f7_7_7289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gastric volvulus in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/7/7289/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7289/contributors\">",
"     Jon O Wee, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/7/7289/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7289/contributors\">",
"     David I Soybel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/7/7289/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/7/7289/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/7/7289/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9592225\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric volvulus is characterized by rotation of the stomach along its long or short axis leading to variable degrees of gastric outlet obstruction, which may present acutely, or chronically. Rotation of the stomach more than 180&deg; causes complete gastric outlet obstruction, and potentially strangulation of the stomach leading to ischemia, and potentially necrosis, perforation, and abdominal sepsis. Mortality related to acute gastric volvulus is high if unrecognized, underscoring the need for early diagnosis and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classification, clinical manifestations, diagnosis, and treatment of gastric volvulus will be reviewed here. General considerations for gastric outlet obstruction are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=see_link\">",
"     \"Gastric outlet obstruction in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606324891\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric volvulus is rare. The incidence peaks after the fifth decade with adults constituting 80 to 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/5\">",
"     5",
"    </a>",
"    ]. No association with sex or race has been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606324922\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for gastric volvulus in adults include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;50 years",
"     </li>",
"     <li>",
"      Diaphragmatic abnormalities (eg, paraesophageal hernia, hiatal hernia, other diaphragm hernia)",
"     </li>",
"     <li>",
"      Diaphragm eventration",
"     </li>",
"     <li>",
"      Phrenic nerve paralysis",
"     </li>",
"     <li>",
"      Other anatomic gastrointestinal abnormalities (eg, stomach, spleen)",
"     </li>",
"     <li>",
"      Kyphoscoliosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606324982\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric volvulus is characterized by abnormal rotation of the stomach along its horizontal or vertical axis. The stomach is normally maintained in position by several ligaments that fix the stomach to other abdominal structures and to the diaphragm, including the gastrocolic, gastrohepatic, gastrosplenic and gastrophrenic ligaments (",
"    <a class=\"graphic graphic_figure graphicRef86322 \" href=\"UTD.htm?2/12/2243\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1\">",
"     1",
"    </a>",
"    ]. Together with the gastroesophageal junction and pylorus, these ligaments anchor the stomach and prevent rotation. Gastric outlet obstruction occurs to a varying degree depending upon the amount of rotation. (See",
"    <a class=\"local\" href=\"#H289880427\">",
"     'Acute symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With stomach rotation &gt;180&deg;, gastric outlet obstruction occurs, but with lesser degrees of rotation, the gastric obstruction is partial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/6\">",
"     6",
"    </a>",
"    ]. Chronic rotation of the stomach can cause decreased venous return and increased capillary pressure that can lead to gastric bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606329650\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric volvulus is classified as primary (idiopathic) or secondary depending upon its etiology, organoaxial or mesenteroaxial according to axis of rotation, and acute or chronic depending upon the clinical presentation. (See",
"    <a class=\"local\" href=\"#H289880427\">",
"     'Acute symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26691034\">",
"    <span class=\"h2\">",
"     Primary versus secondary gastric volvulus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric volvulus is classified based upon whether the etiology is primary (idiopathic) or secondary. Primary (idiopathic) gastric volvulus is defined as volvulus due to abnormalities of the gastric ligaments [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/7\">",
"     7",
"    </a>",
"    ]. Failure of the gastric fixation can occur as a result of agenesis, elongation, or disruption of the gastric ligaments due to neoplasia, adhesions, or skeletal deformity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, kyphoscoliosis can lead to primary gastric volvulus due to displacement of the viscera producing abnormal tension, and therefore elongation of the ligaments over time [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/8\">",
"     8",
"    </a>",
"    ]. Primary gastric volvulus presents more commonly with chronic symptoms.",
"   </p>",
"   <p>",
"    Secondary gastric volvulus occurs in two-thirds of patients with gastric volvulus and is defined as volvulus due to other anatomic abnormalities (ie, not primarily the gastric attachments), such as paraesophageal hernia, diaphragmatic hernia (Morgagni hernia, Bochdalek hernia, traumatic hernia), diaphragmatic eventration, phrenic nerve paralysis, as well as anatomic abnormalities of other organs (eg, stomach, spleen) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1,3,4,6,9-13\">",
"     1,3,4,6,9-13",
"    </a>",
"    ]. In adults, the most commonly associated diaphragmatic defect is paraesophageal hernia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1,6,11\">",
"     1,6,11",
"    </a>",
"    ], whereas in children, congenital diaphragmatic hernia is the most commonly associated anatomic abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/11,12,14,15\">",
"     11,12,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26691041\">",
"    <span class=\"h2\">",
"     Axis of rotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric volvulus can also be classified based upon the axis of abnormal rotation (long versus short axis).",
"   </p>",
"   <p>",
"    Organoaxial rotation refers to rotation of the stomach along its long axis through a line that connects the gastroesophageal junction and the pylorus (",
"    <a class=\"graphic graphic_figure graphicRef83731 \" href=\"UTD.htm?19/21/19796\">",
"     figure 2",
"    </a>",
"    ). The antrum rotates anterosuperiorly and the fundus rotates posteroinferiorly. The greater curvature of the stomach comes to rest superior to the lesser curvature of the stomach in an inverted position (upside-down stomach) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1\">",
"     1",
"    </a>",
"    ]. Organoaxial volvulus is the most common type of abnormal rotation, occurring in 60 percent of cases of gastric volvulus, and is associated with secondary etiologies (eg, paraesophageal hernias, diaphragmatic hernia, and diaphragmatic eventration) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. Strangulation of the stomach is more common with this type of volvulus, occurring in up to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26691034\">",
"     'Primary versus secondary gastric volvulus'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    With mesenteroaxial volvulus, the stomach rotates around its short axis through a perpendicular line connecting the greater and lesser curvatures of the stomach (",
"    <a class=\"graphic graphic_figure graphicRef83731 \" href=\"UTD.htm?19/21/19796\">",
"     figure 2",
"    </a>",
"    ). The antrum becomes displaced above the gastroesophageal junction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1\">",
"     1",
"    </a>",
"    ]. With mesenteroaxial volvulus, rotation is usually partial (&lt;180&deg;) and is not generally associated with a secondary anatomic defect. (See",
"    <a class=\"local\" href=\"#H26691034\">",
"     'Primary versus secondary gastric volvulus'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A complex form of gastric volvulus combines elements of organoaxial and mesenteroaxial rotation (",
"    <a class=\"graphic graphic_figure graphicRef83731 \" href=\"UTD.htm?19/21/19796\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102192354\">",
"    <span class=\"h2\">",
"     Acute versus chronic gastric volvulus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations associated with gastric volvulus vary depending upon the degree of gastric outlet obstruction and rapidity of onset. With rotation &gt;180&deg;, the patient will present with symptoms of acute gastric outlet obstruction (ie, acute gastric volvulus), whereas in those with lesser degrees of rotation, symptoms of partial gastric obstruction occur that can be intermittent and chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/6\">",
"     6",
"    </a>",
"    ]. About 40 percent of patients with gastric volvulus present with an acute onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with chronic gastric volvulus can also present with acute symptoms superimposed on their chronic picture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26691754\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with gastric volvulus come to medical attention because of symptoms, which can present acutely or chronically, most commonly with abdominal or chest pain. It is a rare condition, so it is often not initially considered as the underlying cause of these symptoms. The general approach to the patient with abdominal or chest pain is discussed elsewhere. Clinical features related to gastric volvulus are presented below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A history of risk factors associated with gastric volvulus as well as any prior injuries, surgeries, and known anatomic abnormalities should be sought. A history of other upper gastrointestinal diseases, such as a history gastroesophageal reflux may indicate the presence of a paraesophageal hernia and suggest the diagnosis, whereas a history of peptic ulcer disease may point to an alternative etiology for gastric outlet obstruction. (See",
"    <a class=\"local\" href=\"#H606324922\">",
"     'Risk factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H102194220\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289880441\">",
"    <span class=\"h2\">",
"     Acute gastric volvulus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute symptoms include pain in the upper abdomen or lower chest associated with severe vomiting (which may become unproductive). The combination of pain, vomiting, and an inability to pass a nasogastric tube, known as Borchardt&rsquo;s triad, is present in as many as 70 percent of patients with acute gastric volvulus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. Hematemesis can occur due to mucosal ischemia or mucosal tears from vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1,10,17\">",
"     1,10,17",
"    </a>",
"    ]. Also reported are pain related to pancreatic or omental ischemia, omental avulsion, or splenic rupture due to traction on these structures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1,6,15,17,18\">",
"     1,6,15,17,18",
"    </a>",
"    ]. With complete gastric outlet obstruction, the stomach becomes dilated and fluid-filled, manifesting as upper abdominal distention with dullness to percussion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. The physical examination may also reveal evidence of volume depletion. Auscultation may reveal gastric sounds in the chest. Signs of peritonitis (abdominal wall rigidity, rebound tenderness) may be present if significant gastric ischemia due to strangulation or perforation has occurred.",
"   </p>",
"   <p>",
"    Most patients undergo initial laboratory testing for the evaluation of acute abdominal or chest pain that includes a complete blood count, electrolytes, and possibly liver function tests and pancreatic enzymes. These studies may help identify patients who are volume depleted or experiencing complications but do not help establish a diagnosis of gastric volvulus. (See",
"    <a class=\"local\" href=\"#H289879710\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with recurrent vomiting may have electrolyte abnormalities, including hypokalemia or a hypochloremic metabolic alkalosis, or evidence of volume depletion. (See",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/causes-of-metabolic-alkalosis?source=see_link\">",
"     \"Causes of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory findings may also include an elevated white cell count, which may be due to inflammation, and acute stress and pain related to acute gastric distention. However, if the white cell count remains elevated following decompression of the stomach and measures to control pain, it may relate to ischemia, gastric perforation, and abdominal sepsis requiring urgent abdominal exploration. (See",
"    <a class=\"local\" href=\"#H606326238\">",
"     'Gastric decompression'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1642632866\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other nonspecific laboratory findings may include elevated pancreatic enzymes, and anemia related to mucosal ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102192728\">",
"    <span class=\"h2\">",
"     Chronic gastric volvulus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic or intermittent gastric volvulus have vague and often subclinical presentations. Chronic symptoms include mild upper abdominal discomfort, dysphagia, bloating, and heartburn, and occasionally patients present with symptoms of pancreatitis. Chronic rotation of the stomach can lead to gastric ulceration, low level bleeding, and chronic anemia. Some patients with chronic gastric volvulus will have a history of multiple transfusions. The physical examination in patients with chronic gastric volvulus may be relatively nonspecific. Since the stomach is often located in the chest, there can be minimal abdominal distention. Patients may also lack abdominal tenderness.",
"   </p>",
"   <p>",
"    In patients with chronic gastric volvulus, laboratory studies obtained in the course of evaluating the patient with chronic abdominal or chest complaints may show chronic anemia from gastric ulceration due to the abnormal stomach rotation. Pancreatic enzymes may also be elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289879710\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of gastric volvulus cannot be made with history and physical examination alone. Because it is a rare condition, it is usually not the foremost diagnosis expected as the cause of upper abdominal pain, nausea, and vomiting. The evaluation of abdominal or chest pain typically involves plain radiographs or computed tomography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289880427\">",
"    <span class=\"h2\">",
"     Acute symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients suspected of acute gastric volvulus based upon clinical features, we suggest plain radiography as the initial diagnostic test. Classic findings may confirm the diagnosis indicating immediate nasogastric decompression, without further delay. (See",
"    <a class=\"local\" href=\"#H606326238\">",
"     'Gastric decompression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The classic finding of acute gastric volvulus on plain abdominal radiograph is a single large spherical gas bubble located in the upper abdomen or chest with an air-fluid level (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83730 \" href=\"UTD.htm?0/41/657\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/19\">",
"     19",
"    </a>",
"    ]. There is generally a paucity of air in the distal bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/18\">",
"     18",
"    </a>",
"    ]. With other etiologies of gastric outlet obstruction, the stomach retains a more normal contour (ie, not spherical) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65449 \" href=\"UTD.htm?38/41/39568\">",
"     image 2",
"    </a>",
"    ). A distinguishing feature of organoaxial volvulus is that it lies in a horizontal plane when viewed on plain radiographs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83732 \" href=\"UTD.htm?27/43/28341\">",
"     image 3A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/6,10,11\">",
"     6,10,11",
"    </a>",
"    ]. Mesenteroaxial volvulus will have a spherical stomach on supine images but two air-fluid levels on upright films, with the antrum positioned superior to the fundus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83734 \" href=\"UTD.htm?14/16/14595\">",
"     image 3B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/4,20\">",
"     4,20",
"    </a>",
"    ]. Prior placement of a nasogastric tube may dissipate the gastric bubble, but the course of the nasogastric tube will remain abnormal.",
"   </p>",
"   <p>",
"    If the classic features are not present on plain radiography, but acute gastric volvulus is suspected, we suggest computed tomography rather than gastrointestinal contrast studies. Both will show the abnormal position of the stomach, but CT has the added advantage of showing the relationship of the stomach to surrounding structures and identifying anatomic abnormalities associated with secondary gastric volvulus. (See",
"    <a class=\"local\" href=\"#H26691034\">",
"     'Primary versus secondary gastric volvulus'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Computed tomography (CT) of the abdomen or chest typically demonstrates a dilated stomach, often abnormally positioned in the chest (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83733 \" href=\"UTD.htm?0/50/803\">",
"     image 4",
"    </a>",
"    ). A swirl sign, in which the esophagus and stomach rotate around each other on transverse plane images, may also be evident [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. CT also defines other anatomic abnormalities, such as diaphragmatic defects, and is also sensitive for detecting small amounts of free air, gastric pneumatosis, or free fluid in the abdomen. CT can also be used to exclude other abdominal pathology as the source of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/2,6,10,15,19\">",
"     2,6,10,15,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289880434\">",
"    <span class=\"h2\">",
"     Chronic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of chronic gastric volvulus relies on demonstrating abnormal positioning of the stomach on imaging studies (plain film, computed tomography), which are typically obtained as part of the evaluation of chronic abdominal or chest complaints. The classic features of gastric volvulus typical for acute gastric volvulus on plain chest and abdominal films are frequently absent in patients with incomplete or partial volvulus (rotation &lt;180&deg;). (See",
"    <a class=\"local\" href=\"#H289880427\">",
"     'Acute symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Plain radiographs may demonstrate abnormal positioning of the stomach, but the findings may be subtle. If a degree of obstruction is present, the stomach bubble is less dramatic and air will be present in the distal bowel. These patients may exhibit no evidence of obstruction at imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/18\">",
"     18",
"    </a>",
"    ]. If plain films are unrevealing, computed tomography of the abdomen may show the abnormal position of the stomach, and has the advantage of showing the relationship of the stomach to surrounding structures.",
"   </p>",
"   <p>",
"    If the diagnosis remains in question, upper gastrointestinal (UGI) series are another imaging option and are sensitive and specific when performed with the stomach in the &ldquo;twisted&rdquo; state [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/4,7,18,21\">",
"     4,7,18,21",
"    </a>",
"    ]. The greater curve will be inverted above the lesser curve (organoaxial volvulus) or the pylorus will be seen above the gastric fundus (mesenteroaxial volvulus) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83732 graphicRef83734 \" href=\"UTD.htm?11/3/11321\">",
"     image 3A-B",
"    </a>",
"    ). A disadvantage of UGI is that is does not identify other anatomic abnormalities that might be associated with secondary volvulus.",
"   </p>",
"   <p>",
"    Patients with chronic upper abdominal symptoms often undergo upper endoscopy as part of their evaluation. However, endoscopy is unreliable for a diagnosis of gastric volvulus. In one study, a diagnosis of gastric volvulus was missed in 68 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/22\">",
"     22",
"    </a>",
"    ]. However, endoscopy may be helpful for ruling out other upper gastrointestinal diseases in the differential diagnosis, aiding placement of a nasogastric tube, or providing stomach fixation using a percutaneous gastrostomy (PEG) tube. (See",
"    <a class=\"local\" href=\"#H102194220\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H606326238\">",
"     'Gastric decompression'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H102193667\">",
"     'Endoscopic de-rotation and PEG tube gastric fixation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102194220\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions can cause acute abdominal pain and gastric outlet obstruction manifesting with acute gastric distention on imaging studies. Acute gastric dilation can also occur in the absence of mechanical obstruction related to psychological disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/23\">",
"     23",
"    </a>",
"    ]. However, with acute gastric volvulus, the stomach contour assumes a more spherical contour (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83730 \" href=\"UTD.htm?0/41/657\">",
"     image 1",
"    </a>",
"    ) due to the abnormal rotation. When the stomach is not twisted, the stomach is distended but maintains a relatively normal stomach contour (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65449 \" href=\"UTD.htm?38/41/39568\">",
"     image 2",
"    </a>",
"    ). The past medical history may suggest an alternative cause for nausea, vomiting, and abdominal pain, and, for many causes of gastric outlet obstruction, the pathology will be apparent on imaging studies (eg, mass, inflammation). The diagnosis and differential diagnosis of abdominal pain and the many causes of gastric outlet obstruction are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=see_link&amp;anchor=H18#H18\">",
"     \"Gastric outlet obstruction in adults\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link\">",
"     \"Etiology and diagnosis of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102193888\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients diagnosed with gastric volvulus come to medical attention because of acute symptoms. If the diagnosis is made at a physician office or in the emergency department, admission to the hospital should be arranged. Direct admission to a surgical service or surgical consultation is appropriate for any symptomatic patient with gastric volvulus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/11,15\">",
"     11,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial medical management of gastric volvulus involves stabilizing the patient (fluid resuscitation and correction of electrolyte abnormalities) and immediate nasogastric decompression (",
"    <a class=\"graphic graphic_algorithm graphicRef86323 \" href=\"UTD.htm?4/51/4927\">",
"     algorithm 1",
"    </a>",
"    ). Intravenous lines should be placed and fluid and electrolyte therapy administered, as needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immediate nasogastric decompression relieves symptoms associated with acute gastric distention and prevents complications. With adequate gastric decompression, the stomach may also spontaneously de-rotate. If nasogastric decompression is successful, further management can be planned with less urgency; however, under most circumstances, repair should be accomplished during the same hospitalization. Given that most adults who present with gastric volvulus are older, medical evaluation should be undertaken to determine the patient&rsquo;s anesthetic risk for surgery, which may alter the nature of the repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During the period of time prior to repair, the patient should remain pain free, hemodynamically stable, and have no systemic signs (eg, fever, increasing white blood cell count) that might indicate tissue ischemia or abdominal sepsis. If abdominal pain develops or recurs following adequate gastric decompression, or other signs indicate that a complication has developed (eg, perforation), abdominal exploration is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606326238\">",
"    <span class=\"h2\">",
"     Gastric decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with acute symptoms and severe gastric distention on imaging or imaging features that suggest gastric volvulus, a nasogastric tube should be placed immediately [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Gastric decompression reduces tension in the stomach wall and improves perfusion, decreasing the risk for gastric ischemia and necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=see_link&amp;anchor=H26#H26\">",
"     \"Gastric outlet obstruction in adults\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9480?source=see_link&amp;anchor=H522921948#H522921948\">",
"     \"Nasogastric and nasoenteric tubes\", section on 'Tube placement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With successful passage of the nasogastric tube into the distal stomach, there is usually immediate resolution of gastric distension and abdominal pain; however, the stomach may or may not de-rotate spontaneously. Although distal gastric obstruction from stomach rotation may remain, the risk of gastric necrosis is reduced. If the nasogastric tube cannot be passed easily, endoscopy can be used to assist with guiding placement of the tube and decompressing the stomach.",
"   </p>",
"   <p>",
"    Endoscopy can be used to assist placement of a nasogastric tube if placement of a nasogastric tube at the bedside has failed. In patients with acute gastric volvulus, endoscopic decompression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    de-rotation are best performed with a controlled airway (ie, patient anesthetized and intubated). Pulmonary aspiration of gastric contents can occur, and patient cooperation with nasogastric tube placement is often limited by discomfort related to the volvulus. Endoscopy can be accomplished in an operating room or appropriately-equipped endoscopy suite with anesthesia availability.",
"   </p>",
"   <p>",
"    Endoscopic decompression can be accomplished by directing the endoscope under vision into the stomach. While guiding the scope, minimal or no insufflation should be used. Once the scope is in the distal stomach, the accumulated air and gastric contents are suctioned to the extent that is possible. A nasogastric tube can then be placed either blindly following the endoscope, or under direct vision. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12442?source=see_link\">",
"     \"Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the nasogastric tube is placed, a repeat abdominal film should be performed to confirm the position of the tube, effectiveness in decompressing the stomach, and course of the tube. The nasogastric tube should remain in place to keep the stomach decompressed until repair can be accomplished.",
"    <br/>",
"   </p>",
"   <p>",
"    Strangulation, which is evident by an inability to decompress the stomach with a nasogastric tube or endoscopic-assisted techniques, indicates the need for immediate surgical decompression followed by repair. (See",
"    <a class=\"local\" href=\"#H1642632866\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1642638797\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric volvulus is a rare condition and treatment is based upon case series and retrospective reviews showing better outcomes for patients who undergo some form of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1,3,5,7\">",
"     1,3,5,7",
"    </a>",
"    ]. Without treatment, volvulus can recur leading to the return of symptoms and potentially complications. (See",
"    <a class=\"local\" href=\"#H1642634680\">",
"     'Recurrence'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The approach to treatment needs takes into account the clinical presentation (acute or chronic), etiology (primary or secondary) and the patient&rsquo;s surgical anesthetic risk. These are discussed below within the framework of the clinical presentation, which is either acute or chronic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606333781\">",
"    <span class=\"h2\">",
"     Acute gastric volvulus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute gastric volvulus is a surgical emergency that is associated with mortality rates that range from 30 to 50 percent when the diagnosis is missed and treatment is delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with acute secondary gastric volvulus and good surgical risk, we suggest surgical repair of the anatomic defect (open surgical, laparoscopic, or a combination of the two) (",
"    <a class=\"graphic graphic_algorithm graphicRef86323 \" href=\"UTD.htm?4/51/4927\">",
"     algorithm 1",
"    </a>",
"    ). Surgical repair consists of de-rotating the stomach, removing any nonviable tissue, reducing any hernias, and repairing anatomic defects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1,3,15,24,25\">",
"     1,3,15,24,25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1642632866\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A less invasive approach can be used in patients who have medical comorbidities that preclude surgery (",
"    <a class=\"graphic graphic_algorithm graphicRef86323 \" href=\"UTD.htm?4/51/4927\">",
"     algorithm 1",
"    </a>",
"    ). This approach consists of endoscopic de-rotation and gastric fixation, without repair of the anatomic defect [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/2,4,10,14,24\">",
"     2,4,10,14,24",
"    </a>",
"    ]. The same approach is used for the rare patient who presents with acute primary gastric volvulus. If endoscopic de-rotation is successful, percutaneous endoscopic gastrostomy (PEG) tubes are placed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. However, if endoscopic de-rotation is unsuccessful, de-rotation will be necessary, which is usually accomplished laparoscopically, followed by PEG placement in the operating room. (See",
"    <a class=\"local\" href=\"#H102193667\">",
"     'Endoscopic de-rotation and PEG tube gastric fixation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Placement of PEG tubes can also serve as a temporizing measure in hemodynamically unstable patients with acute gastric volvulus who have de-rotated (spontaneously or endoscopically), allowing time for the patient to be adequately resuscitated and permit surgical repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606334133\">",
"    <span class=\"h2\">",
"     Chronic gastric volvulus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic gastric volvulus is more likely primary in etiology, although patients with secondary volvulus can also present in this manner. (See",
"    <a class=\"local\" href=\"#H26691754\">",
"     'Clinical presentations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with primary chronic gastric volvulus, gastric fixation alone after successful de-rotation",
"    <span class=\"nowrap\">",
"     (laparoscopic/endoscopic)",
"    </span>",
"    may be adequate for preventing recurrent rotation. (See",
"    <a class=\"local\" href=\"#H102193667\">",
"     'Endoscopic de-rotation and PEG tube gastric fixation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with moderate to severe symptoms and secondary chronic gastric volvulus, we suggest surgical repair in good risk surgical candidates (",
"    <a class=\"graphic graphic_algorithm graphicRef86323 \" href=\"UTD.htm?4/51/4927\">",
"     algorithm 1",
"    </a>",
"    ). For those with minimal symptoms, conservative management without intervention may be more appropriate, particularly if the patient has limited life-expectancy or is a poor candidate for repair [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/22,31-33\">",
"     22,31-33",
"    </a>",
"    ]. Observations from retrospective reviews that support conservative management over surgery for those with minimal chronic symptoms (mostly paraesophageal hernia) include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The annual probability of developing acute symptoms requiring emergency surgery was estimated in one review to be 1.2 percent per year, with a lifetime risk of 18 percent in patients over the age of 65 [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although recurrent symptoms occur in up to two-thirds of patients, few patients require emergency surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/32-38\">",
"       32-38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In asymptomatic patients, it has been estimated that perioperative mortality needs to be below 1 percent to derive a benefit from intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102193562\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treating patients with gastric volvulus are restoring the stomach back to a more normal anatomic position, repairing any associated anatomic abnormalities, and preventing future stomach rotation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1,3,15,24,25\">",
"     1,3,15,24,25",
"    </a>",
"    ]. These goals can be accomplished with endoscopic or surgical (open or laparoscopic) techniques. However, endoscopic management does not address anatomic abnormalities, and thus, may be less optimal for patients with secondary volvulus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102193667\">",
"    <span class=\"h2\">",
"     Endoscopic de-rotation and PEG tube gastric fixation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic de-rotation and percutaneous endoscopic gastrostomy (PEG) tube placement are often used as a first-line therapy to manage patients with primary gastric volvulus, and in those patients with secondary gastric volvulus who are poor candidates for surgical repair (",
"    <a class=\"graphic graphic_algorithm graphicRef86323 \" href=\"UTD.htm?4/51/4927\">",
"     algorithm 1",
"    </a>",
"    ). However, endoscopic de-rotation maneuvers may not be successful, and a surgical approach may, nevertheless, be needed.",
"   </p>",
"   <p>",
"    If the stomach remains rotated on repeat radiography following nasogastric tube placement (bedside or endoscopic-assisted), endoscopic de-rotation can be attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The endoscope is guided through the stomach beyond the twist and manipulated within the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. If the stomach de-rotates, the endoscope should be guided into the duodenum, ensuring the stomach is fully de-rotated. If the stomach is unable to be reduced endoscopically, then operative decompression and de-rotation will be needed. (See",
"    <a class=\"local\" href=\"#H1642632866\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If the stomach returns to a normal position, PEG tubes can be placed to fix the stomach into position. From a practical standpoint, we place at least two PEG tubes to prevent future rotation (organoaxial or mesenteroaxial) when fixating the stomach. One of the PEG tubes is placed into the gastric body and another is placed more distal in the stomach. With only a single PEG tube, the stomach can still rotate around the axis from the PEG to the gastroesophageal junction. PEG tubes are left in place for several weeks to allow adhesions to form between the stomach and abdominal wall. Thereafter, the tubes are discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1642632866\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical repair of secondary volvulus consists of reducing and de-rotating the stomach, removing any nonviable tissue, and repairing associated anatomic defects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1,3,24,25\">",
"     1,3,24,25",
"    </a>",
"    ]. For patients with primary gastric volvulus, gastric fixation alone after successful de-rotation is usually sufficient to prevent recurrent volvulus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606336310\">",
"    <span class=\"h3\">",
"     Open versus laparoscopic repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good risk surgical candidates can be managed using open or laparoscopic techniques, or a combination of the two (",
"    <a class=\"graphic graphic_algorithm graphicRef86323 \" href=\"UTD.htm?4/51/4927\">",
"     algorithm 1",
"    </a>",
"    ). The choice between these surgical approaches depends largely upon the experience and preference of the surgeon, and the available resources.",
"   </p>",
"   <p>",
"    The surgical management of gastric volvulus is traditionally performed as an open procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/1\">",
"     1",
"    </a>",
"    ]. Although there are no randomized trials directly comparing long-term outcomes, observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/21,24,41-45\">",
"     21,24,41-45",
"    </a>",
"    ] as well as indirect evidence from the approach to the repair of paraesophageal hernia and other diaphragmatic hernias suggest that a laparoscopic approach may be preferred to open surgery because it is less invasive and has the advantages of a shorter hospital stay and reduced perioperative morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/4,21,28,41-43\">",
"     4,21,28,41-43",
"    </a>",
"    ]. Since gastric volvulus is more often associated with paraesophageal hernias in older adult patients, a laparoscopic approach may be desirable, particularly in those with medical comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1642634680\">",
"     'Recurrence'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606333176\">",
"    <span class=\"h3\">",
"     Techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical techniques used in the management of gastric volvulus can include reduction and de-rotation of the stomach, gastrectomy, repair of anatomic defects,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastropexy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduction and de-rotation of the stomach &ndash; Reduction of the stomach from the hernia sac is started anteriorly with gentle downward traction on the stomach. There are often adhesions of the stomach or omentum that will not be appreciated until the stomach is nearly reduced. With methodical dissection, the stomach will eventually be delivered into the abdomen where it can be manually de-rotated.",
"     </li>",
"     <li>",
"      Gastrectomy &ndash; Once reduced, the stomach should be examined for areas of ischemia. Decompression and de-rotation of the stomach results in rapid reperfusion. Ischemic areas that remain are at risk for perforation and should be resected. Partial gastrectomy or, rarely, subtotal gastrectomy may be needed; however, because of the robust circulation to the stomach, this is uncommon. If ischemic areas are observed, the tissue should be observed intraoperatively for 10 to 15 minutes after de-rotation. If color and pliability do not improve, resection should be performed or a second look operation planned.",
"     </li>",
"     <li>",
"      Repair of anatomic defects &ndash; When gastric volvulus is found to be due to a diaphragmatic defect (usually paraesophageal hernia), repair of the defect reduces the risk of recurrent volvulus. Once the stomach has been reduced and de-rotated, the hernia sac is resected. The distal esophagus is mobilized, and an antireflux procedure and closure of the hiatus with or without mesh is performed. The surgical techniques related to paraesophageal hernia are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19128?source=see_link\">",
"       \"Paraesophageal hernia: Clinical features and surgical repair\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gastric fixation &ndash; Gastric fixation involves tethering the anterior wall of the stomach to the posterior aspect of the abdominal wall, which can be accomplished intraoperatively using percutaneous endoscopic gastrostomy (PEG) tubes, or by directly suturing the stomach to the abdominal wall (open or laparoscopic gastropexy). Gastric fixation is not required following repair of an anatomic defect and is not routinely performed in clinical practice. (See",
"      <a class=\"local\" href=\"#H102193667\">",
"       'Endoscopic de-rotation and PEG tube gastric fixation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1642634680\">",
"    <span class=\"h1\">",
"     RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of unrepaired gastric volvulus is common. In a study of patients with chronic volvulus, recurrent symptoms in 44 conservatively managed patients occurred in 64 percent of patients, but did not lead to any serious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are very few data with regard to recurrence of gastric volvulus following repair. In theory, surgically-corrected gastric volvulus should not recur, and if it does, it indicates failure of the anatomic repair or inadequate fixation of the stomach to the abdominal wall. In a study comparing recurrence rates associated with gastric fixation alone, recurrence occurred in 42 percent of patients using a laparoscopic approach versus 15 percent with the open approach [",
"    <a class=\"abstract\" href=\"UTD.htm?7/7/7289/abstract/47\">",
"     47",
"    </a>",
"    ]. In the paraesophageal hernia repair literature, a recurrence rate of 8 percent is reported; however this does not reflect recurrence related to gastric volvulus, but rather the recurrence of a hernia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19128?source=see_link&amp;anchor=H613238126#H613238126\">",
"     \"Paraesophageal hernia: Clinical features and surgical repair\", section on 'Patient outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9592311\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastric volvulus is a rare condition that can be life-threatening. Gastric volvulus is characterized by abnormal rotation of the stomach along its long or short axis, which leads to varying degrees of gastric outlet obstruction. If rotation is more than 180&deg;, gastric outlet obstruction is complete. (See",
"      <a class=\"local\" href=\"#H9592225\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H606324891\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The peak age incidence occurs after the fifth decade with adults constituting 80 to 90 percent of cases. The main risk factors for gastric volvulus include age &gt;50 years, and diaphragmatic or other anatomic abnormalities that alter normal stomach fixation. (See",
"      <a class=\"local\" href=\"#H606324891\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary (idiopathic) gastric volvulus is defined as volvulus due to abnormalities of the gastric ligaments. Secondary gastric volvulus occurs in two-thirds of patients with gastric volvulus and is defined as volvulus due to other anatomic abnormalities (ie, not primarily the gastric attachments), the most common of which in adults is paraesophageal hernia. Stomach rotation is described as organoaxial, twisting along the stomach&rsquo;s long axis from the pylorus to esophagogastric junction, or mesenteroaxial, twisting along its short axis. (See",
"      <a class=\"local\" href=\"#H606329650\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastric volvulus can present acutely without prior symptoms as a complete gastric outlet obstruction, or as a partial gastric outlet obstruction that may be intermittent. Acute gastric volvulus is a surgical emergency, and is associated with a high mortality if not promptly recognized and treated. Borchadt&rsquo;s triad, which is abdominal or chest pain, vomiting, and an inability to pass a nasogastric tube, occurs in as many as 70 percent of acute cases. (See",
"      <a class=\"local\" href=\"#H289880441\">",
"       'Acute gastric volvulus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with acute gastric volvulus, classic findings on plain abdominal radiograph include a single large spherical gas bubble in the upper abdomen and a paucity of air in the distal bowel. These clinical features may be absent in patients with chronic gastric volvulus, and further imaging, such as computed tomography or upper gastrointestinal series, will be needed. (See",
"      <a class=\"local\" href=\"#H289879710\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients diagnosed with acute gastric distention due to gastric volvulus, we suggest initial gastric decompression by placing a nasogastric tube rather than endoscopic decompression (",
"      <a class=\"graphic graphic_algorithm graphicRef86323 \" href=\"UTD.htm?4/51/4927\">",
"       algorithm 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is initially attempted at the bedside, but, if unsuccessful, may require endoscopic assistance. In addition to nasogastric decompression, initial management includes fluid resuscitation and correction of electrolyte abnormalities. (See",
"      <a class=\"local\" href=\"#H102193888\">",
"       'Initial management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=see_link&amp;anchor=H26#H26\">",
"       \"Gastric outlet obstruction in adults\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients who present with symptoms due to gastric volvulus will require some form of repair. The goals of repair are restoring the stomach back to a more normal anatomic position, repairing any associated anatomic abnormalities, and preventing future stomach rotation. These goals can be accomplished with endoscopic or surgical (open or laparoscopic) techniques. However, endoscopic repair does not address anatomic abnormalities, and thus, is less optimal for patients with secondary volvulus. (See",
"      <a class=\"local\" href=\"#H102193562\">",
"       'Treatment options'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For symptomatic patients with secondary gastric volvulus and good surgical anesthetic risk, we suggest surgical repair of the anatomic defect (eg, paraesophageal hernia), rather than gastric fixation alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Surgical repair appears to reduce the risk of future recurrence. For patients with significant medical comorbidities, not repairing the anatomic defect is an acceptable alternative, provided de-rotation and gastric fixation can be accomplished (laparoscopic or endoscopic).",
"     </li>",
"     <li>",
"      For symptomatic patients with primary gastric volvulus (acute or chronic), we suggest gastric fixation (laparoscopic or percutaneous endoscopic gastrostomy [PEG] tubes) to anchor the stomach into position to minimize recurrence rather than conservative therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/1\">",
"      Rashid F, Thangarajah T, Mulvey D, et al. A review article on gastric volvulus: a challenge to diagnosis and management. Int J Surg 2010; 8:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/2\">",
"      Chau B, Dufel S. Gastric volvulus. Emerg Med J 2007; 24:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/3\">",
"      Godshall D, Mossallam U, Rosenbaum R. Gastric volvulus: case report and review of the literature. J Emerg Med 1999; 17:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/4\">",
"      Teague WJ, Ackroyd R, Watson DI, Devitt PG. Changing patterns in the management of gastric volvulus over 14 years. Br J Surg 2000; 87:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/5\">",
"      Wu MH, Chang YC, Wu CH, et al. Acute gastric volvulus: a rare but real surgical emergency. Am J Emerg Med 2010; 28:118.e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/6\">",
"      Shivanand G, Seema S, Srivastava DN, et al. Gastric volvulus: acute and chronic presentation. Clin Imaging 2003; 27:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/7\">",
"      Wasselle JA, Norman J. Acute gastric volvulus: pathogenesis, diagnosis, and treatment. Am J Gastroenterol 1993; 88:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/8\">",
"      Flanagan NM, McAloon J. Gastric volvulus complicating cerebral palsy with kyphoscoliosis. Ulster Med J 2003; 72:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/9\">",
"      Ayala JA, Naik-Mathuria B, Olutoye OO. Delayed presentation of congenital diaphragmatic hernia manifesting as combined-type acute gastric volvulus: a case report and review of the literature. J Pediatr Surg 2008; 43:E35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/10\">",
"      McElreath DP, Olden KW, Aduli F. Hiccups: a subtle sign in the clinical diagnosis of gastric volvulus and a review of the literature. Dig Dis Sci 2008; 53:3033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/11\">",
"      Darani A, Mendoza-Sagaon M, Reinberg O. Gastric volvulus in children. J Pediatr Surg 2005; 40:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/12\">",
"      Gerstle JT, Chiu P, Emil S. Gastric volvulus in children: lessons learned from delayed diagnoses. Semin Pediatr Surg 2009; 18:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/13\">",
"      Cribbs RK, Gow KW, Wulkan ML. Gastric volvulus in infants and children. Pediatrics 2008; 122:e752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/14\">",
"      Al-Salem AH. Acute and chronic gastric volvulus in infants and children: who should be treated surgically? Pediatr Surg Int 2007; 23:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/15\">",
"      Kotobi H, Auber F, Otta E, et al. Acute mesenteroaxial gastric volvulus and congenital diaphragmatic hernia. Pediatr Surg Int 2005; 21:674.",
"     </a>",
"    </li>",
"    <li>",
"     Borchardt M. Kur Pathologie and Therapie des magen volvulus. Arch Kin Chir 1904;74:243.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/17\">",
"      Estev&atilde;o-Costa J, Soares-Oliveira M, Correia-Pinto J, et al. Acute gastric volvulus secondary to a Morgagni hernia. Pediatr Surg Int 2000; 16:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/18\">",
"      Peterson CM, Anderson JS, Hara AK, et al. Volvulus of the gastrointestinal tract: appearances at multimodality imaging. Radiographics 2009; 29:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/19\">",
"      Oh SK, Han BK, Levin TL, et al. Gastric volvulus in children: the twists and turns of an unusual entity. Pediatr Radiol 2008; 38:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/20\">",
"      Gurney JW, Olson DL, Schroeder BA. The gastric bubble: roentgen observations. Radiographics 1989; 9:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/21\">",
"      Al-Balas H, Hani MB, Omari HZ. Radiological features of acute gastric volvulus in adult patients. Clin Imaging 2010; 34:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/22\">",
"      Hsu YC, Perng CL, Chen CK, et al. Conservative management of chronic gastric volvulus: 44 cases over 5 years. World J Gastroenterol 2010; 16:4200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/23\">",
"      Lunc S, Rikkers A, Stnescu A. Acute massive gastric dilatation: severe ischemia and gastric necrosis without perforation. Rom J Gastroenterol 2005; 14:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/24\">",
"      Channer LT, Squires GT, Price PD. Laparoscopic repair of gastric volvulus. JSLS 2000; 4:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/25\">",
"      Mangray H, Latchmanan NP, Govindasamy V, Ghimenton F. Grey's Ghimenton gastropexy: an anatomic make-up for management of gastric volvulus. J Am Coll Surg 2008; 206:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/26\">",
"      Eckhauser ML, Ferron JP. The use of dual percutaneous endoscopic gastrostomy (DPEG) in the management of chronic intermittent gastric volvulus. Gastrointest Endosc 1985; 31:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/27\">",
"      Baudet JS, Armengol-Mir&oacute; JR, Medina C, et al. Percutaneous endoscopic gastrostomy as a treatment for chronic gastric volvulus. Endoscopy 1997; 29:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/28\">",
"      Morelli U, Bravetti M, Ronca P, et al. Laparoscopic anterior gastropexy for chronic recurrent gastric volvulus: a case report. J Med Case Rep 2008; 2:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/29\">",
"      Tsang TK, Johnson YL, Pollack J, Gore RM. Use of single percutaneous endoscopic gastrostomy in management of gastric volvulus in three patients. Dig Dis Sci 1998; 43:2659.",
"     </a>",
"    </li>",
"    <li>",
"     Bhandarkar DS, Shah R, Dhawan P. Laparoscopic gastropexy for chronic intermittent gastric volvulus. Indian J Gastroenterol 2001;20:111.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/31\">",
"      Stylopoulos N, Gazelle GS, Rattner DW. Paraesophageal hernias: operation or observation? Ann Surg 2002; 236:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/32\">",
"      Treacy PJ, Jamieson GG. An approach to the management of para-oesophageal hiatus hernias. Aust N Z J Surg 1987; 57:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/33\">",
"      Allen MS, Trastek VF, Deschamps C, Pairolero PC. Intrathoracic stomach. Presentation and results of operation. J Thorac Cardiovasc Surg 1993; 105:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/34\">",
"      Skinner DB, Belsey RH. Surgical management of esophageal reflux and hiatus hernia. Long-term results with 1,030 patients. J Thorac Cardiovasc Surg 1967; 53:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/35\">",
"      Hill LD. Incarcerated paraesophageal hernia. A surgical emergency. Am J Surg 1973; 126:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/36\">",
"      Ozdemir IA, Burke WA, Ikins PM. Paraesophageal hernia. A life-threatening disease. Ann Thorac Surg 1973; 16:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/37\">",
"      Wiechmann RJ, Ferguson MK, Naunheim KS, et al. Laparoscopic management of giant paraesophageal herniation. Ann Thorac Surg 2001; 71:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/38\">",
"      Geha AS, Massad MG, Snow NJ, Baue AE. A 32-year experience in 100 patients with giant paraesophageal hernia: the case for abdominal approach and selective antireflux repair. Surgery 2000; 128:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/39\">",
"      Tsang TK, Walker R, Yu DJ. Endoscopic reduction of gastric volvulus: the alpha-loop maneuver. Gastrointest Endosc 1995; 42:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/40\">",
"      Bhasin DK, Rana SS, Chandail VS, et al. Secondary gastric volvulus after successful resolution of perisplenic pseudocyst by endoscopic transpapillary nasopancreatic drainage. Gastrointest Endosc 2007; 65:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/41\">",
"      Bradley T, Stephenson J, Drugas G, Avansino JR. Laparoscopic management of neonatal paraesophageal hernia with intrathoracic gastric volvulus. J Pediatr Surg 2010; 45:E21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/42\">",
"      Palanivelu C, Rangarajan M, Shetty AR, Senthilkumar R. Laparoscopic suture gastropexy for gastric volvulus: a report of 14 cases. Surg Endosc 2007; 21:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/43\">",
"      Koger KE, Stone JM. Laparoscopic reduction of acute gastric volvulus. Am Surg 1993; 59:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/44\">",
"      Katkhouda N, Mavor E, Achanta K, et al. Laparoscopic repair of chronic intrathoracic gastric volvulus. Surgery 2000; 128:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/45\">",
"      Siu WT, Leong HT, Li MK. Laparoscopic gastropexy for chronic gastric volvulus. Surg Endosc 1998; 12:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/46\">",
"      Tanner NC. Chronic and recurrent volvulus of the stomach with late results of \"colonic displacement\". Am J Surg 1968; 115:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/7/7289/abstract/47\">",
"      Hashemi M, Peters JH, DeMeester TR, et al. Laparoscopic repair of large type III hiatal hernia: objective followup reveals high recurrence rate. J Am Coll Surg 2000; 190:553.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16404 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7289=[""].join("\n");
var outline_f7_7_7289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9592311\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9592225\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H606324891\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606324922\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H606324982\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H606329650\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26691034\">",
"      Primary versus secondary gastric volvulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26691041\">",
"      Axis of rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102192354\">",
"      Acute versus chronic gastric volvulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26691754\">",
"      CLINICAL PRESENTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H289880441\">",
"      Acute gastric volvulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102192728\">",
"      Chronic gastric volvulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H289879710\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H289880427\">",
"      Acute symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H289880434\">",
"      Chronic symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102194220\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102193888\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606326238\">",
"      Gastric decompression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1642638797\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606333781\">",
"      Acute gastric volvulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606334133\">",
"      Chronic gastric volvulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102193562\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102193667\">",
"      Endoscopic de-rotation and PEG tube gastric fixation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1642632866\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606336310\">",
"      - Open versus laparoscopic repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606333176\">",
"      - Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1642634680\">",
"      RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9592311\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/16404\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16404|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?4/51/4927\" title=\"algorithm 1\">",
"      Acute gastric volvulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16404|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/41/657\" title=\"diagnostic image 1\">",
"      Gastric volvulus on plain chest film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/41/39568\" title=\"diagnostic image 2\">",
"      Drug packets stomach plain XR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/43/28341\" title=\"diagnostic image 3A\">",
"      Organoaxial gastric volvulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/16/14595\" title=\"diagnostic image 3B\">",
"      Mesenteroaxial gastric volvulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/50/803\" title=\"diagnostic image 4\">",
"      Gastric volvulus on computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16404|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/12/2243\" title=\"figure 1\">",
"      Gastric attachments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/21/19796\" title=\"figure 2\">",
"      Gastric volvulus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=related_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=related_link\">",
"      Gastric outlet obstruction in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9480?source=related_link\">",
"      Nasogastric and nasoenteric tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12442?source=related_link\">",
"      Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19128?source=related_link\">",
"      Paraesophageal hernia: Clinical features and surgical repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_7_7290="Atazanavir: Pediatric drug information";
var content_f7_7_7290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atazanavir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"    see \"Atazanavir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/51/9013?source=see_link\">",
"    see \"Atazanavir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Reyataz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Reyataz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Protease Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12864277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Not recommended due to risk of kernicterus",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"      see \"Atazanavir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (use in combination with other antiretroviral agents):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants 1 to &lt;3 months: Not recommended due to risk of kernicterus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &ge;3 months and Children &lt;6 years: Not approved for use; dose not established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;6 years and Adolescents &lt;18 years:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage is based on body weight; do not exceed recommended adult dose; use a combination of the available capsule strengths to achieve the recommended dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Antiretroviral-naive patients:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ritonavir unboosted regimen;",
"     <b>",
"      Note:",
"     </b>",
"     Ritonavir boosted atazanavir dosing regimen is preferred; data from an ongoing Phase II clinical trial indicate that higher atazanavir dosing (ie, higher on a mg/kg or mg/m",
"     <sup>",
"      2",
"     </sup>",
"     basis than predicted by adult dosing guidelines) may be needed when atazanavir is used without ritonavir boosting in children and adolescents [DHHS (pediatric), 2011].",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;6 years to &lt;13 years: Dose not established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;13 years and &ge;39 kg",
"     <b>",
"      who are not able to tolerate ritonavir",
"     </b>",
"     : Atazanavir 400 mg once daily (without ritonavir)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ritonavir boosted regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     15 kg to &lt;25 kg: Atazanavir 150 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 80 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     25 kg to &lt;32 kg: Atazanavir 200 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     32 kg to &lt;39 kg: Atazanavir 250 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;39 kg: Atazanavir 300 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer labeling: Children and Adolescents &ge;6  to &lt;18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     15 kg to &lt;20 kg: Atazanavir 150 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     20 kg to &lt;40 kg: Atazanavir 200 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &ge;40 kg: Atazanavir 300 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Antiretroviral-experienced patients:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ritonavir unboosted regimen: Atazanavir",
"     <b>",
"      without",
"     </b>",
"     ritonavir is",
"     <b>",
"      not",
"     </b>",
"     recommended in antiretroviral-experienced patients with prior virologic failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ritonavir boosted regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;25 kg: Dose not established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     25 kg to &lt;32 kg: Atazanavir 200 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     32 kg to &lt;39 kg: Atazanavir 250 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;39 kg: Atazanavir 300 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;18 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Antiretroviral-naive patients:",
"     </b>",
"     Atazanavir 300 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"     <b>",
"      or",
"     </b>",
"     atazanavir 400 mg once daily in patients unable to tolerate ritonavir.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended (with ritonavir) as a first-line therapy with tenofovir/emtricitabine in nonpregnant antiretroviral-naive patients (DHHS, 2011). If using without ritonavir, consider also using two nucleoside reverse transcriptase inhibitors (other than didanosine/emtricitabine or didanosine/lamivudine) (DHHS, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Antiretroviral-experienced patients:",
"     </b>",
"     Atazanavir 300 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Atazanavir without ritonavir is not recommended in antiretroviral-experienced patients with prior virologic failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pregnant patients (antiretroviral-naive):",
"     </b>",
"     Atazanavir 300 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Postpartum dosage adjustment not needed. Observe patient for adverse events, especially within 2 months after delivery. Dose adjustments required for concomitant tenofovir",
"     <i>",
"      or",
"     </i>",
"     H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist use (insufficient information for dose adjustment if",
"     <i>",
"      both",
"     </i>",
"     tenofovir and an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist are used).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       Dosage adjustments for concomitant therapy:",
"      </span>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Coadministration with bosentan:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Coadministration of bosentan in patients currently receiving atazanavir/ritonavir: For patients receiving ritonavir for at least 10 days, begin with bosentan 62.5 mg once daily or every other day based on tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Coadministration of atazanavir/ritonavir in patients currently receiving bosentan: Discontinue bosentan 36 hours prior to the initiation of ritonavir. After at least 10 days of atazanavir/ritonavir; resume bosentan 62.5 mg once daily or every other day based on tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Coadministration with efavirenz:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Antiretroviral-naive patients: Atazanavir 400 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily (as a single dose, administered with food); give with efavirenz 600 mg (administered on an empty stomach, preferably at bedtime); do",
"     <b>",
"      not",
"     </b>",
"     use efavirenz and atazanavir without booster doses of ritonavir. This combination/dose may be used after the first trimester in pregnant women when other alternatives are not available (DHHS [perinatal], 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Antiretroviral-experienced patients: Concurrent use not recommended due to decreased atazanavir exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Coadministration with H",
"      <sub>",
"       2",
"      </sub>",
"      -receptor antagonists:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Antiretroviral-naive patients: Atazanavir 300 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily given simultaneously with, or at least 10 hours after, the H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonist; dosage of H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonist must be limited to the equivalent of a 40 mg dose of famotidine twice daily; administer with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Patients unable to tolerate ritonavir: Atazanavir 400 mg once daily given at least 2 hours before or at least 10 hours after an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist; dosage of H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonist must be limited to the equivalent daily dose of &le;40 mg famotidine (single dose: &le;20 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Antiretroviral-experienced patients: Atazanavir 300 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily given simultaneously with, or at least 10 hours after, the H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonist; dosage of H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonist must be limited to the equivalent of a 20 mg dose of famotidine twice daily; administer with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Antiretroviral-experienced pregnant patients in the second or third trimester: Atazanavir 400 mg plus ritonavir 100 mg simultaneously with, or at least 10 hours after an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist.",
"     <b>",
"      Note:",
"     </b>",
"     Insufficient information for dose adjustment if tenofovir",
"     <b>",
"      and",
"     </b>",
"     an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist are used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Coadministration with maraviroc:",
"     </b>",
"     Atazanavir 300 mg plus ritonavir 100 mg once daily plus maraviroc 150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Coadministration with phosphodiesterase-5 enzyme (PDE-5) inhibitor:",
"     </b>",
"     Pulmonary arterial hypertension: Atazanavir coadministered with tadalafil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patient receiving atazanavir with or without ritonavir for at least 1 week: Initiate tadalafil at 20 mg once daily; increase to 40 mg once daily based on individual tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patient receiving tadalafil when initiating atazanavir with or without ritonavir: Stop tadalafil at least 24 hours prior to starting atazanavir (with or without ritonavir). After at least 1 week following the initiation of atazanavir (with or without ritonavir), resume tadalafil at 20 mg once daily; increase to 40 mg once daily based on individual tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Coadministration with proton pump inhibitor:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Antiretroviral-naive patients: Atazanavir 300 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily given 12 hours after the proton pump inhibitor; dosage of proton pump inhibitor must be limited to the equivalent of a 20 mg dose of omeprazole/day; administer with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Antiretroviral-experienced patients: Concurrent use",
"     <b>",
"      not",
"     </b>",
"     recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Coadministration with didanosine buffered or enteric-coated formulations:",
"     </b>",
"     Administer atazanavir 2 hours before or 1 hour after didanosine buffered or enteric coated formulations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Coadministration with tenofovir:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Antiretroviral-naive patients: Atazanavir 300 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg given with tenofovir 300 mg (all as a single daily dose); administer with food; do",
"     <b>",
"      not",
"     </b>",
"     use tenofovir and atazanavir without booster doses of ritonavir; if H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonist is coadministered, increase atazanavir to 400 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily (see Coadministration with H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonist)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Antiretroviral-experienced patients: Atazanavir 300 mg plus ritonavir 100 mg given with tenofovir 300 mg (all as a single daily dose); if H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist coadministered (not to exceed equivalent daily dose of &le;40 mg famotidine), increase atazanavir to 400 mg (plus ritonavir 100 mg) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Antiretroviral-experienced pregnant patients in the second or third trimester: Atazanavir 400 mg plus ritonavir 100 mg.",
"     <b>",
"      Note:",
"     </b>",
"     Insufficient information for dose adjustment if tenofovir",
"     <b>",
"      and",
"     </b>",
"     an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist are used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients with renal impairment, including severe renal impairment who are not managed with hemodialysis: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients with end-stage renal disease managed with hemodialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Antiretroviral-naive patients: Atazanavir 300 mg",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Antiretroviral-experienced patients: Do not use atazanavir; dosage is not known",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate hepatic insufficiency: Use with caution; if moderate hepatic impairment (Child-Pugh class B) and no prior virologic failure, consider dose reduction to 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment (Child-Pugh Class C): Do not use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients with underlying hepatitis B or C or those with marked elevations in transaminases prior to treatment may be at increased risk of hepatic decompensation or further increases in transaminases with atazanavir therapy (monitor patients closely). Combination therapy with ritonavir in patients with hepatic impairment is",
"     <b>",
"      not",
"     </b>",
"     recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reyataz&reg;: 100 mg, 150 mg, 200 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food to enhance absorption; swallow capsules whole, do not open. Administer atazanavir 2 hours before or 1 hour after didanosine buffered formulations, didanosine enteric-coated capsules, other buffered medications, or antacids. Administer atazanavir (with ritonavir) simultaneously with, or at least 10 hours after, H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonists; administer atazanavir (without ritonavir) at least 2 hours before or at least 10 hours after H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonist. Administer atazanavir (with ritonavir) 12 hours after proton pump inhibitor.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection in combination with other antiretroviral agents (FDA approved in ages &ge;6 years and adults) [",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended; low-dose ritonavir (booster dose) is recommended in combination with atazanavir in antiretroviral-experienced patients with prior virologic failure]",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F137377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Includes data from both treatment-naive and treatment-experienced patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: AV block",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, fever, headache, insomnia, peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cholesterol increased, hyperglycemia, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, amylase increased, diarrhea, lipase increased, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hemoglobin decreased, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, bilirubin increased, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, rhinorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia, arthralgia, AV block (second- and third-degree, rare), cholecystitis, cholelithiasis, cholestasis, diabetes mellitus, DRESS syndrome, edema, erythema multiforme, immune reconstitution syndrome, left bundle branch block, macropapular rash, nephrolithiasis, pancreatitis, PR prolongation, pruritus, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, Stevens-Johnson syndrome, torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to atazanavir or any component; concurrent therapy with medications that largely rely on cytochrome P450 isoenzyme CYP3A or UGT1A1 for clearance and that have an association between increased plasma concentrations and serious or life-threatening effects including the following: Alfuzosin, cisapride, dihydroergotamine, ergotamine, ergonovine , irinotecan, lovastatin, methylergonovine, midazolam (oral), pimozide, sildenafil [when used for pulmonary artery hypertension (eg, Revatio&reg;)], simvastatin, triazolam; concurrent therapy with indinavir, rifampin, or the herbal medicine St John's wort  (",
"     <i>",
"      Hypericum perforatum",
"     </i>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Atazanavir may prolong the P-R interval; rare cases of second-degree AV block and other conduction abnormalities have also been reported; use with caution in patients with pre-existing conduction abnormalities or with medications which prolong A-V conduction (dosage adjustment is required with some agents). Concomitant use of salmeterol is not recommended due to increased risk of cardiovascular adverse events, including QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation. Hyperglycemia, changes in glucose tolerance, exacerbation of diabetes, DKA, and new-onset diabetes mellitus have been reported in patients receiving protease inhibitors; use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use atazanavir with caution in patients with mild to moderate hepatic impairment; consider dosage adjustment in patients with moderate hepatic dysfunction; atazanavir is",
"     <b>",
"      not",
"     </b>",
"     recommended for use in patients with severe hepatic impairment; the use of atazanavir",
"     <b>",
"      plus",
"     </b>",
"     ritonavir is not recommended in patients with hepatic impairment. Do not use concurrently with colchicine in patients with renal or hepatic impairment. Atazanavir may exacerbate pre-existing hepatic dysfunction; use with caution in patients with hepatitis B or C or in patients with marked elevations in hepatic transaminases. Use with caution and adjust dose (and add ritonavir) in antiretroviral-naive patients with end-stage renal disease managed with hemodialysis; do not use atazanavir in antiretroviral-experienced patients with end-stage renal disease managed with hemodialysis. Use with caution in patients with hemophilia; spontaneous bleeding episodes have been reported in patients with hemophilia type A and B receiving protease inhibitors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established); less common with atazanavir than other protease inhibitors. May cause hypercholesterolemia less frequently than with other protease inhibitors. Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents, including atazanavir; this syndrome may require further patient assessment and therapy. May cause cough; reported incidence in children 21%. May cause fever; higher incidence observed in children compared to adults (19% vs 2%).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Atazanavir is an inhibitor of cytochrome P450 isoenzyme CYP3A and uridine diphosphate glucuronosyl transferase (UGT1A1; a glucuronidation enzyme). Administration of atazanavir with drugs that are primarily metabolized by CYP3A or UGT1A1 may result in increased serum concentrations of the other drug and lead to an increase or prolongation of adverse effects. Due to potential serious and/or life-threatening drug interactions, some drugs are contraindicated or not recommended for concurrent use; other drug interactions require dosage or regimen adjustment or monitoring of serum concentrations of drugs coadministered with atazanavir.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Asymptomatic elevations in unconjugated (indirect) bilirubin occur commonly (in approximately 50% of patients) during therapy with atazanavir; this reversible hyperbilirubinemia is related to inhibition of uridine diphosphate glucuronosyl transferase; consider alternative therapy if bilirubin is &gt;5 times upper limits of normal (long-term safety data is not available for such patients) or if jaundice or scleral icterus become a cosmetic concern for the patient; evaluate alternative etiologies if elevated transaminase also occur. Do not use atazanavir in infants &lt;3 months of age due to potential risk of kernicterus. Pharmacokinetic profile of atazanavir in patients 3 months to &lt;6 years of age has not been established.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Skin rash may occur with atazanavir use, usually mild to moderate; maculopapular; reported incidence: Pediatric patients: 14% (Grade 2-4); adults: 21% (all grades); median onset: 7.3 weeks; treatment may be continued if rash is mild to moderate (rash may resolve; median duration: 1.4 weeks); discontinue therapy in cases of severe rash. Postmarketing cases of nephrolithiasis have been reported; consider temporary interruption of therapy or discontinuation if signs or symptoms of nephrolithiasis occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F137366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C8 (weak), CYP2C9 (weak), CYP3A4 (strong), UGT1A1",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Protease Inhibitors may increase the serum concentration of ALPRAZolam.  Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir. Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Atazanavir may increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Atazanavir.  Management: Concurrent use of atazanavir (without ritonavir) and bosentan is not recommended.  Bosentan dose adjustments are required when used together with atazanavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: Atazanavir may increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir.  Management: Avoid this combination in patients un-boosted atazanavir due to possible decreased atazanavir concentrations.  This combination is not contraindicated in patients also receiving ritonavir, but monitoring for buprenorphine toxicity is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Protease Inhibitors may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Atazanavir may increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Atazanavir may decrease the serum concentration of Didanosine. Reported with enteric coated didanosine capsules. Didanosine may decrease the serum concentration of Atazanavir. Specifically, the buffered formulation of didanosine may decrease atazanavir absorption.  Management: To avoid therapeutic failure of atazanavir the drug should be administered 2 hours before or 1 hour after didanosine.  This recommendation applies to both buffered didanosine products and enteric coated didanosine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Atazanavir. Management: When used with efavirenz, the atazanavir regimen should be atazanavir 400 mg/ritonavir 100 mg daily for treatment-naive patients; treatment-experienced patients should not use atazanavir together with efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Atazanavir may increase the serum concentration of Etravirine. Etravirine may decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Atazanavir. Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Atazanavir may enhance the adverse/toxic effect of Indinavir. Indinavir may enhance the adverse/toxic effect of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Atazanavir may increase the serum concentration of Irinotecan. The metabolism (via glucuronidation) of the active SN-38 metabolite may be primarily impacted by this interaction.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Minocycline: May decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: Atazanavir may increase the serum concentration of Nevirapine. Nevirapine may decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pitavastatin: Atazanavir may increase the serum concentration of Pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Atazanavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Atazanavir. Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Atazanavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Atazanavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Atazanavir may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Atazanavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: Atazanavir may increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Atazanavir.  Management: When combined use required, tenofovir 300 mg and atazanavir 300 mg should be used with ritonavir 100 mg (adult doses), all given in single daily dose with food.   Atazanavir without ritonavir should not be used with tenofovir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Atazanavir may increase the serum concentration of TraZODone.  Management: Consider using a lower dose of trazodone when used in combination with atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Atazanavir may decrease the serum concentration of Voriconazole. Atazanavir may increase the serum concentration of Voriconazole. Voriconazole may decrease the serum concentration of Atazanavir.  Management: Voriconazole should not be used in a patient who is being treated with ritonavir-boosted atazanavir unless the benefits of the combination outweigh the potential risks.  Extra monitoring for both loss of effectivness and toxicity is warranted.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Atazanavir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1051211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food increases oral bioavailability and decreases interpatient pharmacokinetic variability.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F137339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies. Atazanavir crosses the placenta with cord blood concentrations reported as 13% to 21% of maternal serum concentrations at delivery. An increased risk of teratogenic effects has not been observed based on information collected by the antiretroviral pregnancy registry. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and protease inhibitors (PIs) should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk. Hyperbilirubinemia or hypoglycemia may occur in neonates following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to atazanavir, although data are conflicting.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The DHHS Perinatal HIV Guidelines recommend atazanavir as a preferred PI when combined with low-dose ritonavir boosting. Pharmacokinetic studies suggest that standard dosing during pregnancy may provide decreased plasma concentrations and some experts recommend increased doses during the second and third trimesters. However,  the manufacturer notes that dose adjustment is not required unless using concomitant H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor blockers or tenofovir or for ARV-naive pregnant women taking efavirenz. May give as once-daily dosing.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CD4 cell count, HIV RNA plasma levels, serum glucose, bilirubin, triglycerides, cholesterol, liver enzyme tests (especially in patients with a history of hepatitis B or C)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An azapeptide protease inhibitor which acts on an enzyme (protease) late in the HIV replication process after the virus has entered into the cell's nucleus. Atazanavir binds to the protease activity site and inhibits the activity of the enzyme, thus preventing cleavage of viral polyprotein precursors (gag-pol protein precursors) into individual functional proteins found in infectious HIV. This results in the formation of immature, noninfectious viral particles.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: CSF: Plasma concentration ratio (range): 0.0021-0.0226",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 86%; binds to both alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein and albumin (similar affinity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively metabolized in the liver, primarily by cytochrome P450 isoenzyme CYP3A; also undergoes biliary elimination; major biotransformation pathways include mono-oxygenation and deoxygenation; minor pathways for parent drug or metabolites include glucuronidation, N-dealkylation, hydrolysis and oxygenation with dehydrogenation; 3 minor inactive metabolites have been identified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 6.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with hepatic impairment: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 13% of the dose is excreted in the urine (7% as unchanged drug); 79% of the dose is excreted in feces (20% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not appreciably removed during hemodialysis. Only 2.1% of the dose was removed during a 4 hour dialysis session; however, mean AUC, peak, and trough serum concentrations were 25% to 43% lower (versus adults with normal renal function) when atazanavir was administered either prior to, or after hemodialysis; mechanism of the decrease is not currently known.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/51/9013?source=see_link\">",
"      see \"Atazanavir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting atazanavir, tell your doctor if you have liver problems, hepatitis B or C, end stage kidney disease managed with hemodialysis, diabetes, or hemophilia. Atazanavir may cause changes in the ECG (notify physician if dizziness or lightheadedness occur); elevated bilirubin levels and yellowing of the skin or whites of the eye (other medication can be used if these side effects are of concern); kidney stones (notify healthcare provider if you experience pain in your side, blood in the urine, or pain when urinating), gallstones or inflammation of the gallbladder. Atazanavir may cause a skin rash that will usually go away with continued use of the drug (notify healthcare provider if skin rash occurs). In rare cases, the skin rash may be associated with symptoms that can be serious or potentially fatal; stop using atazanavir and notify healthcare provider immediately if a skin rash with any of the following symptoms occurs: Blisters, fever, flu-like symptoms, mouth sores, muscle or joint aches, red or inflamed eyes, shortness of breath, or swelling of face.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some medicines should not be taken with atazanavir; report the use of other medications, nonprescription medications and herbal or natural products to your physician and pharmacist; avoid the herbal medicine St John's wort. Atazanavir is not a cure for HIV; take atazanavir everyday as prescribed; do not change dose or discontinue without physician's advice; if a dose is missed, take it as soon as possible, then return to normal dosing schedule; if it is within 6 hours of your next dose, do not take the missed dose; if a dose is skipped, do not double the next dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Preliminary studies have shown that appropriate atazanavir serum concentrations are difficult to achieve in pediatric patients even with higher doses (on a mg/kg or m",
"     <sup>",
"      2",
"     </sup>",
"     basis). Optimal dosing in children &lt;6 years of age is under investigation; the addition of low-dose ritonavir (booster doses) to increase atazanavir serum concentrations may be required and is currently being evaluated. Results of a pediatric Phase II clinical trial suggest that when used",
"     <b>",
"      without",
"     </b>",
"     ritonavir boosting, children &ge;6 and &lt;13 years of age require atazanavir 520 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day and adolescents &ge;13 years of age require atazanavir 620 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (once daily doses of 600-900 mg/day). When used in combination",
"     <b>",
"      with",
"     </b>",
"     ritonavir, the study used atazanavir 205 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (once daily doses of 250-375 mg/day) [DHHS (pediatric), 2011].",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Briars LA, Hilao JJ, and Kraus DM, &ldquo;A Review of Pediatric Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Journal of Pharmacy Practice",
"      </i>",
"      , 2004, 17(6):407-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; October 14, 2011;1-167. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, Department of Health and Human Services,\" August 11, 2011;1-268. Available at",
"      <a href=\"file://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\" September 14, 2011; 1-207. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldsmith DR and Perry CM, &ldquo;Atazanavir,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2003, 63(16):1679-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/7/7290/abstract-text/12904086/pubmed\" id=\"12904086\" target=\"_blank\">",
"        12904086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morris JL and Kraus DM, \"New Antiretroviral Therapies for Pediatric HIV Infection,\"",
"      <i>",
"       J Pediatr Pharmacol Ther",
"      </i>",
"      , 2005, 10:215-47.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Musial BL, Chojnacki JK, and Coleman CI, &ldquo;Atazanavir: A New Protease Inhibitor to Treat HIV Infection,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(13):1365-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/7/7290/abstract-text/15287232 /pubmed\" id=\"15287232 \" target=\"_blank\">",
"        15287232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" August 11, 2011. Available at:",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12906 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-EDC393233E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7290=[""].join("\n");
var outline_f7_7_7290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137353\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855135\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051201\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12864277\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051194\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137329\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137315\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051205\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051197\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051204\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137377\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051208\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051193\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051192\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137366\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137323\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051211\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137325\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137339\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051200\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051191\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051207\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051199\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051209\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12906\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12906|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=related_link\">",
"      Atazanavir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/51/9013?source=related_link\">",
"      Atazanavir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_7_7291="Uterine carcinoma grade";
var content_f7_7_7291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Uterine corpus carcinoma grades: degrees of histopathologic differentation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       Cases of carcinoma of the corpus should be grouped with regard to the degree of differentation of the adenocarcinoma as follows:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       G1",
"      </td>",
"      <td>",
"       5 percent or less of a nonsquamous or nonmorular solid growth pattern",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       G2",
"      </td>",
"      <td>",
"       6 percent to 50 percent of a nonsquamous or nonmorular solid growth pattern",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       G3",
"      </td>",
"      <td>",
"       More than 50 percent of a nonsquamous or nonmorular solid growth pattern",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, 7th Edition (2010) published by Springer, New York.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7291=[""].join("\n");
var outline_f7_7_7291=null;
var title_f7_7_7292="Normal echo dimensions";
var content_f7_7_7292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal adult echocardiograhic cardiac dimensions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Aorta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinus level",
"       </td>",
"       <td>",
"        &le;3.7 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascending",
"       </td>",
"       <td>",
"        &le;3.6 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transverse",
"       </td>",
"       <td>",
"        &le;3.0 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Descending",
"       </td>",
"       <td>",
"        &le;2.5 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Left atrium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasternal long axis",
"       </td>",
"       <td>",
"        &le;4.0 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apical 4 chamber",
"       </td>",
"       <td>",
"        &le;5.2 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Left ventricle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septum",
"       </td>",
"       <td colspan=\"1\">",
"        6-11 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior wall",
"       </td>",
"       <td colspan=\"1\">",
"        6-11 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        End-diastolic dimension",
"       </td>",
"       <td>",
"        5-6 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fractional shortening*",
"       </td>",
"       <td colspan=\"1\">",
"        0.28-0.32 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Pulmonary artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Main",
"       </td>",
"       <td>",
"        &le;3.0 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Inferior vena cavae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At right atrial junction",
"       </td>",
"       <td>",
"        &lt;2.0 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Coronary sinus",
"       </td>",
"       <td>",
"        &lt;1.5 cm",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Fractional shortening = (End-diastolic dimension - End-systolic dimension) &divide; End-diastolic dimension.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7292=[""].join("\n");
var outline_f7_7_7292=null;
var title_f7_7_7293="Y system for peritoneal dialysis modified";
var content_f7_7_7293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Y system for peritoneal dialysis (modified design)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 163px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Newer Y systems, in which both dialysis solutions and drain bags are preattached, may lower peritonitis rates since they more effectively flush out possible contamination during attachment than the initial Y systems, and do not require patient manipulation of the connection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7293=[""].join("\n");
var outline_f7_7_7293=null;
var title_f7_7_7294="Pulm embolism and air travel";
var content_f7_7_7294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Incidence of pulmonary embolism according to distance traveled by air",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 402px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure indicates the incidence of pumonary embolism per",
"    <strong>",
"     million",
"    </strong>",
"    passenger arrivals, arranged according to flight distance in kilometers. Error bars indicate 95 percent confidence limits. To convert kilometers to miles, multiply by 0.62.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Lapastolle, F, et al. N Engl J Med 2001; 345:779.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7294=[""].join("\n");
var outline_f7_7_7294=null;
var title_f7_7_7295="Management Brugada syndrome-I";
var content_f7_7_7295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Management of patients with Brugada syndrome according to baseline ECG and symptoms-I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 330px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Class I designation indicates clear evidence that the procedure or treatment is useful or effective; Class II, conflicting evidence about usefulness or efficacy; Class IIa, weight of evidence is in favor of usefulness or efficacy; and Class IIb, usefulness or efficacy is less well established.",
"    <div class=\"footnotes\">",
"     BS: Brugada syndrome; NAR: nocturnal agonal respiration; and SCD: sudden cardiac death.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659. Copyright &copy; 2005 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_7_7295=[""].join("\n");
var outline_f7_7_7295=null;
